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Gene therapy has become a promising strategy for treatment of numerous diseases such as 
cancer, hemophilia, and neurodegenerative diseases. Glybera® (alipogene tiparvovec) became the 
first gene therapy approved in the European Union, for the treatment of lipoprotein lipase 
deficiency (LPLD). Promising late-stage clinical trials of this drug may herald the first gene 
therapy to be approved in the United States. The advancement of vectors (viral and nonviral) for 
efficient and safe gene delivery has garnered significant attention recently. Although viral vectors 
(e.g., retroviruses and adenoviruses) are the most effective vectors, applied in 70% of gene therapy 
clinical trials, they present several notable challenges including safety concerns (e.g., 
immunogenicity and pathogenicity), production difficulties, and rapid clearance from circulation. 
In contrast, nonviral vectors could be promising gene carriers due to their low cost, ease of 
synthesis, and decreased immunogenicity relative to viral vectors.  
Key progress has been made in the development of several nonviral gene delivery vectors. 
The use of cell penetrating peptides (CPPs) to deliver genetic materials for gene therapy has been 
a topic of interest for more than 20 years. One strategy is through covalent conjugation  of CPPs 
with genetic materials, which requires complex synthesis procedures. In contrast, electrostatic 
complexation of CPPs with genetic materials is relatively simple and has been demonstrated to 
improve gene delivery both in vitro and in vivo. Reported herein, a simple method to generate 
small CPP complexes (100-200 nm) capable of high transfection efficiency was explored. 
Positively charged CPPs (e.g., polyarginine 9 [R9] and polylysine 9 [K9]) were complexed with 
plasmid DNA (pDNA), which resulted in unstable large particles (~1 micron). These were then 
condensed into small nanoparticles using Ca2+. CPPs also displayed negligible cytotoxicity. These 
CPP-pDNA-Ca2+ complexes showed high transfection efficiency and low cytotoxicity in vitro 
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(human and mouse cell lines) and in vivo (syngeneic mice). Thus, Ca2+-condensed CPP complexes 
emerged as simple, attractive candidates for future studies on nonviral gene delivery.  
Futhermore, the relationships between transfection efficiency and polyarginine molecular 
weight, polyarginine-pDNA charge ratios, and calcium concentrations were studied. Polyarginine 
7 was significantly more effective than other polyarginines under most formulation conditions, 
suggesting a link between molecular weight and transfection efficiency. Furthermore, Polylysine 
9 was complexed with angiotensin II type 2 receptor (AT2R) plasmid DNA (pAT2R). The 
polylysine 9 complexe (K9-pAT2R-Ca2+) showed high transfection efficiency and negligible in 
vitro cytotoxicity towards human and mouse cell lines. This complex demonstrated cancer-
targeted gene delivery in vivo when administered via intravenous injection or intratracheal spray. 
A single administration of this complex markedly attenuated lung cancer growth.  
Mechanistic understanding of CPP-mediated membrane insertion and intracellular 
translocation of nonviral gene complexes would allow rational design of next-generation CPPs for 
gene delivery. To this aim, we employed zwitterionic and anionic phospholipid monolayers as 
models to mimic the membrane composition of the outer leaflet of cell plasma and intracellular 
vesicular membranes at relevant intracellular pH. Subsequently, we investigated the membrane 
insertion potential of CPPs and gene complexes (CPP-pDNA-Ca2+ complexes) into model 
membranes. The insertion potential of CPPs and complexes were recorded using a Langmuir 
monolayer approach that records peptides and complexes adsorption to model membranes. Results 
showed that small changes to amino acids and peptide sequences resulted in dramatically different 
insertion potentials and membrane reorganization.  
Lastly, the effect of CPP charge type, charge spacing, and hydrophobicity on transfection 
efficiency was investigated by replacing three residues of the polyarginine 9 with a hydrophilic 
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residue (histidine) or hydrophobic residues (alanine, leucine, and tryptophan) at positions 3, 4, and 
7. R9 and RW9 complexes appeared especially effective compared to other CPP complexes, 
whereas RH9, RA9, and RL9 complexes seemed to have moderate- to low-gene expression. 
Initially, this suggested CPPs with better membrane penetration yielded higher gene expression. 
After further exploration, we discovered the charge spacing of CPPs affected the ability of CPPs 
to complex with nucleic acids and this property correlated to gene expression levels. In conclusion, 
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1.1. Introduction to Noncovalently Associated Cell Penetrating Peptides for Nonviral Gene 
Delivery Applications 
The past decade has witnessed a dramatic acceleration in the production of new therapeutic 
macromolecules, such as proteins, peptides, and nucleic acids, with the interest of overcoming 
limitations of small-molecule drugs such as specificity, poor potency and rapid elimination. Gene 
therapy, which involves the delivery of large macromolecules of nucleic acids, has emerged as a 
popular topic among researchers because of its potential to treat severe and challenging-to-cure 
diseases, such as inherited genetic diseases, viral infections and various cancers 1. Genetic 
treatment of these diseases has garnered significant attention over the past 20 years 2 and is nearly 
a reality, as supported by the hundreds of clinical trials 3.  
Gene therapy utilizes the delivery of genetic material into target cells to replace a gene that 
is missing, mutated or poorly expressed. Gene therapy also used to silence gene expression and 
production of proteins using siRNA 4. Clinical applications, however, have been hindered by 
formulation issues, poor in vivo stability, problems with delivery to target cells, and inefficient 
cellular uptake 5. One of the main hindrances for administering genetic material is the inability of 
DNA or RNA to reach cellular and intracellular target sites such as nuclei and mitochondria 6, 7. 
The cellular plasma membrane is an impermeable barrier for most hydrophilic macromolecules 8. 
Transporting nucleic acids across the plasma membrane, however, is necessary since these 
therapeutic agents must be internalized for biological activity 9. 
Notable effort is being made to develop viral and nonviral vectors that can cross the plasma 
membrane and deliver therapeutic agents into target cells 10. Viral vectors (e.g., adenoviruses, 
adeno-associated viruses, and retroviruses) can be highly efficient and are currently used in the 
majority of ongoing clinical trials. Viral vectors have the natural ability to attach and enter target 
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cells while protecting genetic material and providing long-term gene expression. In some cases, 
however, dependency of the virus on certain cellular receptors compromises the efficiency of the 
viral vector. In addition, viral vectors introduce safety concerns such as the risk of oncogenesis 
and immunogenicity 11. Consequently, nonviral vectors are being pursued as flexible, easy, and 
potentially safer alternatives 12, 13, yet, they continue to lack the necessary efficiency required for 
clinical application 14. 
Since their discovery two decades ago, cell penetrating peptides (CPPs) have been used for 
a diverse number of applications in numerous types of cells 1. CPPs are generally defined as 
cationic or amphipathic peptides consisting of 30 or fewer amino acids with a structure that can 
mediate movement across a plasma membrane into the cell cytoplasm 15-17. CPPs translocate into 
cells without cytotoxic effects, are efficiently internalized across cell membranes and aid in 
carrying cargo into live cells 18. Although the internalization mechanisms are debatable, the 
application of CPPs is growing rapidly 19. Some studies suggest that CPPs directly penetrate (e.g., 
carpet, inverted micelle, and toroidal) through the lipid bilayer of the cell membrane, and others 
suggest that CPPs employ diverse endocytic pathways (e.g., macropinocytosis, clathrin-dependent, 
caveolae-mediated, and clathrin-/caveolae-independent) (Figure 1) 16, 20, 21. Additionally, some 
CPPs are capable of using both direct penetration and endocytosis for cellular internalization. One 
study indicated that the internalization mechanism of arginine-containing CPPs is dominated by 
direct membrane penetration, while the internalization mechanism of arginine-containing CPPs 
mediating delivery of DNA is dominated by endocytosis 22. Another study found that direct 
membrane penetration occurs at low extracellular CPP concentrations, while endocytosis is 
activated at higher peptide concentrations 23. This review focuses mainly on current classifications, 
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formulation approaches, and applications relating to strategies that use noncovalent association of 
CPPs and gene vectors (viral and nonviral) to improve delivery of genetic material. 
 
Figure 1. Three proposed endocytic pathways for cell penetrating peptide entry. Cell penetrating 
peptides may enter target cells through macropinocytosis, clathrin-dependent endocytosis, 
caveolae-mediated endocytosis, or clathrin-/caveolae-independent endocytosis. 
 
1.2. Overview of Current Classifications 
CPPs are used to enhance cellular internalization of different biomolecules or vectors (e.g., 
pDNA, siRNA, oligonucleotides, liposomes, peptides, proteins and viruses) 4. The existence of 
diverse internalization mechanisms is of great importance when considering the use of CPPs as 
drug transporters. The exact mechanism, however, is not well understood. Some researchers 
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indicated that uptake pathways of CPPs do not involve cellular receptors 24. Other studies have 
reported that the electrostatic interaction of cationic CPP with negatively charged heparan sulfate 
proteoglycans that are found abundantly on the cell membrane triggers endocytotic internalization 
25. The exact mechanism of internalization is governed by cell type, cargo type and CPP properties, 
such as sequence, molecule length, and secondary structure 26. The nature of the CPPs (e.g., size, 
surface charge, or hydrophilicity) 27 and whether the CPPs are covalently or noncovalently 
attached (Figure 2) influence the internalization mechanism 28. The origin of a CPP also provides 
some insight into the mechanism of internalization. 
Over the past two decades, more than 100 diverse peptide sequences (5–40 peptide 
residues), isolated from various sources, have been identified as being capable of mediating the 
transport of diverse biological molecules, such as pDNA, siRNA, and large molecules, such as 
viruses 29. The TAT of HIV, which was discovered in 1988, was found to efficiently enter 
mammalian cells 30. In 1991 Joliot et al. discovered that Drosophila Antennapedia homeodomain 
could translocate into neuronal cells 31. A short while later in 1996, Derossi and colleagues 
demonstrated that the peptide Antennapedia, commonly called penetratin 
(RQIKIYFQNRRMKWKK), could be covalently bound to cargo and translocate into cells 32. The 
minimum peptide sequence of TAT (YGRK-KRRQRRR) thought to be necessary for cellular 
uptake was identified by Vives et al. in 1997 33. 
CPPs can be classified in different ways, and one manner of classification is on the basis 
of their origin. This classification sort CPPs into three major classes: 
 Protein derived peptides (e.g., TAT and penetratin); 
 Chimeric peptides (e.g., transportan); 
 Synthetic peptides (e.g., polylysine [PLL]) 34. 
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CPPs can also be divided into two groups based on the internalization mechanism: energy-
dependent (endocytosis) and energy-independent (direct translocation) transport through the cell 
membrane 35. Another way of classifying CPPs is based on their physicochemical properties. Here, 
CPPs are divided into three classes: 
 Cationic CPPs, which are short peptide residue sequences that mostly consist of arginine, 
lysine, and/or histidine (e.g., TAT and PLL); 
 Amphipathic CPPs, which have a lipophilic (non-polar) domain and a hydrophilic (polar) 
domain (e.g., MPG); 
 Hydrophobic CPPs, which consist of hydrophobic residues, such as valine, leucine and 
tryptophan (e.g., Bip and FGF12) 36. 
1.3. Formulation Strategies 
Two main strategies have explored the use of CPPs to deliver cargo (Figure 2). The first 
strategy uses chemical linkers to covalently attach CPPs to their cargo, and the second strategy 
relies on electrostatic, self-assembly to form noncovalent complexes between CPPs and their 
cargo. Various CPPs including peptides derived from TAT 37, penetratin, 38, transportan 39 and 
polyarginine peptides 40 have been covalently attached to viral and nonviral gene and 41-43 shown 
to increase transfection and biological effects 44.  
Approaches for forming conjugates include mainly thioester or disulfide bonds 45. 
Muratovska and Eccles investigated the transfection efficiency of different CPPs (e.g., penetratin) 
conjugated to siRNA via disulfide bonds and reported that these CPP–siRNAs efficiently reduced 
transient and stable expression of reporter transgenes in different cell types equivalent or better 
than cationic liposomes. Disulfide bonds were said to increase CPP affinity for genetic material 
(e.g., DNA or RNA) by the ‘chelate effect’, which increases the complex stability and reduces 
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cytotoxicity by rapid degradation in the cytoplasmic space 46, 47. Other studies have observed that 
cysteine residues added onto CPPs can have a significant impact on delivery. One study, for 
example, demonstrated that the introduction of a single cysteine residue on the C-terminal of 
various CPPs (e.g., TAT and transportan) resulted in formation of peptide dimers that greatly 
enhanced the transfection efficiency of DNA in HEK293T cells 48. 
 
Figure 2. Approaches to forming viral and nonviral vector complexes. Formation of (A) covalently 





Cargos without thiol groups or disulfide bonds can be altered by chemical synthesis and/or 
recombinant techniques. One example is a study where two types of CPP–oligonucleotide 
conjugates were prepared in order to improve the transfection efficiency. Unexpectedly, the CPP–
oligonucleotide conjugates were more effective in the presence of serum than when used with 
serum-free medium, which is in notable contrast to most other approaches to gene delivery 49. The 
development of CPP-conjugated cargo necessitates careful assessment to determine if there is a 
therapeutic benefit gained by conjugation 24. 
The second strategy of using CPPs foregoes the formation of chemical bonds and simply 
complexes CPPs or CPP-containing molecules with cargo via electrostatic interactions. MPG 50, 
51, Pep-1 52 and TAT 53 were among the first CPPs used following this method for complex 
formation and gene delivery 54. This strategy has recently been extended to other CPPs, such as 
polyarginine 55. CPP complexation with genetic material originally devised to facilitate exploration 
of numerous peptides that may condense nucleic acids or favor endosomal escape 24. 
1.4. Motivation for Using Noncovalently Associated CPPs 
Both viral and nonviral vectors suffer from drawbacks that hinder the advancement of gene 
therapy beyond the clinical trial stages, and there is much emphasis on design of improved vectors 
56. CPPs provide an additional strategy for improving existing vectors. Such improvements include 
enhanced transfection efficiency, increased cargo capacity, low cytotoxicity and reduced 
immunogenicity 2. While there is the potential for significant enhancement of existing vectors, 
there are also some drawbacks associated with CPPs and the methods by which they are associated 
with the genetic cargo. For example, one shortcoming of CPPs is their general lack of specificity 
57, 58. A second drawback is associated with the covalent attachment of CPPs. While covalently 
bound CPPs form well-defined chemical entities that are more likely to be approved for clinical 
9 
 
use than less defined nanoparticles formed through electrostatics, the chemical linking of CPPs to 
the cargo has been reported to lead to loss of biological activity in some cases. For example, one 
study found that chemical conjugation of CPPs to methotrexate improved the intracellular 
concentration of the drug but reduced its potency by 20-fold compared with the unconjugated drug 
59. 
Covalent conjugation of cationic CPPs has been observed to enhance cellular uptake by 
engaging the cell surface 60, but many have asserted that the covalent bond between CPP and vector 
must be reversible inside the cellular environment for desired cytoplasmic and nuclear localization 
61. Since conjugation of cargo with CPPs may affect nuclear localization and lead to loss of 
biological activity, an attractive approach is to develop linker strategies that will enable genetic 
material to be cleaved from CPPs as soon as the vector reaches the cytoplasm 24. The linker 
chemistry, however, becomes more difficult and complicated when dealing with CPPs and nucleic 
acids or viruses, since several functional components are represented. In addition, the CPP-
conjugated vector should be easy to produce and cost-effective to manufacture in order to develop 
this strategy at an industrial scale for clinical applications 56. Furthermore, as mentioned earlier, 
the risk of diminishing the biological activity of the cargo may limit the benefit of this strategy. 
Although chemical conjugation of CPPs appears promising, several concerns and questions are 
still under investigation 62. 
Strategies that do not rely on chemical conjugation of CPPs also offer promise for 
developing gene vectors 1. This method is advantageous because it usually employs simple mixing 
of the two components, thus eliminating the need to imbue reactive sites or optimize synthetic 
schemes. The dense positive charge of CPPs assists with electrostatic packaging of the negatively 
charged genetic material and often yields a positively charged particle 63-65. This strategy is often 
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favored over chemical reactions when exploring gene therapy in preclinical studies 1. In addition, 
the use of cationic or amphipathic CPPs to form complexes with nucleic acids was found to 
improve the transfection efficiency and nuclear uptake of siRNA within non-dividing cells 64, 65. 
The following sections review some current applications of noncovalently associated CPPs for 
improving viral and nonviral gene delivery. Table 1 contains a list of classical CPPs that have 




















Table 1. Current applications of noncovalent strategies of classical cell penetrating peptides. 































































1.5. Current Applications Using the Noncovalent Strategy for Nonviral Gene Delivery 
1.5.1. CPP-Enhanced Nonviral Gene Delivery 
The inefficiency of nonviral vectors is due mainly to difficulty overcoming barriers 
between the administration site and the nucleus of the target cells. Examples of barriers include 
the physico-chemical stability of the genetic material and its delivery vehicle in the extracellular 
space; efficient cellular uptake, which may depend on the size of the complex; escape from the 
endosomal network before degradation within lysosomes; and genetic material unpackaging and 
entry into the nucleus (Figure 3). Overcoming these barriers is one of the greatest challenge for 
efficacious nonviral gene delivery 3. Because of the ability of CPPs to transport cargo across the 
cell membrane, these peptides are an attractive option for helping nonviral particle overcome some 
of the barriers to gene delivery. A common approach for complexing CPPs to the nonviral vector 
is simple electrostatic formation of a complex between cationic CPPs and anionic nucleic acids. 
One example of how useful CPPs can be is the incorporation of CPPs in a PLL–siRNA polyplex 
44. The investigators in this study used a PLL, modified to bind to CPPs, to first form an 
electrostatic complex with siRNA. The resulting polyplex was subsequently bound by CPPs to 
produce a CPP–PLL–siRNA polyplex. The investigators reported high transfection efficiency, but 
also emphasized the importance of the siRNA being released from the polyplex in order to 
function. While activity is not adversely affected as it may be when CPPs are chemically 
conjugated directly to the genetic material 66, unpackaging remains a concern with vectors formed 
through noncovalently bound CPPs. Additional studies have established various applications of 
electrostatic complexes by using diverse CPPs and conditions. The following section discusses 




















Figure 3. Barriers to nonviral gene delivery. (A) The physiochemical stability of nonviral 
complexes in the extracellular space. (B) Cellular uptake. (C) Escape from the endosome. (D) 
Genetic material unpackaging and entry into the nucleus. 
 
1.5.2. Genetic Material Condensation with CPPs  
Cationic CPPs interact with the negatively charged phosphate backbone of genetic material 
(e.g., pDNA and siRNA) through electrostatic interaction 63, 67. This process can result in genetic 
material condensation and protection from nuclease enzyme digestion 68. If carried out properly, 
this approach leads to small nano-particles with a net positive charge that are capable of interaction 
with moieties such as heparan sulfate proteoglycans on cell surfaces 69, 70. 
PLL, a well-known nonviral DNA condensing agent used to mediate gene delivery, was 
one of the first cationic peptides studied. There is some toxicity associated with PLL, however, 
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and as with many polycations, the cytotoxicity increases as the molecular weight of the PLL 
increases. One group investigating the structure property relationships of PLL describe the in 
vitro cytotoxicity of PLL-based cations and demonstrated that both molecular weight and 
architecture were important factors 71. Another group studied a library of 13 PLL–graft–
imidazoleacetic acid conjugates to examine the collective effects of polymer molecular weight, 
DNA:polymer ratio, and side chain change on DNA/polycation interaction, transfection efficiency, 
and cytotoxicity. They found that the in vitro cytotoxicity of the polymers increased while total 
protein expression decreased, with increasing molecular weight 72. 
While higher molecular-weight PLL possesses greater toxicity, it is able to bind DNA 
tighter and form more stable complexes than low-molecular-weight PLL due to the greater 
abundance and density of positive charges 73. Numerous scientists have turned to the development 
of homogenous PLL-containing peptides due to the lack of chemical control and poly-dispersity 
of PLL 74, 75. In order to determine the optimal lysine chain length for DNA condensation and 
transfection efficiency, a group of researchers systematically studied different lengths of the 
cationic peptide Cys-Trp-Lysn three to 36 lysine residues. Shorter peptides of eight or fewer lysine 
residues formed large particles due to weakly bound DNA, while peptides containing 13 or more 
lysine residues were able to strongly bind DNA and form small particles (from 50 to 200 nm) 76. 
Another study reported that peptides containing 18 lysine residues could condense and protect 
DNA from degradation, while a short peptide containing less than eight residues could not prevent 
DNA degradation 77. 
The chemical nature of cationic residues has been found to influence cellular uptake 78-80. 
Arginine tends to mediate cell uptake better than ornithine or lysine and at least six to eight cationic 
residues were reported to be the minimum number required for DNA condensation 80. Studies 
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demonstrated that when lysine residues were replaced with arginine residues in a penetratin 
variant, the modified penetratin had better cellular uptake than itself 81, 82. Arginine-rich CPPs have 
also been reported to be more efficient than lysine-rich CPPs 82, 83. In fact, polyarginine peptides 
have been demonstrated to play an important role in cytosol-to-nucleus transport and nuclear 
localization of plasmid DNA (Figure 4) 84, 85.  
The polyarginine peptides used by Kim et al. demonstrated significant co-localization of 
CPP and DNA near the nucleus, with some material located within the nucleus. Although, the 
majority of the complexes appears to have remained outside the nucleus in a perinuclear 
compartment. Location of the complexes near the nucleus will undoubtedly improve gene delivery 
to the nucleus, but the limited nuclear entry indicates the additional need for some type of active 
transport into the nucleus, such as an addition of a nuclear localization signal (NLS). 
 
 
Figure 4. Arginine peptide-improved transportation of DNA around and into the nucleus in live 
cells. The cells were treated with FITC-labeled arginine peptide/rhodamine-labeled DNA 
complexes and imaged using confocal microscopy. (A) Rhodamine-labeled DNA (red); (B) FITC-
labeled arginine peptide (green); (C) differential interference contrast; and (D) a merge of A, B, 






Polyarginine peptides have a strong tendency to electrostatically interact with both siRNA 
86, 87 and with DNA67. One study indicated that as with PLL and other polycations, the length of 
polyarginine may affect transfection efficiency and cytotoxicity. A minimum chain length of six 
to ten amino acids is needed for delivery of genetic material, which is enough to condense DNA 
into stable complexes. With polyarginine 9, only four to five arginine residues were thought to be 
involved in forming the complexes with genetic material, while the extra arginine residues were 
available for interaction with the cell membrane. Furthermore, they have considered the possibility 
that genetic material may not be released from the complexes when the cationic CPPs bind too 
strongly with the negatively charged genetic material 47. 
The size of polyarginines has been explored by several groups. One group studied the 
transfection efficiency of different polyarginine peptides (arginine 9, 12 and 16), which was found 
to increase when the molecular weight increased 67. Another group examined the transfection 
efficiency of different polyarginine molecular weights complexed with pDNA. They found that 
the high-molecular-weight polyarginines (41 and 83 kDa) demonstrated 100-times higher 
transfection efficiency (RLU/ug protein) than the lower molecular-weight polyarginine 
approximately (10 kDa) 88. 
In addition to molecular weight and residue charge, peptide hydrophobicity has also been 
studied. One study examined the effects of introducing a hydrophobic group onto CPPs such as 
TAT and polyarginine. They found that N-terminal stearylation of these CPPs increased the 
transfection efficiency by approximately 100-fold to reach the same order of magnitude as that of 
Lipofectamine 2000™ (Invitrogen, Paisley, UK). They suggested that the hydrophobic moieties 
contributed to absorption of the complexes on the surface of cell membrane thereby destabilizing 
the membrane. This explanation provides a possible understanding for the high transfection 
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efficiency of theses complexes 89. Another study tested the hypothesis that hydrophobically 
modified CPPs, cholesteryl polyarginine 9, may stabilize and improve tumor regression efficacy 
of the VEGF targeting siRNA. They indicated that this nonconjugate complexation of the siRNA 
with cholesteryl polyarginine 9 efficiently transfected siRNA into cells in vitro. Polyarginine 
peptide offers efficient siRNA packaging and cell membrane interaction. The cholesterol moiety 
was able to engage the hydrophobic residues of the extracellular cell surface, which enhanced the 
transfection efficiency of the complexes 87. 
Furthermore, calcium chloride was used as a condensing agent for large CPP complexes 
with DNA or RNA. The transfection of different CPPs (e.g., arginine 7 and TAT) complexed with 
siRNA or pDNA was practically nil; however, the addition of calcium chloride decreased the large 
size of these complexes through ‘soft’ cross-links. Adding calcium chloride to the CPP complexes 
led to an increase in transfection efficiency 62, 90. In another report, arginine-rich CPPs (PR9, SR9 
and HR9) were used to deliver genetic material into target cells. The researchers proposed that 
calcium condensed CPPs/DNA complexes into small particles and that including calcium chloride 



























Figure 5. Cell penetrating peptide-mediated delivery of Cy3-labeled DNA into cells. Cells were 
treated with: (A) phosphate-buffered saline as a negative control; (B) Cy3-labeled DNA only; (C) 
peptide HR9 only; (D) SR9/Cy3-labeled DNA; (E) HR9/Cy3-labeled DNA; or (F) PR9/Cy3-
labeled DNA. The fluorescent microscopy indicates the location of Cy3-labeled DNA inside cells. 
CPP: Cell penetrating peptide. 
 
1.5.3. Endosomolytic and Fusogenic CPPs 
One of the major limitations in the delivery of genetic material using CPPs complexes is 
the entrapment of the complexes within endosomal vesicles. In order to avoid this problem and 
enhance the transfection efficiency, an endosomolytic agent, such as chloroquine, may be used, 
but, unfortunately, this is not feasible for in vivo gene delivery 62. Endosomolytic CPPs can be 
used to overcome this obstacle as they are able to enhance gene delivery by inducing release from 
endosomes. Several peptides with high charge density were surmised to act as a ‘proton sponge’ 
and become endosomolytic at the acidic environment of the endosome. These peptides can either 
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fuse with the endosomal membrane leading to pore formation or act as a ‘proton sponge’ causing 
lysis 68, 91-93. In order to apply the lysis activity to CPPs, histidine residues were added to CPP 
sequences. The imidazole group of histidine (pKa approximately 6.0) can remain neutrally charged 
at physiological pH. Then, it can become protonated in the acidic environment of the endosome, 
thus, imparting selective membrane disruption 68. Histidine residues have been inserted into PLL 
in order to enhance the transfection efficiency of noncovalent complexes 94. A published study 
offered a comparative analysis of the ability of various CPPs (e.g., MPG and penetratin) to 
complex siRNA molecules and induces efficient cellular internalization 95. Other investigators 
studied the gene expression of three arginine-rich CPPs (SR9, PR9 and HR9). Researchers 
indicated that HR9 was superior, possibly because of the histidine facilitated DNA endosomal 
escape 46. Another group indicated that efficient endosomolytic peptides, such as EB1, can be 
applied to enhance the ability of CPP/siRNA complexes to effectively deliver siRNA across the 
endosomal membrane 95. 
Fusogenic CPPs are short peptides with the potential to promote membrane destabilization, 
endosomal escape and delivery of genetic material to the cytosol and/or nucleus. Numerous 
fusogenic CPPs are derived from different proteins that interact with cell membranes such as TAT, 
transportan, and melittin. Fusogenic CPPs have hydrophilic and hydrophobic domains resulting in 
helical structures of the CPPs at endosomal pH, which can interact with the endosomal membrane 
to cause pore formation 96. A group of researchers used short peptides derived from the influenza 
virus hemagglutinin HA-2 and found that DNA polyplexes containing the influenza peptide as a 
fusogenic peptide conjugated to PLL could mediate significant gene expression when compared 
with complexes without the fusogenic peptide 93. Melittin has been developed into gene delivery 
CPPs that can condense DNA97. GALA is the synthetic fusogenic CPP that has a repeating unit of 
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glutamic acid-alanine-leucine-alanine that gives melittin an amphipathic character. GALA can 
bind to bilayer membranes and induce leakage. Although GALA has fusogenic activity, it cannot 
bind and condense DNA for effective transfection due to the negative charge of this peptide. In 
order to increase the DNA condensation and transfection efficiency of GALA, some alanine 
residues have been substituted with lysine residues and glutamic acid was reduced, yielding the 
cationic KALA peptide. DNA complexes prepared with KALA were able to effectively transfect 
different cell lines98. 
1.5.4. Nuclear Localization CPPs  
The passage of pDNA from the cytoplasm into the nucleus is one of the main barriers to 
nonviral gene delivery. The nuclear membrane of human cells is permeable to particles of up to 
approximately 9 nm. Transfer of large molecules such as pDNA through nuclear pore complexes 
is signal-mediated and energy dependent 99. NLS peptides mediate the transport of pDNA or RNA 
from the cytoplasm into the nucleus through nuclear pore complexes 100. The highly positively 
charged NLS peptides can efficiently interact with the negatively charged pDNA. There is a 
possibility that the NLS peptides dissociate from the pDNA before reaching the nucleus. In order 
to enhance the nuclear targeting of complexes, another condensation agent or CPPs may be added 
96. NLS of SV40 large T-antigen is the most common nuclear localization peptide that has been 
used 101 for efficiently transferring pDNA from cytoplasm to nucleus by forming noncovalent 
complexes with pDNA 102. Another NLS peptide noncovalently complexed with pDNA is the M9 
peptide, which was also complexed with SV40 large T-antigen to enhance ionic interaction with 
pDNA and increase gene expression 103. TAT, another NLS peptide, has been demonstrated to 
mediate the import of diverse cargos into the cell nucleus, including dye-labeled streptavidin 
protein and quantum dots for kinetic measurement. One study reported that TAT peptide could 
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import 90 nm beads into the cell nucleus, suggesting that its interaction with the nuclear envelope 
follows a mechanism different from that of other NLS 104. 
1.5.5. Noncovalently Associated CPPs for Targeted Delivery 
Targeted gene delivery seeks to differentiate between healthy cells and diseased cells. The 
specificity for a target site is one of the main challenges that belie the efficiency of noncovalent 
gene complexes 105. The first example of this approach was done by a group of scientists who fused 
a short peptide derived from RVG to RVG-9R, and then complexed RVG-9R with siRNA to 
specifically target neuronal cells 55. Additionally, gene vectors that bind integrin with the help of 
peptide ligands have been used in the improvement of targeted vectors. Integrins are cell receptors, 
which have many roles such as cell migration, signal transduction, and cell to cell interactions. 
Integrin-binding peptides commonly have short sequences of amino acids and can bind a 
widespread variety of the receptors or be specific for a single peptide 106. A group used the lectin-
like oxidized LDL receptor as a target receptor. They sequenced and identified 60 innovative 
peptides, which will be beneficial for the selective target of gene transfer vectors to endothelial 
cells expressing the lectinlike oxidized LDL receptor and in particular dysfunctional endothelial 
cells associated with atherosclerosis and hypertension 107. Lastly, a study observed differential 
transfection of cells overexpressing ICAM-1 when treated with a TAT–PEG–LABL peptide 
complexed with pDNA and condensed with calcium chloride. The results demonstrated the 






1.6. Thesis Overview 
This thesis work aimed to identify safe, and effective nonviral gene vectors. Short cationic 
cell penetrating peptides (CPPs) have been explored as carriers for gene delivery. In chapter 2, 
complexes of low-molecular-weight polyarginine and pDNA were condensed with calcium. These 
complexes showed high transfection efficiency and low cytotoxicity in A549 carcinomic human 
alveolar basal epithelial cells. The relationships between transfection efficiency and polyarginine 
size (5, 7, 9, or 11 amino acids), polyarginine/pDNA charge ratios, and calcium concentrations 
were studied. Polyarginine 7 was significantly more effective than other polyarginines under most 
formulation conditions, suggesting a link between cell penetration ability and transfection 
efficiency. 
In chapter 3, a synthetic CPP (polylysine, K9 peptide) was complexed with angiotensin II 
type 2 receptor (AT2R) plasmid DNA (pAT2R) and complexes were condensed using calcium 
chloride. The resulting complexes were small (~150 nm) and showed high levels of gene 
expression in vitro and in vivo. This simple nonviral formulation approach showed negligible 
cytotoxicity in four different human cell lines (cervix, breast, kidney, and lung cell lines) and one 
mouse cell line (a lung cancer cell line). In addition, this K9-pDNA-Ca2+ complex demonstrated 
cancer-targeted gene delivery when administered via intravenous injection or intratracheal spray. 
The transfection efficiency was evaluated in Lewis lung carcinoma (LLC) cell lines cultured in 
vitro and in orthotopic cancer grafts in syngeneic mice. Immunohistochemical analysis confirmed 
that the complex effectively delivered pAT2R to the cancer cells, where it was expressed mainly 
in cancer cells along with bronchial epithelial cells. A single administration of these complexes 
markedly attenuated lung cancer growth, offering preclinical proof-of-concept for a novel nonviral 
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gene delivery method exhibiting effective lung tumor gene therapy via either intravenous or 
intratracheal administration.  
In chapter 4, when designing synthetic CPPs for drug delivery applications, it is important 
to understand their ability to penetrate the cell membrane. Anionic or zwitterionic phospholipid 
monolayers at the air−water interface are used as model cell membranes to monitor the membrane 
insertion potential of synthetic CPPs. The insertion potential of CPPs (five hydrophilic CPPs 
[dTAT, R9, L9, H9, and RH9] and three amphiphilic CPPs [RA9, RL9, and RW9]) having 
different cationic and hydrophobic amino acids were recorded using a Langmuir monolayer 
approach that records peptide adsorption to model membranes. Fluorescence microscopy was used 
to visualize alterations in phospholipid packing due to peptide insertion. All CPPs had the highest 
penetration potential in the presence of anionic phospholipids. In addition, two of three 
amphiphilic CPPs penetrated into zwitterionic phospholipids, but none of the hydrophilic CPPs 
did. All the CPPs studied induced disruptions in phospholipid packing and domain morphology, 
which were most pronounced for amphiphilic CPPs. Overall, small changes to amino acids and 
peptide sequences resulted in dramatically different insertion potentials and membrane 
reorganization. Designers of synthetic CPPs for efficient intracellular drug delivery should 
consider small nuances in CPP electrostatic and hydrophobic properties. 
In chapter 5, we show that calcium condensed gene complexes containing different 
hydrophilic (i.e., dTAT, K9, R9, and RH9) and amphiphilic (i.e., RA9, RL9, and RW9) CPPs 
formed stable cationic complexes of hydrodynamic radii 100 nm at neutral pH. However, 
increasing the acidity caused the complexes to become neutral or anionic and increase in size. 
Using zwitterionic and anionic phospholipid monolayers as models that mimic the membrane 
composition of the outer leaflet of cell membranes and intracellular vesicles, and pHs that mimic 
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the intracellular environment, we study the membrane insertion potential of these seven gene 
complexes (CPP-pDNA-Ca2+ complexes) into model membranes. At neutral pH, all gene 
complexes demonstrated the highest insertion potential into anionic phospholipid membranes, 
with complexes containing amphiphilic peptides showing the maximum insertion. However, at 
acidic pH, the gene complexes demonstrated maximum monolayer insertion into zwitterionic 
lipids, irrespective of the chemical composition of the CPP in the complexes. Our results suggest 
that in the neutral environment, the complexes are unable to penetrate the zwitterionic lipid 
membranes, but can penetrate through the anionic lipid membranes. However, the acidic pH 
mimicking the local environment in the late endosomes leads to a significant increase in adsorption 
of the complexes to zwitterionic lipid headgroups, and decreases for anionic headgroups. These 
membrane-gene complex interactions may be responsible for the ability of the complexes to 
efficiently enter the intracellular environment through endocytosis and escape from the endosomes 
to effectively deliver their genetic payload. 
Finally, in chapter 6, small changes in CPP charge type, charge spacing, and 
hydrophobicity were studied by using five arginine-rich CPPs: the well-known hydrophilic 
polyarginine R9 peptide, a hydrophilic RH9 peptide, and three amphiphilic peptides (RA9, RL9, 
and RW9) with charge distributions that favor membrane penetration. Condensing these CPP-
pDNA complexes via addition of calcium chloride produces small and stable nanoparticles with 
high levels of gene expression. This simple formulation offered high transfection efficiency and 
negligible cytotoxicity in HEK-293 (a virus-immortalized kidney cell) and A549 (a human lung 
cancer cell line). R9 and RW9 complexes were significantly more effective than the other CPPs 
under most formulation conditions. However, these CPPs exhibit large differences in membrane 
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penetration potential. Maximum transfection resulted from an appropriate balance of complexing 
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Many studies have shown that nucleic acids complex electrostatically with polycations to 
form polyplexes. Unfortunately, the most effective polycations are often the most toxic. 
Polyethylenimine (PEI), polylysine and similar polycations can mediate high levels of gene 
expression, but high-molecular-weight polycations are often required to effectively condense the 
DNA to small particles 1-10. The needed increase in molecular weight; however, often increases 
cytotoxicity 2, 11-13. Cytotoxicity of polycations may be minimized by different approaches such as 
conjugation with hydrophilic or degradable polymers (e.g. hydroxypropyl methacrylamide 
(HPMA) or polyethylene glycol (PEG)) 11, 14-16. A simple alterative is to identify ways to form 
small polyplexes using less cytotoxic polycations such as cell penetrating peptides (CPPs) 1, 17-19. 
CPPs are short sequences of amino acids characterized by their cationic or amphipathic 
nature that aid cellular uptake of different molecular cargo 1, 20-23. Two general methods have been 
examined for CPP-mediated gene delivery, which are chemical conjugation of CPPs with nucleic 
acids or complexation 11, 24-27. The negative charge of genetic material (e.g. DNA or siRNA) and 
the positive charge of CPPs can impede direct conjugation. On the other hand, genetic material 
can be electrostatically bound and neutralized when complexed with CPPs 1, 11, 28. 
The most commonly known CPPs are human immunodeficiency virus-1 (HIV-1) 
transcriptional activator (TAT) protein, and the herpes simplex virus structural protein VP22. 
Sequence similarities between TAT, and VP22 indicate the importance of basic amino acids, such 
as arginine or lysine. Short peptides containing only arginine have the ability to translocate through 
cell membranes 1, 9, 24, 29-33. Furthermore, polymers or CPPs with some of their residues altered 
with arginine or the guanidine group displayed highly enhanced transfection efficiency 32, 34.  
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The size, charge, and molecular weight of CPPs (e.g. polyarginine) play important roles in 
condensing DNA for delivering genetic material to target cells 35. CPPs containing cationic amino 
acids such as lysine or arginine were found to complex genetic material efficiently 36-38. CPPs rich 
with arginine also tended to possess high transfection efficiency 39-42. Often, polyarginine peptides 
delivered genetic material into cells more efficiently than other homopolymer peptides (e.g. 
polylysine and polyhistidine) of equal length. A study also determined the uptake of different 
polyarginine lengths (e.g. R3, R6, R9, R15 and R30) and found that simply increasing the length 
of polyarginine did not necessarily increase the uptake. Polyarginines between R7 and R20 
maximized uptake by cells 41, 43, 44. Other groups studied the translocation of different polyarginine 
lengths (R4, R6, R8, R10, R12 and R16) and found that the R8 peptide maximized cellular uptake, 
while others found R6 to R9 translocated optimally through the cell membrane. An analogous 
result occurred using polyarginines to mediate protein delivery 30, 41, 44. Thus, polyarginine size is 
essential for membrane permeability.  
Some reports have suggested that-low molecular-weight polyarginine peptides are able to 
form complexes with DNA and promote transfection in different mammalian cell types 32, 45-47. 
Although reports suggest low-molecular-weight polyarginine-pDNA complexes may achieve 
modest transfection with negligible cytotoxicity, the large particle size (microparticles) is a 
limitation 32. Indeed, high-molecular-weight polycations often have the ability to condense DNA 
into small and stable complexes while low-molecular-weight polycations often yield large and 
unstable complexes 32, 47-49. A major shortcoming with high-molecular-weight polyarginines is 




Calcium phosphate precipitation is a well-established approach to DNA condensation and 
gene delivery. Numerous in vitro studies demonstrated that the transfection efficiency of DNA 
increased when formulated as a calcium phosphate-DNA co-precipitate. Other studies found that 
calcium chloride has a positive effect on the transfection efficiency of plasmid DNA (pDNA)-
cationic liposome complexes 1, 50-53. Still other studies showed that calcium might increase the 
endocytosis rate or accelerate endosomal release before degradation by lysosomes 54, 55. While the 
effect of calcium on transfection is unclear, these studies encouraged exploration of calcium with 
complexes formed using CPPs, such as polyarginine. Consequently, calcium was found to 
condense these large complexes and increase the positive charge, which dramatically enhanced 
transfection 1, 11, 56. In fact, titrating calcium can directly affect complex size and stability. Also, 
released polyarginines may maintain CPP properties since they are not chemically conjugated 
using this approach.  
Thus, the delivery of polyarginine-pDNA complexes condensed with calcium chloride may 
offer a safe nonviral gene delivery technique with potential for clinical application.1 This simple 
formulation (polyarginine-pDNA-Ca2+) maintained the viability of A549 lung cancer epithelial 
cells while achieving high transfection efficiency. This method also yields a small and stable 
particle size and is suitable for delivering large amounts of genetic material. In order to determine 
the importance of polyarginine molecular weight, in vitro transfection efficiency studies were 
conducted using different polyarginines (R5, R7, R9, and R11) (Table 1), and different calcium 




    Table 1: Sequence and size of polyarginine 5, 7, 9 and 11. 
 
2.2. Materials and Methods 
2.2.1. Materials  
Plasmid DNA (pDNA) encoding firefly luciferase (pGL3, 4818 bp) was obtained from Promega 
(Madison, Wisconsin). The pDNA purity level was determined by UV-Spectroscopy and agarose 
gel electrophoresis. Polyarginine (polyarginine 5, 7, 9 and 11) were purchased from Biomatik 
(Cambridge, Ontario, Canada). Branched polyethylenimine (PEI, 25 kDa) was obtained from 
Sigma-Aldrich (Milwaukee, Wisconsin). A549 carcinomic human alveolar basal epithelial cell 
line was obtained from American Type Culture Collection (ATCC; Rockville, Maryland). The cell 
culture medium (F-12K Nutrient Mixture, Kaighn's modified with L-glutamine) was purchased 
through Cellgro (Mediatech, Inc., Manassas, VA). Fetal bovine serum (FBS) was purchased from 
Hyclone (Logan, UT). Penicillin-streptomycin was purchased from MB Biomedical, LLC (Solon, 
OH). Trypsin-EDTA was purchased from Invitrogen (Carlsbad, CA). Luciferase Assay System 
Freezer Pack and CellTiter 96® AQueous one solution cell proliferation assay (MTS) were 
obtained from Promega (Madison, Wisconsin). BCA Protein Assay Reagent (bicinchoninic acid) 
was purchased from Thermo Fisher Scientific Inc. Tris-acetate-EDTA (TAE) Buffer (10 x) was 
purchased from Promega (Madison, Wisconsin). Sterile water (DNase, RNase free) was purchased 
from Fisher Scientific. Calcium chloride dihdrate (CaCl2. 2H2O) was purchased from Fisher 
Polyarginine Sequence Molecular Weight (Da) 
5 RRRRR 797.97 
7 RRRRRRR 1110.35 
9 RRRRRRRRR 1422.73 
11 RRRRRRRRRRR 1735.11 
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Scientific. Agarose (Medium-EEO/Protein Electrophorisis Grade) was purchased from Fisher 
Scientific. Bench Top DNA Ladder was purchased from Promega (Madison, WI). SYBR Green I 
Nucleic Acid Gel Stain was obtained from Invitrogen (Carlsbad, CA).  
2.2.2. Preparation of Polyarginine-pDNA-Ca2+ Complexes 
Polyarginine-pDNA complexes were prepared by adding 15 µL of polyarginine solution (different 
polymer nitrogen to pDNA phosphate (N/P) ratios) to 10 µL (0.1 µg/µL) of pDNA (TAE Buffer 
(1 x) was used as a solution for DNA storage), followed by fast pipetting for 20 seconds. At that 
point, 15 µL of identified molarity (e.g., 50, 300, and 600 mM) CaCl2 was added and mixed by 
fast pipetting. After preparing the complexes, they were stored at 4°C for 20-25 minutes.  
2.2.3. Preparation of PEI-pDNA Complexes 
PEI-pDNA complexes were prepared by adding 15 µL of PEI solution (N/P ratio 10) to 10 µL (0.1 
µg/µL) of pDNA followed by fast pipetting for 20 seconds. After preparing the complexes, they 
were stored at 4°C for 20-25 minutes. Complexes were prepared immediately before each 
experiment. 
2.2.4. Agarose Gel Electrophoresis 
Complexes were prepared as defined previously and subsequently 4 µL of Tris-acetate-EDTA 
(TAE) buffer was added. Then, 4 µL of SYBR Green 1 was mixed with the complexes. Afterwards, 
the mixture was stored at 4°C for 20 to 25 minutes. After the storage, 7 µL of 6X DNA Loading 
Dye was added. A one kb DNA ladder was used. The mixture solutions were loaded onto a 1 % 






2.2.5. Size and Zeta Potential 
The particle size (effective diameter (nm)) of polyarginine-pDNA complexes with or without 
calcium chloride was determined by dynamic light scattering (Brookhaven Instruments, Holtsville, 
NY). The zeta potentials of the complexes were measured by Zeta PALS dynamic light scattering 
(Brookhaven Instrument, Holtsville, NY). All samples intended for particle size and zeta potential 
measurements were prepared using 10 mM Tris buffer, pH 7.4. 
2.2.6. Cell Culture 
A549 carcinomic human alveolar basal epithelial cells were grown in F-12K Nutrient Mixture 
media (Kaighn's modified with L-glutamine) with 1% (v/v) Penicillin-streptomycin and 10% (v/v) 
fetal bovine serum (FBS) at 37°C in 5% CO2 humidified air. 
2.2.7. Transfection Studies 
A549 cells were cultured in 96-well plates for 24 hours prior to transfection. The concentration of 
the cells in every well was approximately 80,000 cells/mL. The wells were washed once with 
serum-free media (SFM) and afterwards a 100 µL sample (which consisted of 20 µL of complex 
and 80 µL of SFM) was added to each well. Subsequently, a 96-well plate was incubated for 5 
hours in an incubator. After 5 hours incubation, the sample was replaced with 100 µL of fresh 
serum medium and then incubated again for approximately 48 hours. In order to determine the 
gene expression of the complexes, the Luciferase Reporter Assay from Promega was used. The 
results of the transfections were expressed as Relative Light Units (RLU) per milligram (mg) of 
cellular protein, and PEI-pDNA was used as a control. BCA Protein Assay Reagent (bicinchoninic 
acid) was used to measure total cellular protein concentration in the cell extracts. The Luciferase 




2.2.8. Cytotoxicity Assay of Polyarginine 
Cytotoxicity of polyarginines was determined using a CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay (MTS) obtained from Promega (Madison, Wisconsin). A549 cells were 
cultured in a 96-well plate as described previously. After 24 hours of incubation, the media were 
replaced with a sample consisting of 100 µL of fresh serum medium and 20 µL of MTS. Then, the 
plate was incubated for 3 hours. In order to determine cell viability, the absorbance of each well 
was measured by a microplate reader (SpectraMax; Molecular Devices Crope, CA) at 490 nm and 
normalized to untreated control cells. 
2.2.9. Optical Microscopy 
Cells were cultured, grown and incubated as mentioned above. Then, the complexes were added 
and cells were incubated again for 5 hours and 48 hours. Data were obtained using a Zeiss Axiovert 
100 Microscope (Axiocam HRM). 
2.2.10. Statistical Analysis 
Data were analyzed by using GraphPad software. Statistical evaluation comparing the significance 
of the difference in gene expression (RLUs/mg protein) between the means of two data sets was 
performed using an unpaired t test. One-way ANOVA, Tukey post-test was used to analyze the 









2.3. Results and Discussion  
Agarose gel electrophoresis studies indicated that the complexes without calcium were 
robust enough to immobilize DNA when complexed with polyarginine 7, 9 and 11. DNA 
complexes with polyarginine 5 were less stable without calcium than with calcium (Figure 1). The 
ability of the four distinct molecular weights of polyarginine to form complexes with pDNA was 
also studied using agarose gel electrophoresis at N/P ratios of 5, 10, 20, 30, 40, and 60. 
Polyarginines 5, 7, 9 and 11 were complexed with pDNA at these different N/P ratios and then 
condensed with calcium chloride (300 mM) (Figure 2). The immobilization of pDNA indicated 
that different polyarginine peptides could form complexes with pDNA even with the lowest N/P 













Figure 1. Agarose gels of polyarginine-pDNA complexes with and without CaCl2 (300 mM) at 
N/P ratios of 5, 10, 20, 30, 40, and 60. (A) Polyarginine 5-pDNA complexes without CaCl2 and 
(B) with CaCl2. (C) Polyarginine 7-pDNA complexes without CaCl2 and (D) with CaCl2. “C” 




















Figure 2. Agarose gels of polyarginine-pDNA complexes condensed with CaCl2 (300 mM) at N/P 
ratios of 5, 10, 20, 30, 40, and 60. (A) Polyarginine 5-pDNA-Ca2+ complexes, (B) polyarginine 7-
pDNA-Ca2+ complexes, (C) polyarginine 9-pDNA-Ca2+ complexes, and (D) polyarginine 11-
pDNA-Ca2+ complexes. “C” refers to control (pDNA). “M” Refers to the size marker. 
 
An important characteristic of the polyarginine-pDNA-Ca2+ complex is the size.  A broad 
study of the relationship between the calcium concentration (150, 300, and 600 mM) and the 
particle size was conducted. The particle sizes of polyarginine 5, 7, 9 and 11 complexed with 
pDNA as a function of calcium chloride concentration (Figure 3A and B). The polyarginine-
pDNA complexes generally showed a decrease in particle size as calcium concentration increased, 
whereas the complexes without calcium showed a large particle size. The total positive charge of 
complexes also plays an important role in transfection efficiency and can increase the attractive 
force to the negative charge of the cell surface. Overall, the zeta potential of polyarginine of 5, 7, 
9 and 11-pDNA complexes increased considerably with increasing concentrations of calcium 
chloride. For example, the zeta potential of polyarginine 7-pDNA complexes increased 
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significantly from less than 5 to more than 20 mV with increasing concentration of calcium 
chloride (Figure 3C). Clearly, PEI-pDNA complexes had the highest positive zeta potential. The 

















Figure 3. The effect of different calcium chloride concentrations on the particle size at (A) N/P 
ratio 5 and (B) N/P ratio 10 and zeta potential at (C) N/P ratio 10 of PEI-pDNA complexes and 
polyarginine 5, 7, 9 and 11-pDNA complexes.Results are presented as mean ± SD (n = 3). 
 
The cellular uptake of free polyarginine was previously reported to be proportional to the 
guanidine content 43, 57-60. Here, different polyarginines were complexed with pDNA and the 





concentration, and N/P ratio. Polyarginine-pDNA-Ca2+ complexes generally achieved high gene 
expression. Interestingly, there was no notable gene expression observed for the polyarginine 
complexes without calcium. Polyarginine 5 complexes had low gene expression with or without 
calcium. On the other hand, polyarginine 7, 9 and 11 complexes yielded high gene expression only 
when adding calcium chloride. Additionally, the transfection efficiency of the best polyarginine-
pDNA-Ca2+ complexes (polyarginine 7 complex) was superior to PEI-pDNA complexes. 
Polyarginine 7 appeared significantly effective compared to the other polyarginines (Figure 4). 
Figure 5 compares the same data to illustrate the difference in transfection efficiency between the 

































Figure 4. The transfection efficiency was determined for polyarginine-pDNA complexes at N/P 
ratios of 5, 10, 20, and 30 with different concentrations of added CaCl2 (50,100, 150, 300, and 600 
mM). (A) Polyarginine 5-pDNA-Ca2+ complexes, (B) polyarginine 7-pDNA-Ca2+ complexes, (C) 
polyarginine 9-pDNA-Ca2+ complexes, (D) polyarginine 11-pDNA-Ca2+ complexes. PEI (N/P 
ratio 10) was used as a standard. RLUs refers to relative light units. Results are presented as mean 
± SD (n = 4). The p of different polyarginine complexes were compared with PEI complexes (* = 





















Figure 5. The transfection efficiency was determined for polyarginine-pDNA complexes at N/P 
ratios of 5, 10, 20, and 30 with different concentrations of added CaCl2 (100 and 150 mM) for (A) 
polyarginine 5-pDNA-Ca2+ complexes and (B) polyarginine 7-pDNA-Ca2+ complexes. PEI (N/P 
ratio 10) was used as a standard. RLUs refers to relative light units. Results are presented as mean 
± SD (n = 4), (* = p < 0.0001, + = p < 0.005, and x = p < 0.05, one-way ANOVA,Tukey post-test). 
 
Calcium is an important component to condense the complexes, yielding small complexes 
with optimized DNA release.48 Consequently, only the combination of calcium and polyarginine 
effectively boosted gene transfection. In addition, others found that the cellular uptake of free 
polyarginine 16 was considerably higher than polyarginine 8, but the translocation of polyarginine 
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16 into the cytosol was less efficient than polyarginine 8. In light of this, it is possible that the 
polyarginines near 8 amino acids may mediate uptake of the complexes and optimize cytosolic 
release 30. This may help explain why polyarginine 7 had the highest gene expression (RLUs/mg 
protein) compared to other polyarginines. Moreover, Figure 6 indicates that the transfection 
efficiency of pDNA-Ca2+ complexes without polyarginine peptides was significantly lower than 












Figure 6. The transfection efficiency was determined for pDNA-Ca2+ complexes and compared to 
polyarginine 7-pDNA-Ca2+ complexes with different concentrations of added CaCl2 (50, 100, 150, 
300, and 600 mM), (+ = p < 0.005, and x = p < 0.05, one-way ANOVA,Tukey post-test). 
 
Finally, an effective gene delivery vector must be able to deliver genetic material safely to 
target cells without cytotoxicity. Arginine is converted to ornithine by an enzyme called arginase. 
Ornithine is the precursor of numerous polyamines, which are essential for cell proliferation 31. 
However, high-molecular-weight CPPs (e.g. polyarginine) can precipitate serum proteins and 
exhibit cytotoxicity at high concentration 27. Decreasing the molecular weight of polyarginine 
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tends to decrease cytotoxicity. Here, a cytotoxicity assay was used to measure the cytotoxicity of 
free PEI and polyarginines (Figure 7). Polyarginine 5, 7, 9 and 11 showed little evidence of 
cytotoxicity against A549 cells even at very high concentrations (1 mg/mL). These results 
supported the promise that polyarginine-pDNA-Ca2+ complexes had high transfection efficiency 










Figure 7. Polyarginine peptide 5, 7, 9 and 11 showed negligible cytotoxicity in comparison to PEI. 
Viability is expressed as a function of peptide concentration. Results are presented as mean ± SD 
(n = 3). 
 
Micrographs of A549 cells showed that PEI-pDNA complexes had a negative effect on cell 
growth compared to polyarginine-pDNA-Ca2+ complexes (Figure 8).  Images of the cells after 5 
hours and 48 hours were similar when incubated with PEI-pDNA complexes suggesting inhibition 
of cell growth. On the other hand, the cells proliferated as expected when incubated with 
polyarginine 7-pDNA-Ca2+ complexes. Other reports suggest that PEI inhibits cell proliferation 
and alternatively, arginine may even have a slight enhancing effect 48, 61, 62. Additionally, we 
noticed that there was no precipitation when we used the low concentrations of CaCl2 (≤ 300 mM), 
but there was precipitation with the high concentrations of CaCl2 (> 300 mM). Micrographs were 
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also supported by plots of total protein after 48 hours of incubation (Figure 9). In general, 
polyarginine 5, 7, 9 and 11 had higher protein levels than PEI and were similar to control cell 












Figure 8. Representative images of A549 cells after incubation of PEI-pDNA complexes and 
polyarginine 7-pDNA-Ca2+ complexes. (A) PEI-pDNA complexes without calcium after 5 hours. 
(B) PEI-pDNA complexes without calcium after 48 hours. (C) Polyarginine 7-pDNA complexes 
with 50 mM calcium chloride after 5 hours. (D) Polyarginine 7-pDNA complexes with 50 mM 








































Figure 9. The mass of protein after 48 hours in cell cultures treated with polyarginine-pDNA 
complexes at N/P ratios of 5, 10, 20, and 30 with different concentrations of added CaCl2 (50, 100, 
150, 300, and 600 mM). The protein level of different polyarginine-pDNA complexes was 
typically higher than PEI-pDNA complexes. (A) Polyarginine 5-pDNA-Ca2+ complexes, (B) 
polyarginine 7-pDNA-Ca2+ complexes, (C) polyarginine 9-pDNA-Ca2+ complexes, (D) 










Polyarginines have been successfully used as cell penetrating peptides for delivering large cargos 
such as genetic material. Polyarginine-pDNA complexes condensed with calcium chloride 
possessed excellent transfection efficiency compared to PEI complexes in A549 lung epithelial 
cells. Calcium chloride concentration played a significant role in controlling the complex size and 
charge which were important for cell transfection. Moreover, calcium condensation of complexes 
allows the incorporation and release of low-molecular-weight polyarginine CPPs in the range of 7 
to 11 amino acids, which may locally increase cell membrane permeability (e.g. within 
intracellular vesicles). Polyarginine 7 appeared especially effective compared to the other 
polyarginines. Polyarginine 5 was ineffective compared to the other polyarginines suggesting the 
minimum size should be > 5 amino acids. Furthermore, the low-molecular-weight polyarginine 
peptides (5, 7, 9 and 11) showed negligible cytotoxicity up to 5 mg/mL and maintained the 
expected cell proliferation rates. The incorporation of CPPs into polyelectrolyte complexes using 











2.5. References  
1. Baoum, A. A.; Berkland, C.  Calcium condensation of DNA complexed with cell‐
penetrating peptides offers efficient, noncytotoxic gene delivery. Journal of pharmaceutical 
sciences 2011, 100, (5), 1637-1642. 
2. Wang, C. F.; Lin, Y. X.; Jiang, T.; He, F.; Zhuo, R. X.  Polyethylenimine-grafted 
polycarbonates as biodegradable polycations for gene delivery. Biomaterials 2009, 30, (27), 4824-
4832. 
3. Midoux, P.; Monsigny, M.  Efficient gene transfer by histidylated polylysine/pDNA 
complexes. Bioconjugate chemistry 1999, 10, (3), 406-411. 
4. Mady, M.; Mohammed, W.; El-guendy, N. M.; Elsayed, A.  Eeffect of the polymer 
molecular weight on the DNA/PEI polyplexes properties. Rom. J. Biophys 2011, 21, (2), 151-165. 
5. Godbey, W.; Mikos, A.  Recent progress in gene delivery using non-viral transfer 
complexes. Journal of controlled release 2001, 72, (1), 115-125. 
6. Wiethoff, C. M.; Middaugh, C. R.  Barriers to nonviral gene delivery. Journal of 
pharmaceutical sciences 2002, 92, (2), 203-217. 
7. Felgner, P.; Barenholz, Y.; Behr, J.; Cheng, S.; Cullis, P.; Huang, L.; Jessee, J.; Seymour, 
L.; Szoka, F.; Thierry, A.  Nomenclature for synthetic gene delivery systems. Human gene therapy 
1997, 8, (5), 511-512. 
8. Duchardt, F.; Fotin‐Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R.  A Comprehensive 
Model for the Cellular Uptake of Cationic Cell‐penetrating Peptides. Traffic 2007, 8, (7), 848-866. 
9. Mann, A.; Thakur, G.; Shukla, V.; Singh, A. K.; Khanduri, R.; Naik, R.; Jiang, Y.; Kalra, 
N.; Dwarakanath, B.; Langel, U.  Differences in DNA condensation and release by lysine and 
60 
 
arginine homopeptides govern their DNA delivery efficiencies. Molecular Pharmaceutics 2011, 
8, (5), 1729-1741. 
10. Kircheis, R.; Kichler, A.; Wallner, G.; Kursa, M.; Ogris, M.; Felzmann, T.; Buchberger, 
M.; Wagner, E.  Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. 
Gene therapy 1997, 4, (5), 409. 
11. Baoum, A.; Ovcharenko, D.; Berkland, C.  Calcium condensed cell penetrating peptide 
complexes offer highly efficient, low toxicity gene silencing. International journal of 
pharmaceutics 2012, 427, (1), 134-142. 
12. Mayhew, E.; Harlos, J.; Juliano, R.  The effect of polycations on cell membrane stability 
and transport processes. Journal of Membrane Biology 1973, 14, (1), 213-228. 
13. Kadlecova, Z.; Baldi, L.; Hacker, D.; Wurm, F. M.; Klok, H. A.  A Comparative Study on 
the in-vitro Cytotoxicity of Linear, Dendritic and Hyperbranched Polylysine Analogues. 
Biomacromolecules 2012, 13, (2), 3127-3137. 
14. Greenwald, R.  PEG drugs: an overview. Journal of controlled release 2001, 74, (1), 159-
171. 
15. Qi, R.; Gao, Y.; Tang, Y.; He, R. R.; Liu, T. L.; He, Y.; Sun, S.; Li, B. Y.; Li, Y. B.; Liu, 
G.  PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. The 
AAPS journal 2009, 11, (3), 395-405. 
16. Putnam, D.; Zelikin, A. N.; Izumrudov, V. A.; Langer, R.  Polyhistidine–PEG: DNA 
nanocomposites for gene delivery. Biomaterials 2003, 24, (24), 4425-4433. 
17. Vicent, M. J.; Duncan, R.  Polymer conjugates: nanosized medicines for treating cancer. 
Trends in biotechnology 2006, 24, (1), 39-47. 
61 
 
18. Soundara Manickam, D.; Bisht, H. S.; Wan, L.; Mao, G.; Oupicky, D.  Influence of TAT-
peptide polymerization on properties and transfection activity of TAT/DNA polyplexes. Journal 
of controlled release 2005, 102, (1), 293-306. 
19. Davidson, T. J.; Harel, S.; Arboleda, V. A.; Prunell, G. F.; Shelanski, M. L.; Greene, L. A.; 
Troy, C. M.  Highly efficient small interfering RNA delivery to primary mammalian neurons 
induces MicroRNA-like effects before mRNA degradation. The Journal of neuroscience 2004, 24, 
(45), 10040-10046. 
20. Mo, R. H.; Zaro, J. L.; Shen, W. C.  Comparison of Cationic and Amphipathic Cell 
Penetrating Peptides for siRNA Delivery and Efficacy. Molecular Pharmaceutics 2011, 9, (2), 
299-309. 
21. Gautam, A.; Singh, H.; Tyagi, A.; Chaudhary, K.; Kumar, R.; Kapoor, P.; Raghava, G.  
CPPsite: a curated database of cell penetrating peptides. Database: The Journal of Biological 
Databases and Curation 2012, DOI: 10.1093/database/bas015. 
22. Chiu, Y. L.; Ali, A.; Chu, C.; Cao, H.; Rana, T. M.  Visualizing a correlation between 
siRNA localization, cellular uptake, and RNAi in living cells. Chemistry & biology 2004, 11, (8), 
1165-1175. 
23. Crombez, L.; Aldrian-Herrada, G.; Konate, K.; Nguyen, Q. N.; McMaster, G. K.; Brasseur, 
R.; Heitz, F.; Divita, G.  A new potent secondary amphipathic cell–penetrating peptide for siRNA 
delivery into mammalian cells. Molecular Therapy 2008, 17, (1), 95-103. 
24. Gupta, B.; Levchenko, T. S.; Torchilin, V. P.  Intracellular delivery of large molecules and 
small particles by cell-penetrating proteins and peptides. Advanced drug delivery reviews 2005, 
57, (4), 637-651. 
62 
 
25. Futaki, S.  Oligoarginine vectors for intracellular delivery: Design and cellular‐uptake 
mechanisms. Peptide Science 2005, 84, (3), 241-249. 
26. Munyendo, W. L. L.; Lv, H.; Benza-Ingoula, H.; Baraza, L. D.; Zhou, J.  Cell penetrating 
peptides in the delivery of biopharmaceuticals. Biomolecules 2012, 2, (2), 187-202. 
27. Howl, J.; Nicholl, I.; Jones, S.  The many futures for cell-penetrating peptides: how soon 
is now? Biochemical Society Transactions 2007, 35, 767-769. 
28. Stevenson, M.; Ramos-Perez, V.; Singh, S.; Soliman, M.; Preece, J. A.; Briggs, S. S.; Read, 
M. L.; Seymour, L. W.  Delivery of siRNA mediated by histidine-containing reducible polycations. 
Journal of Controlled Release 2008, 130, (1), 46-56. 
29. Meyer, M.; Wagner, E.  Recent developments in the application of plasmid DNA-based 
vectors and small interfering RNA therapeutics for cancer. Human gene therapy 2006, 17, (11), 
1062-1076. 
30. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y.  
Arginine-rich peptides. Journal of Biological Chemistry 2001, 276, (8), 5836-5840. 
31. Kim, H. H.; Choi, H. S.; Yang, J. M.; Shin, S.  Characterization of gene delivery in vitro 
and in vivo by the arginine peptide system. International journal of pharmaceutics 2007, 335, (1), 
70-78. 
32. Koo, H.; Kang, H.; Lee, Y.  Analysis of the relationship between the molecular weight and 
transfection efficiency/cytotoxicity of Poly-L-arginine on a mammalian cell line. Notes 2009, 30, 
(4), 927. 
33. Saleh, A. F. A.; Aojula, H. S.; Pluen, A.  Enhancement of gene transfer using YIGSR 
analog of Tat‐derived peptide. Biopolymers 2008, 89, (1), 62-71. 
63 
 
34. El-Sayed, A.; Futaki, S.; Harashima, H.  Delivery of macromolecules using arginine-rich 
cell-penetrating peptides: ways to overcome endosomal entrapment. The AAPS journal 2009, 11, 
(1), 13-22. 
35. Emi, N.; Kidoaki, S.; Yoshikawa, K.; Saito, H.  Gene transfer mediated by polyarginine 
requires a formation of big carrier-complex of DNA aggregate. Biochemical and biophysical 
research communications 1997, 231, (2), 421-424. 
36. Brooks, H.; Lebleu, B.; Vivès, E.  Tat peptide-mediated cellular delivery: back to basics. 
Advanced drug delivery reviews 2005, 57, (4), 559-577. 
37. Zhao, M.; Weissleder, R.  Intracellular cargo delivery using tat peptide and derivatives. 
Medicinal research reviews 2003, 24, (1), 1-12. 
38. Rudolph, C.; Plank, C.; Lausier, J.; Schillinger, U.; Müller, R. H.; Rosenecker, J.  
Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid 
DNA into cells. Journal of Biological Chemistry 2003, 278, (13), 11411-11418. 
39. Tung, C. H.; Weissleder, R.  Arginine containing peptides as delivery vectors. Advanced 
drug delivery reviews 2003, 55, (2), 281-294. 
40. Liu, B. R.; Lin, M. D.; Chiang, H. J.; Lee, H. J.  Arginine-rich cell-penetrating peptides 
deliver gene into living human cells. Gene 2012. 
41. Bolhassani, A.  Potential efficacy of cell-penetrating peptides for nucleic acid and drug 
delivery in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2011, 1816, (2), 232-
246. 
42. Melikov, K.; Chernomordik, L.  Arginine-rich cell penetrating peptides: from endosomal 
uptake to nuclear delivery. Cellular and molecular life sciences 2005, 62, (23), 2739-2749. 
64 
 
43. Mitchell, D.; Steinman, L.; Kim, D.; Fathman, C.; Rothbard, J.  Polyarginine enters cells 
more efficiently than other polycationic homopolymers. The Journal of Peptide Research 2002, 
56, (5), 318-325. 
44. Won, Y. W.; Kim, H. A.; Lee, M.; Kim, Y. H.  Reducible poly (oligo-D-arginine) for 
enhanced gene expression in mouse lung by intratracheal injection. Molecular Therapy 2009, 18, 
(4), 734-742. 
45. McKenzie, D. L.; Collard, W. T.; Rice, K. G.  Comparative gene transfer efficiency of low 
molecular weight polylysine DNA‐condensing peptides. The Journal of peptide research 2003, 
54, (4), 311-318. 
46. Kim, H. H.; Lee, W. S.; Yang, J. M.; Shin, S.  Basic peptide system for efficient delivery 
of foreign genes. BBA-Rev. Cancer 2003, 1640, (2), 129-136. 
47. de Raad, M.; Teunissen, E. A.; Lelieveld, D.; Egan, D. A.; Mastrobattista, E.  High-content 
screening of peptide-based non-viral gene delivery systems. Journal of Controlled Release 2012, 
158, (3), 433-442. 
48. Khondee, S.; Baoum, A.; Siahaan, T. J.; Berkland, C.  Calcium Condensed LABL-TAT 
Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells. Molecular 
pharmaceutics 2011, 8, (3), 788-798. 
49. Reschel, T.; Koňák, Č.; Oupický, D.; Seymour, L. W.; Ulbrich, K.  Physical properties and 
in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic 
polycations. Journal of controlled release 2002, 81, (1), 201-217. 
50. Loyter, A.; Scangos, G. A.; Ruddle, F. H.  Mechanisms of DNA uptake by mammalian 
cells: fate of exogenously added DNA monitored by the use of fluorescent dyes. Proceedings of 
the National Academy of Sciences 1982, 79, (2), 422-426. 
65 
 
51. Roy, I.; Mitra, S.; Maitra, A.; Mozumdar, S.  Calcium phosphate nanoparticles as novel 
non-viral vectors for targeted gene delivery. International journal of pharmaceutics 2003, 250, 
(1), 25-33. 
52. Lam, A. M. I.; Cullis, P. R.  Calcium enhances the transfection potency of plasmid DNA–
cationic liposome complexes. Biochim. Biophys. Acta 2000, 1463, (2), 279-290. 
53. Haberland, A.; Knaus, T.; Zaitsev, S. V.; Stahn, R.; Mistry, A. R.; Coutelle, C.; Haller, H.; 
Böttger, M.  Calcium ions as efficient cofactor of polycation-mediated gene transfer. Biochim. 
Biophys. Acta 1999, 1445, (1), 21-30. 
54. Zaitsev, S.; Haberland, A.; Otto, A.; Vorob'ev, V.; Haller, H.; Böttger, M.  H1 and HMG17 
extracted from calf thymus nuclei are efficient DNA carriers in gene transfer. Gene therapy 1997, 
4, (6), 586. 
55. Mozafari, M. R.  Calcium Based Non-viral Gene Delivery: An Overview of Methodology 
and Applications. Acta Medica Iranica 2010, 48, (3). 
56. Zaitsev, S.; Buchwalow, I.; Haberland, A.; Tkachuk, S.; Zaitseva, I.; Haller, H.; Böttger, 
M.  Histone H1-mediated transfection: role of calcium in the cellular uptake and intracellular fate 
of H1-DNA complexes. Acta histochemica 2002, 104, (1), 85-92. 
57. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. 
B.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: 
peptoid molecular transporters. Proceedings of the National Academy of Sciences 2000, 97, (24), 
13003-13008. 
58. Schmidt, N.; Mishra, A.; Lai, G. H.; Wong, G. C. L.  Arginine-rich cell-penetrating 
peptides. FEBS letters 2010, 584, (9), 1806-1813. 
66 
 
59. Åmand, H. L.; Rydberg, H. A.; Fornander, L. H.; Lincoln, P.; Nordén, B.; Esbjörner, E. K.  
Cell surface binding and uptake of arginine-and lysine-rich penetratin peptides in absence and 
presence of proteoglycans. BBA-Rev. Cancer 2012. 
60. Ye, S.; Tian, M.; Wang, T.; Ren, L.; Wang, D.; Shen, L.; Shang, T.  Synergistic Effects of 
Cell Penetrating Peptide Tat and Fusogenic Peptide HA2 Enhance Cellular Internalization and 
Gene Transduction of Organosilica Nanoparticles. Nanomedicine: Nanotechnology, Biology and 
Medicine 2011. 
61. Singh, R.; Pervin, S.; Karimi, A.; Cederbaum, S.; Chaudhuri, G.  Arginase activity in 
human breast cancer cell lines: Nω-hydroxy-L-arginine selectively inhibits cell proliferation and 
induces apoptosis in MDA-MB-468 cells. Cancer research 2000, 60, (12), 3305-3312. 
















AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung 




Alhakamy, N. A.; Ishiguro, S.; Uppalapati, D.; Berkland, C. J.; Tamura, M.  AT2R Gene 
Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after 















3.1. Introduction  
Lung cancer is the third most prevalent form of cancer behind prostate and breast cancer; 
however, treatment options are lagging 1, 2. Even though progress has been made in early detection 
and prevention, mortality and morbidity associated with lung cancer is still unacceptably high 3. 
In 2015, the American Cancer Society reported more than 430,000 people in the U.S. are living 
with lung cancer yielding the largest annual financial burden of any cancer type 1. Although 
incremental improvements have been made in the palliative care, currently available therapies have 
had minimal impact in reducing deaths 3. In particular, the need for completely new therapeutics 
to treat the most aggressive lung cancers is especially great.  
Gene therapy is experiencing a renaissance in the U.S. and around the globe. The European 
Union has recently approved the first gene therapy drug, Glybera®, for the treatment of 
Lipoprotein Lipase Deficiency (LPLD). Promising late stage clinical trials suggest the first gene 
therapy may be approved in the U.S. in 2016. Most gene therapy clinical trials (64.4%) have aimed 
at treating cancer, and yet cancer gene therapies have been slow to advance 4, 5. Theoretical, and 
practical limitations still exist for gene therapy application to lung cancer. Biological barriers and 
toxicity continue to confound lung cancer treatment, even though the lungs may be accessed via 
inhalation or intravenous administration.   
Gene vectors (viral and nonviral vectors) have steadily improved over the past 20 years. 
Viral vectors (e.g., adenoviral) are highly efficient, and facilitate strong transgene expression in 
different tumor tissues 6, 7. While these vectors are the most effective vectors applied in 70% of 
clinical trials, they continue to suffer from safety concerns (e.g., immunogenicity and 
pathogenicity) 8-11, rapid clearance from circulation, and production problems 11-14. For these 
reasons, nonviral vectors could be more promising gene carriers due to easy synthesis, low cost, 
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and decreased immunogenicity compared to viral vectors 10, 14-18. These attributes suggest nonviral 
vectors could offer a safer approach for repeated dosing regimens when treating primary as well 
as recurrent cancers. 
Nucleic acids complexed with cationic polymers (polyplexes) or cationic lipids 
(lipoplexes) are the most commonly used nonviral synthetic gene carriers 16, 19-21. Cationic 
polymers interact with cell membranes or extracellular components (e.g. glycosaminoglycans) via 
the positive charge of the amino acid residues (e.g. lysine and arginine) 22. The molecular weight 
and charge of polycations play important roles in complexing nucleic acids for delivering genetic 
materials 18. High-molecular-weight polycations often condense the genetic material (e.g., plasmid 
DNA (pDNA)) into small and stable complexes. On the other hand, low-molecular-weight 
polycations often produce large and unstable complexes 18, 23, 24. Unfortunately, low-molecular-
weight polycations have historically exhibited poor transfection efficiency while high-molecular-
weight polycations have been plagued with cytotoxicity 18.  
Polylysine was one of the first polycations used for gene delivery 25. Polylysine-pDNA 
complexes have traditionally required polylysine chains with more than 20 residues to efficiently 
complex DNA, but yielding modest transfection efficiency and concerns about cytotoxicity 14. 
Many attempts were made to increase transfection efficiency or reduce cytotoxicity by either 
chemically modifying polylysine (e.g., PEGylation) or by adding excipients 26. Most research 
efforts focused on improving tolerability of high-molecular-weight polylysine 10, 27, 28, but we show 
that short polylysines with much lower cytotoxicity can indeed condense pDNA into small 
complexes when calcium is added. Such particles offer an interesting opportunity for repeat dosing 
to treat lung cancer if efficient transfection can be balanced with low cytotoxicity.   
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Here, a nine amino acid polylysine (K9) was complexed with pDNA and condensed with 
calcium chloride. This simple formulation (the K9-pDNA-Ca2+ complex) was explored using four 
different human cell lines: 1) A549 (a lung cancer cell), 2) HeLa (a cervix cancer cell), 3) MDA-
MB-231 (a breast cancer cell), 4) HEK-293 (a virus-immortalized kidney cell)) and one mouse 
cell line, LLC (a lung cancer cell) using a luciferase reported plasmid DNA (pLUC) to assess 
transfection efficiency. Angiotensin II type 2 receptor (AT2R) is known to stimulate apoptosis and 
inhibit cell proliferation in different cell lines such as endothelial cells, cardiomyocytes, neuronal 
cells, prostate cancer cells and lung cancer cells 5, 16, therefore, AT2R plasmid DNA (pAT2R) was 
delivered to LLC tumor-bearing mice. These K9-pAT2R complexes were administered via 
intravenous (IV) injection and/or via intratracheal (IT) spray to determine lung cancer attenuation 
in LLC tumor-bearing mice.  
 
3.2. Materials and Methods  
3.2.1. Materials 
Plasmid DNA (pDNA) encoding firefly luciferase (pLUC, pGL3) was obtained from Promega 
(Madison, WI). Plasmid DNA (pDNA) encoding human AT2R (pAT2R, pcDNA3.1þ) was 
obtained from the UMR cDNA Resource Center (University of Missouri, Rolla, MO). K9 peptide 
(KKKKKKKKK; Mw = 1170.65 Da; Purity > 95%) was purchased from Biomatik Corporation 
(Cambridge, Ontario, Canada). Branched polyethylenimine (PEI, 25 kDa), mouse serum albumin 
(MSA) and glucose were from Sigma-Aldrich (Milwaukee, WI). Calcium chloride dihydrate 
(CaCl2·2H2O) was obtained from Fisher Scientific (Pittsburgh). A549 (CCL-185), Lewis lung 
carcinoma (LLC; CRL-1642), and HeLa (CCL-2) cell line were obtained from American Type 
Culture Collection (ATCC; Rockville, Maryland). MDA-MB-231 and HEK-293 cell line were 
gifts from Dr. Nikki Cheng (University of Kansas Medical Center).  
71 
 
3.2.2. Preparation of the K9-pDNA-Ca2+ Complex 
For the in vitro studies, the K9-pLUC-Ca2+ complex solution was prepared by adding 15 µL K9 
peptide solution (polymer nitrogen to pLUC phosphate (N/P) ratio 10) to 10 µL pDNA (0.1 µg 
/µL in 1 x Tris-acetate-EDTA (TAE) Buffer), followed by fast pipetting for 20 seconds. Then, 15 
µL calcium chloride solution (e.g., 19, 114, and 228 mM) was added and mixed by fast pipetting. 
The K9-pDNA-Ca2+ complex solution was incubated at 4°C for 20 to 25 minutes and used for each 
experiment. For the intravenous (IV) administration of the K9-pAT2R-Ca2+ complex, 160 µL 
complex solution was mixed with 40 µL 1% mouse serum albumin (MSA) (the final volume of 
the complex is 200 µl, 4 g pAT2R, and 53 g K9 peptide). For the intratracheal (IT) 
administration, 40 µL the K9-pAT2R-Ca2+ complex solution was mixed with 10 µL 10% glucose 
for the osmolality adjustment (the final volume of the complex is 50 µl, 1 g pAT2R, and 13 g 
K9 peptide).  
3.2.3. Preparation of the PEI-pLUC Complex  
The PEI-pLUC complex solution was prepared by adding 15 µL PEI solution (N/P ratio 10) to 10 
µL pLUC (0.1 µg /µL) followed by fast pipetting for 20 seconds. The PEI-pLUC complex solution 
was incubated at 4°C for 20 to 25 minutes and used for each experiment. The complex solution 
was prepared immediately before each experiment and used as a control for all in vitro studies. 
3.2.4. Agarose Gel Electrophoresis   
The K9-pLUC-Ca2+ complex solution was mixed with 4 µL TAE buffer. Then, 4 µL SYBR Green 
1 was mixed with the complex solution, followed by incubation at 4°C for 20 to 25 minutes. After 
adding 7 µL of 6X DNA Loading Dye, the mixture solutions were loaded onto a 1 % agarose gel, 





3.2.5. Size and Zeta Potential  
The particle size (effective diameter (nm)) of the K9-pLUC complex with or without calcium 
chloride was determined by dynamic light scattering (Brookhaven Instruments, Holtsville, NY). 
The zeta potentials of the complexes were measured by Zeta PALS dynamic light scattering 
(Brookhaven Instrument). Particle size was measured after dispersing the complexes into nuclease-
free water (NFW) or serum-free media (SFM). Zeta potential was measured after dispersing the 
complexes into 1 mM potassium chloride solution. 
3.2.6. Cell Culture  
A549 cell line were grown in F-12K Nutrient Mixture media (Mediatech, Inc., Manassas, VA) 
supplemented with 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan, UT) and 1% (v/v) 
Penicillin-streptomycin (MB Biomedical, LLC, Solon, OH). HeLa, MDA-MB-231, LLC, and 
HEK-293 cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Invitrogen/Life Technologies, Grand Island, NY) supplemented with 10% FBS and 1% 
Penicillin/streptomycin. These cell lines were incubated at 37°C in 5% CO2 humidified the air. 
Cell line was authenticated by short-tandem repeat (STR) DNA profiling. The cells were 
maintained in low passage (<15) for this study. 
3.2.7. Transfection Efficiency of the K9-pDNA-Ca2+ Complexes to Cultured Cells  
MDA-MB-231, LLC, and HEK-293 cell (80,000 cells/well) were cultured in 96-well plates for 24 
hours prior to the transfection. The cells were washed once with SFM and 100 µL transfection 
solution (a mixture of 20 µL of the K9-pLUC-Ca2+ complex and 80 µL of SFM, 0.5 µg pLUC/well) 
was added to each well. After 5 hours of incubation, the transfection solution was replaced with 
100 µL fresh growth medium. After 48 hour of incubation, total cellular protein was collected by 
using BCA Protein Assay Reagent (Thermo Fisher Scientific Inc., Waltham, MA). The efficiency 
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of the gene transfection by the complexes was determined by Luciferase Reporter Assay using 
Luciferase Assay System Freezer Pack (Promega). The Luciferase expression was measured by a 
microplate reader (SpectraMax; Molecular Devices Crope, CA). The transfection efficiency was 
expressed as Relative Light Units (RLUs) per milligram (mg) of cellular protein. 
3.2.8. Cytotoxicity of K9 peptide, PEI, and Calcium Chloride in vitro  
Cytotoxicity of K9 peptide, PEI, and calcium chloride was determined using a CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS) obtained from Promega. A549, HeLa, 
MDA-MB-231, LLC, and HEK-293 cells were cultured in a 96-well plate in growth media as 
described previously. Cells were treated with the samples (0-5 mg/mL as indicated in the Figure 
4) for ~24 hours. After 24 hours of incubation, the media were replaced with a mixture of 100 µL 
of fresh serum medium and 20 µL of MTS. Then, the plate was incubated for 3 hours in the 
incubator. To determine cell viability, the absorbance of each well was measured by a microplate 
reader (SpectraMax) at 490 nm and normalized to untreated control cells. 
3.2.9. Assessment of DNA Accessibility to the K9-pLUC Complex by SYBR Green Assay 
The degree of pLUC accessibility in the K9- or PEI-pLUC complex was assessed by the double-
stranded-DNA-binding reagent SYBR Green. Briefly, 10 μL pLUC (0.1 mg pDNA/mL) was 
mixed with 15 μL of K9 peptide (N/P ratio 10), then 15 μL deionized water or 38 mM calcium 
chloride solution was added. After 30 minutes incubation at room temperature, 120 μL PBS, and 
160 μL 10X SYBR Green solutions (Invitrogen) were added. Then, 100 μL sample was added to 
one well of a 96-well cell culture plate. The fluorescence was measured using a fluorescence plate 






Six-week-old wild-type male C57BL/6 mice were obtained from Charles River Laboratories 
International, Inc. All mice were housed in a clean facility and held for 10 days to acclimatize. All 
animal experiments were carried out under strict adherence to the Institutional Animal Care and 
Use Committee (IACUC) protocols and the Institutional Biosafety Committee set by Kansas State 
University (Manhattan, KS).   
3.2.11. Lung Cancer Graft in Syngeneic Mouse and Treatment with the K9-pAT2R-Ca2+ 
Complex 
Seven week old C57BL/6 mice were intravenously injected with 1.2x106 LLC cells suspended in 
200 μL PBS via the tail vein using a 1 mL syringe with a 27G needle. The K9-pAT2R-Ca2+ 
complex solution was prepared immediately before injection as described above. For the 
intravenous (IV) administration of the K9-pAT2R-Ca2+ complex, 160 µL complex solution was 
mixed with 40 µL 1% mouse serum albumin (MSA). For the intratracheal (IT) administration, 40 
µL the K9-pAT2R-Ca2+ complex solution was mixed with 10 µL 10% glucose for the osmolality 
adjustment. After 7 days of the LLC injection, the mice were injected with 200 and 50 µL of the 
complexes with each composition via IV and IT, respectively. The PBS and K9-Ca2+ solutions 
without pAT2R were used as control. In addition, K9-pLUC-Ca2+ complex prepared as described 
above was also injected into LLC tumor-bearing mice via IV and IT as a non-specific gene control. 
Mice were sacrificed by cervical dislocation under anesthesia at 14 days after the complex 
treatment. The lungs were dissected, and tumor burden were analyzed.  
3.2.12. Immunohistochemical Analysis for AT2R, Cell Proliferation and Apoptosis in LLC 
Allografts 
Fixed lung tissues were sectioned at 4 µm and stained with haematoxylin and eosin (HE) staining 
for histological examination. To analyze the AT2R expression and cell proliferation by Ki-67 in 
75 
 
LLC tumors, sections were deparaffinized and heat-induced epitope unmasking was performed in 
the citrate buffer followed by incubation with 3% H2O2/methanol for 3 minutes to block 
endogenous peroxidase activity. Sections were incubated with polyclonal anti-AT2R (1:100 
dilution, for 18 hours at 4˚C, Abcam) and polyclonal anti-Ki-67 (1:500 dilution, for 18 hours at 
4˚C, Abcam) antibodies. After the incubation with primary antibodies, sections were induced into 
reaction with a biotin-conjugated anti-rabbit IgG antibody (Vector Laboratories) at a 1:100 dilution 
for 1 hour at 37˚C, followed by reaction with the avidin-biotin-peroxidase complex reagent (Vector 
Laboratories) for 40 minutes at 37˚C. Reactions were developed with 3, 3’-diaminobenzidine 
tetrahydrochloride (Sigma) and counterstained lightly with Mayer`s hematoxylin. The cell 
proliferation index was assessed as the fold change of the average percentage of positive cells in 
three randomly selected fields in the tumor nodules. Apoptotic cells in LLC tumors were detected 
by a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay by using the 
DeadEnd Colorimetric TUNEL System (Promega), according to the manufacturer's instructions 
with a slight modification 29. The apoptotic index was assessed as the fold change of the average 
number of positive cells in three randomly selected fields in the tumor nodules. 
3.2.13. Statistical Analysis 
The data was analyzed by using GraphPad software. All values were expressed as the mean ± 
standard error of the mean. All experiments were conducted with multiple sample determinations. 
A statistical evaluation comparing the significance of the difference in gene expression (RLUs/mg 
protein) between the means of two data sets was performed using a t test. One-way ANOVA, 





3.3. Results  
3.3.1. Formation of the K9-pLUC-Ca2+ Complex 
 
The K9-pDNA-Ca2+ and PEI-pDNA complexes were prepared by mixing pLUC or pAT2R 
with K9 peptide at various N/P ratios as described in the materials and methods section. In order 
to demonstrate complex formation, agarose gel electrophoresis assay was performed using 1% 
agarose gel, and electrophoresed for 30 minutes. Uncomplexed pLUC (naked pLUC) was used as 
a control. The K9 peptide and pLUC mixture showed ability to form complexes of pLUC and K9 
peptide regardless of the presence of 38 mM calcium chloride at N/P ratios 5, 10, and 30. Since 
the size of these complexes was significantly bigger than pLUC, the complexes stayed in the 
loading wells without migrating into the gel and no bands were observed in the electrophoresis 
(Figure 1A). Although lower N/P ratios (1 to 4) also showed no bands in the absence of calcium 
chloride, the N/P ratios lower than 0.5 showed bands (Figure 1B). In addition, mixing with 
calcium chloride and pLUC did not form stable complexes (Figure 1C). 
Figure 1. Agraose gel electrophoresis study of K9-pDNA-Ca2+ complexes at N/P ratios of 5, 10, 
or 30 with or without 38 mM calcium chloride (A), K9-pDNA complexes without calcium chloride 
at N/P ratios of 4, 3, 2, 1, 0.5, or 0.1 (B), and pLUC/calcium chloride complexes with 0, 19, 38, or 
114 mM of calcium chloride (C). In the panel I, A, B and C refer to N/P 5, N/P 10, and N/P 30 in 
the presence of 38 mM calcium chloride, respectively, whereas a, b, and c refer to N/P 5, N/P 10, 
and N/P 30 in the absence of calcium chloride, respectively. “M” Refers to the size marker. 
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3.3.2. Physical Characterization of the K9-pLUC-Ca2+ and the PEI-pLUC Complexes 
The effect of calcium chloride concentration on the surface charge and particle size of the 
K9-pLUC complex was investigated. As shown in Figure 2A, addition of calcium chloride of 37.7 
and 113 mM (final concentration) significantly decreased the particle size of the K9-pLUC-Ca2+ 
complex, with relatively narrow polydispersity (~0.1), in both nuclease-free water (NFW) and in 
serum-free F-12 media (SFM). The zeta potential of the K9-pLUC-Ca2+ and PEI-pLUC complexes 
increased significantly with increases in the concentration of calcium chloride (Figure 2B).   
SYBR Green assay provides a non-destructive and simple method to examine pDNA 
accessibility within complexes. As shown in Figure 2C, pLUC was accessible in the K9-pLUC 
complex, whereas pLUC accessibility in the PEI-pLUC complex was low compared to pLUC 
alone. Although pLUC accessibility in the K9-pLUC complex was significantly decreased in the 
presence of 38 mM calcium chloride, DNA accessibility was lower in the PEI-pLUC complex. 
These results suggest that the addition of calcium chloride significantly decreased the size of the 






































Figure 2. Evaluation of the particle sizes (effective diameters), zeta potentials, and SYBR Green 
assay of the K9-pLUC and PEI-pLUC complexes with or without calcium chloride. (A), the 
particle size of the K9-pLUC complexes (N/P ratio = 10) were determined by DLS in the presence 
of various concentrations of calcium chloride (0, 38, and 114 mM) in nuclease-free water (NFW), 
or serum-free F-12 media (SFM). (B), zeta potentials of the K9-pLUC and PEI-pLUC complexes 
(N/P ratio = 10) were determined by Zeta PALS dynamic light scattering in the presence of various 
concentrations of calcium chloride (0, 38, and 114 mM). (C), effect of calcium chloride 
concentration at 0 and 38 mM on pLUC accessibility in K9-pLUC and PEI-pLUC complexes at 
an N/P ratio of 10 was evaluated using the SYBR Green assay. The pLUC alone in the solution 
was used as a control. Results are presented as mean ± SD (n = 3). ***, P < 0.0001, one-way 
ANOVA, Tukey post-test comparison to pDNA. 
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3.3.3. The K9-pLUC-Ca2+ Complex Caused Efficient Gene Transfection with Low 
Cytotoxicity in Vitro 
The in vitro transfection efficiency of the K9-pLUC-Ca2+ and the PEI-pLUC complexes 
was studied using the four different human cell lines and the mouse cell line. Luciferase gene 
expression was evaluated 48 hours after the transfection using the K9-pLUC-Ca2+ and the PEI-
pLUC complexes at N/P ratios 5, 10, 20, and 30, and at various calcium chloride concentrations 
during the complex formulation (Figure 3A). The K9-pLUC-Ca2+ complexes had a high level of 
gene expression at a calcium chloride concentration of 38 mM (N/P ratio 10) in A549 cells. 
Luciferase gene expression was decreased when calcium concentration was higher than 114 mM 
in all N/P ratios tested. This result was further confirmed in other cell lines: A549 cells (Figure 
3B), HeLa cells (Figure 3C), MDA-MB-231 cells (Figure 3D), HEK-293 cells (Figure 3E), and 
LLC cells (Figure 3F). In all cell lines examined, the transfection efficiency of the K9-pLUC-Ca2+ 
with 38 mM calcium chloride was significantly higher than those with PEI-pLUC and the K9-
pLUC-Ca2+ with 114 mM calcium chloride (Figure 3). Significance of including K9 peptide in 
pDNA transfection was further examined by comparing pLUC expression efficiency in the 
presence or absence of the peptide in various cell lines (Figure Appendix 1). The transfection 
efficiency of the pLUC-Ca2+ complex (without K9 peptide) was significantly lower than that of 
the K9-pLUC-Ca2+ complex at the same calcium chloride concentration.  
High transfection efficiency and low cytotoxicity are vital attributes for nonviral gene 
vectors. To examine whether K9, PEI, and calcium chloride affected the viability of live cells, a 
membrane translocalization signal (MTS) cytotoxicity assay was conducted using five different 
cell lines. The five cell lines were individually incubated with up to 5 mg/mL K9, PEI, or calcium 
chloride for 24 hours and then MTS assay was performed (Figure 4). The K9 peptide showed no 
cytotoxicity to 2.5 mg/mL. Only HEK-293 cell viability was decreased at 1 mg/mL levels of K9 
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peptide. Calcium chloride also did not show strong cytotoxicity until 1 mg/mL. However, PEI 
induced significant cytotoxicity even at 10 µg/mL in the four cell lines. Although HEK-293 cells 
were resistant to PEI-induced cytotoxicity, their cell viability was gradually decreased at higher 
concentrations. This MTS assay strongly suggested that the K9-pDNA-Ca2+ complex is a low 
































































Figure 3. The transfection efficiencies of the K9-pLUC complex. (A), the transfection efficiencies 
in various concentrations of calcium chloride (0, 19, 38, 114, and 228 mM) in A549 cells at N/P 
ratios of 5, 10, 20 and 30. The transfection efficiencies of the K9-pLUC complexes with different 
concentrations of added calcium chloride (0, 38, and 114 mM) at an N/P ratio 10 in A549 cells (B), 
HeLa cells (C), MDA-MB-231 cells (D), HEK-293 cells (E) and LLC cells (F). RLUs refers to 
relative light units. Results are presented as mean ± SD (n = 4). ***, P < 0.0001; **, P < 0.001; 
































Figure 4. Cytotoxicity profiles of K9, PEI, and calcium chloride in A549 cells (A), HeLa cells (B), 
MDA-MB-231 cells (C), HEK-293 cells (D), and LLC cells (E). Cell viability was determined by 




3.3.4. Treatment with the K9-pAT2R-Ca2+ Complex via Intravenous Injection or 
Intratracheal Spray Caused Significant Growth Attenuation of Lung Tumors 
 
The effect of the K9-pAT2R-Ca2+ complex delivering the endogenous apoptosis-inducer 
gene AT2R was examined using orthotopic LLC allografts in syngeneic C57BL/6 mice. To 
evaluate the effect of the complex on the lung tumor growth, LLC cells (1.2 x 106) were injected 
via the tail vein. Seven days after cancer cell injection, the mice were treated with a single dose of 
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the K9-pAT2R-Ca2+ complexes containing 4 µg pAT2R intravenously (IV) or 1 µg pAT2R 
intratracheally (IT). The tumor growth attenuating the effect of these complexes was observed both 
macroscopically (Figure 5A) and microscopically (Figure 5B). Macroscopically, a large number 
and large size of tumor nodules were detected in PBS or K9 treated mouse lungs. The average lung 
weight (mg) of the K9-pAT2R-Ca2+ IT (190.6±48.3) and the K9-pAT2R-Ca2+ IV (201.6±67.0) 
treated groups were significantly smaller than that of the control PBS group (325.7±69.4, P<0.05, 
Figure 5C and Table Appendix 1). Histological examination of tumors in H&E stained lung 
sections also displayed only a small number and small size of LLC tumor nodules in mouse lungs 
treated with the K9-pAT2R-Ca2+ complexes (Figure 5B). Average numbers of tumor nodules in 
the lungs in the IT (6.0±4.2) and the IV (4.6±3.4) groups were significantly smaller than that of 
the control PBS group (17.8±6.0, P<0.01, Figure 5D and Table Appendix 2). On the other hand, 
treatment with K9-pLUC-Ca2+ complexes did not show any effect on the average lung weight 
(246.8±70.3 in PBS, 213.9 ±52.3 in K9-pLUC-Ca2+ IV, and 267.3 ±6.9 in K9-pLUC-
Ca2+ IT) and the average numbers of tumor nodules (20.4±4.0, 20.2±11.9, and 25.7±1.5 in the 
same group order as the lung weights described above) in LLC tumor-bearing mouse lung (Figure 
Appendix 2, Table Appendix 3 and 4). Both local (i.e. pulmonary) and systemic treatment with 
the K9-pAT2R-Ca2+ complexes were equally effective in attenuating the growth of LLC lung 








Figure 5.  Macroscopic analysis of LLC tumors in C57BL/6 mouse lungs (A) and microscopic 
views (B) of the lung from PBS, K9-alone IT, K9-alone IV, K9-pAT2R-Ca2+ IT (complex IT), or 
K9-pAT2R-Ca2+ IV (complex IV)-treated mice (n=5). Average lung weight (C) and number of 
tumor nodules (D) in each treatment group were expressed in the bar graphs. Scale bars in panel 
B indicate 500µm. *, P < 0.05; **, P < 0.01 as compared with the level of PBS control. (n=5, one-
way ANOVA Tukey post-test). K9, nine amino acid polylysine; IT, intratracheal; IV, intravenous. 
 
 
3.3.5. Immunohistochemical Analysis of AT2R Expression, Cell Proliferation and Apoptosis 
in LLC Grafts 
The expression of AT2R gene in the lung was determined immunohistochemically (Figure 
6). As shown in Figure 6A, AT2R expression was upregulated in the tumor cells in the K9-
pAT2R-Ca2+ IV and IT spray groups but not in other groups. These observations suggested that 
the K9-pAT2R-Ca2+ administration via IV and IT significantly attenuated the lung tumor growth 
by expressing AT2R in the tumor cells. Immunohistochemical analysis of cell proliferation in 
tumors using anti-Ki-67 antibody did not show many differences (Figure 6B). Although the 
average number of apoptotic cells detected by TUNEL assay tended to increase in the K9-pAT2R-
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Ca2+ treatment groups (Figure 6C), there was no statistical significance between groups due to 
large variations within the samples. Since the analysis was carried out 14 days after treatment with 
the K9-pAT2R-Ca2+ complex, these results may suggest that the treatment with the K9-pAT2R-
Ca2+ complex attenuated tumor growth during an early stage of LLC tumorigenesis. Nevertheless, 
these results support that both IV and IT administration of the K9-pAT2R-Ca2+ offer effective 
modalities for lung cancer targeted nonviral gene therapy. 
 
Figure 6. Immunohistochemical analysis of AT2R expression (A), cell proliferation (B) and 
apoptosis (C) in LLC graft tumors in PBS, K9-alone IT, K9-pAT2R-Ca2+  IT (complex IT), K9-
alone IV or K9-pAT2R-Ca2+ IV (complex IV)-treated mice (n=5). A, Microscopic images of 
immunohistochemistry for AT2R expression (original magnification at 200x). AT2R expression 
was observed in the tumor cells from complex IT or complex IV-treated mice (insets). Scale bars 
in the panel A indicate 100 µm. Cell proliferation index (B) and apoptotic index (C) were evaluated 
by Ki-67 expressions and TUNEL assay in the tumor cells, respectively. K9, nine amino acid 




3.4. Discussion  
Development in the field of gene therapy is presently hindered by the lack of robust gene 
delivery methods. Synthetic, nonviral gene vectors such as polycationic peptides (e.g. polylysine) 
are promising vectors 10, 17, 18. The toxicity of these CPPs may be minimized or eliminated by 
reducing their molecular size. However, the level of transfection efficiency mediated by smaller 
polypeptides is typically low compared to larger polypeptides 17. CPPs have been used to deliver 
various anti-cancer agents (e.g., small molecules, proteins, and nucleic acids) into cells in vivo and 
have been observed to be effective in inhibiting tumor growth in preclinical tumor models 17, 30, 31. 
The main goals of this work were to examine the transfection efficiency of the K9-pDNA-Ca2+ 
complex and to determine whether pDNA (pAT2R) can be distributed to lung cancer cells, 
resulting in therapeutically effective gene expression.  
The in vitro transfection efficiency of the K9-pDNA-Ca2+ complex was evaluated using 
luciferase pDNA (pLUC) in the four different human cell lines (kidney, cervix, breast, and lung) 
and one mouse cancer cell line (lung). Over expression of the AT2R gene in lung cancer cells  32, 
or other type of CPP-pDNA-Ca2+ complex-based IT delivery of the AT2R gene was known to 
reduce lung cancer cell growth.16 IV injection or IT spray of the K9-pAT2R-Ca2+ complexes 
yielded robust gene expression, primarily in lung cancer cells, and significantly attenuated cancer 
growth. Therefore, this study presents an effective in vitro and in vivo gene delivery system using 
a low-molecular-weight cationic CPP (K9 peptide) for lung cancer therapy.  
The formation of complexes between K9 and pDNA was observed in both the K9-pLUC-
Ca2+ and K9-pLUC complexes as observed via agarose gel electrophoresis (Figure 1) when the 
N/P ratio is higher than 0.5. By itself, calcium chloride showed negligible ability to complex naked 
pLUC even at a high concentration (114 mM) (Figure 1B). However, the K9-pLUC complex 
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without calcium chloride exhibited very low gene expression (Figure 3A), and the size of this 
complex was inappropriately large (500 to 1500 nm) for gene delivery (Figure 2A). The addition 
of calcium chloride in the K9-pLUC complex significantly decreased the complex size in water 
and culture medium (Figure 2A) and correspondingly increased gene transfection (Figure 3A). 
Therefore, calcium chloride acted as an effective condensing agent to decrease the particle size of 
the K9-pLUC complex and enhance transfection efficiency. These observations are in good 
agreement with our previous study in which calcium chloride also decreased particle sizes of CPP-
pLUC complexes with other types of CPP 33. In this regard, it is of interest to note that the PEI-
pLUC complex did not show a decrease in particle sizes as calcium chloride increased 17. Calcium 
ion-dependent increase of the total positive charge of the K9-pLUC-Ca2+ complex may also play 
an important role enhancing transfection efficiency by the stronger interaction with the negatively 
charged plasma membrane 34. In addition, accessibility of SYBER green to the pLUC in the K9-
pLUC complex was significantly decreased when calcium chloride (38 mM) was added to the 
complex solution (Figure 2C), suggesting the K9-pLUC complex was effectively condensed, and 
calcium chloride played an essential role in condensation of the complex. The reduction in the 
particle size of the K9-pDNA-Ca2+ complexes likely led to an increase in transfection efficiency.  
The effect of calcium chloride on the transfection efficiency of the K9-pDNA complex was 
first assessed using A549 cells. The best transfection efficiency was achieved at 38-76 mM calcium 
chloride (Figure 3A). Interestingly, no significant level of gene expression was detected without 
calcium chloride. Since calcium chloride appeared to be an essential component in the 
condensation of the K9-pLUC complex, yielding small complexes with optimal pLUC expression, 
the transfection efficiency of the K9-pLUC-Ca2+ and PEI-pLUC complexes (N/P ratio 10) was 
assessed across five cell lines using three different calcium chloride concentrations (0, 38, and 114 
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mM, Figure 3). This experiment confirmed that pLUC transfection by the K9-pLUC-Ca2+ 
complex was highest at 38 mM calcium chloride, and the LUC expression was significantly better 
than that of PEI-pLUC complex (25kDa PEI) 35.  
In another study, the importance of the K9 peptide in gene expression was evaluated by 
comparing pLUC-Ca2+complex (without K9 peptide) and the K9-pLUC-Ca2+ complex in the same 
calcium concentration. The result in Figure Appendix 1 clearly shows that pLUC expression 
resulting from the pLUC-Ca2+complex (without K9 peptide) was significantly lower than that of 
the K9-pLUC-Ca2+ complex suggesting that K9 in the complex is indeed important to achieve the 
high gene expression from the K9-pLUC-Ca2+ complex. The PEI-pDNA complex had high 
transfection efficiency in the absence of calcium chloride 17, 18, 33. 
A successful gene vector should be able to deliver genetic material to the target cells 
without influencing the viability of the host cells. The present study clearly indicated negligible 
cytotoxicity in vitro up to 2.5 mg/mL for K9 peptide and 1 mg/mL for calcium chloride after 24 
hours for all five cell lines, whereas PEI exhibited strong cytotoxicity at low micromolar 
concentrations in all cell lines except for HEK-293 cells (Figure 4). Additionally, the low toxicity 
of the K9-pAT2R-Ca2+ complexes was also observed in the mouse study after IV and IT 
applications, in which all mice receiving K9-alone or the K9-pAT2R-Ca2+ complex survived 
during the experimental period and did not show acute inflammatory reaction or any histologically 
detectable abnormality. Therefore, data strongly suggested that the K9-pAT2R-Ca2+ complex 
represents a safe and efficient gene transfection vector. 
The robust gene expression in various cell lines with negligible cytotoxicity compelled in 
vivo gene transfection studies. An endogenous apoptosis inducer gene, AT2R, was delivered using 
K9-pAT2R-Ca2+ complexes administered to LLC tumor-bearing mice. As shown in Figure 5, the 
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treatment with the K9-pAT2R-Ca2+ complex via either IT or IV administrations significantly 
attenuated tumor growth macroscopically and microscopically, while the treatment with the non-
specific control gene complex (K9-pLUC-Ca2+) did not show any tumor growth attenuation effect 
(Figure Appendix 2). Immunohistochemical analysis of AT2R protein expression in the lung 
indicated that the expression of this gene was detected mainly in lung cancer cells, but not in 
normal lung tissues, which suggests that the K9–pAT2R–Ca2+ complex preferentially delivered 
the therapeutic gene into cancer cells. It has been known that an increased expression of anionic 
molecules in the membrane of cancer cells, such as the phosphatidylserine, O-glycosylated mucins, 
sialylated gangliosides, and heparin sulfate, resulted in an increased net negative charge compared 
to the nonmalignant cell membrane 36.  
These electric characters of cancer cells support that polycationic peptide-based 
nanoparticles are suited for cancer-targeted gene therapy. The observed increase of apoptotic cells 
in the K9-pAT2R-Ca2+ complex treated groups (Figure 6) suggested AT2R expression in the 
tumors induced apoptosis in cancer cells. These results are consistent with earlier studies 
confirming that AT2R expression attenuates growth of various cancer cells including lung cancer 
cells 16, 32, 37-39. Therefore, AT2R gene expression is a potential treatment scheme for primary as 
well as metastatic lung cancers. A single IV bolus injection or IT spray of K9-alone did not 
attenuate cancer growth significantly as compared with the PBS controls (Figure 5). Dosing K9 
alone or K9-pLUC neither exhibited any side effects such as abnormal clinical or histological signs 
in the native tissue of the lung nor altered the tumor growth. These results suggest that K9 peptide 
is a useful and safe vector for cancer gene therapy. 
In the present study, K9-pDNA-Ca2+ complex-based gene delivery was found to be a useful 
tool for in vivo gene delivery system for lung cancer treatment in immunocompetent mice. Since 
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it is obvious that both cellular and humoral immune systems in the tumor microenvironment play 
a significant role in the regulation of tumor growth 36, 40, use of immunocompetent mice for the 
evaluation of the newly developed treatment regimen is appropriate. Although our study has 
provided first proof of principle data using murine lung carcinoma cells and syngeneic 
immunocompetent mouse model, further evaluation of this gene therapy using multiple types of 
human lung cancer cells in mouse xenograft models will solidify this discovery. 
A recent study has evaluated the utilize the use of polylysine dendrimers for the delivery 
of Polo-like kinase 1 (PLK1)-specific short interfering RNA (siRNA) for the treatment of non-
small cell lung cancer in vitro and in vivo 41. The apparent safety and acceptable transfection 
efficiency of polylysine dendrimers may support the calcium condensed polylysine complexes 
used for pDNA delivery in the present study. The K9-pDNA-Ca2+ complex is a simple approach, 














3.5. Conclusions  
The addition of calcium chloride to nascent complexes of polylysine CPP (K9 peptide) and pDNA 
(pLUC and pAT2R) produced small and stable complexes. These complexes exhibited high gene 
expression in various human and mouse cancer cells comparable to PEI-pDNA complexes. Single 
IV or IT administrations of the K9-pAT2R-Ca2+ complexes significantly attenuated the growth of 
LLC cell allografts in mouse lungs, suggesting that K9 peptide-based gene therapy is effective and 
that the AT2R gene is potentially useful for lung cancer gene therapy. K9 peptide showed 
negligible cytotoxicity in cell culture, supporting the notion that this CPP is a safe delivery vehicle 
for genetic materials (e.g., siRNA and pDNA). Although, further studies are required to confirm 
the in vivo safety of the K9-pAT2R-Ca2+ complexes by formal pharmacokinetics, 
pharmacodynamics, and multispecies toxicity studies, these data showed that the K9-pDNA-Ca2+ 
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4.1. Introduction  
Recent research has seen an accelerated development of vectors that aid in the delivery 
and/or cellular uptake of therapeutic macromolecules (e.g. small peptides, proteins, and nucleic 
acids)1-4. Cell penetrating peptides (CPPs) are one of the most efficient and promising nonviral 
vectors that allow transport of large, hydrophilic biomacromolecules through the seemingly 
impenetrable plasma membrane without cellular rupture 5-8. CPPs normally constitute between 5-
30 amino acid sequences, are cationic, can display low toxicity, and are uniquely capable of 
transporting even negatively charged DNA or siRNA through the cell membrane and nuclear 
membrane. They can generally be divided into three categories, depending on their origin: protein-
derived CPPs such as HIV-TAT and penetratin; chimeric peptides like transportan and MPG; and 
synthetic peptides such as polylysine, polyarginine or amphipathic versions of these peptides 8, 9. 
While it is now well accepted that the mechanism of penetration is not receptor-mediated and is 
energy-independent 4, 10, 11, the exact mechanisms of cellular uptake of these CPPs remains a 
significant unanswered piece of the puzzle 8, 12. The absence of signs of internalization by known 
uptake mechanisms has led to the proposal that direct interactions with the phospholipid of plasma 
membrane is an important first step during the early stages of the internalization process 13.  
Since most CPPs generally have a high content of cationic amino acids such as lysine and 
arginine, experimental observations have predominantly stressed the role of electrostatic 
interaction of cationic CPPs with negatively charged phospholipid headgroups or negatively 
charged cell membrane proteoglycans as the primary triggers for internalization 4, 14, 15. A few 
studies have also suggested that hydrophobic interactions or membrane curvature may influence 
the early stages of internalization16. The nature of the CPPs (e.g. molecular weight, chemical 
structure of the residues, charge, and hydrophilicity) influence the internalization mechanisms 8, 
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14. For example, strong experimental evidence suggests that arginine residues play an important 
role in membrane penetration. Consequently, studies to determine the factors that improve cellular 
penetration of natural and synthetic arginine-rich CPPs are an important research effort 17.  
The TAT peptide (derived from the transcriptional activator of the HIV-1 virus) is one of 
the most extensively studied arginine-rich CPPs, and has been shown to interact strongly with 
model membranes18, 19. As a result, synthetic arginine-rich polypeptides offer great potential for 
application in efficient drug delivery, particularly by altering the patterning of the amino acid 
sequence. For example, polyarginine peptides (e.g. R9) with high potency 6, 20 have been advanced 
by the insertion of hydrophobic residues 1, 21, 22. Rydberg et al. demonstrated that the penetration 
efficiency increases with increased tryptophan content (a hydrophobic amino acid); additionally, 
the CPP activity is more efficient if the tryptophan residues are positioned as a block in the center 
of the CPP sequences than if they are placed as a block at the N-terminus 1. Higher polyarginine 
molecular weight can promote more efficient penetration 23, 24, but optimal lengths of polyarginine 
peptides with 7 to 9 residues 25, 26  have shown high penetration activity as well 1, 23, 27.  
Identification of the mode of penetration of CPPs is essential for the design of future CPPs 
and forms the main motivation of this study. Phospholipid monolayers are extensively used as a 
model for one leaflet of the cell membrane 28-31, the charge density and packing of which can be 
simply adjusted by altering the phospholipid composition and/or surface pressure 28. Here, the 
mechanisms of insertion of eight different synthetic CPPs were compared using three different 
phospholipid monolayers. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (POPG) 
(unsaturated phospholipids), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
(unsaturated phospholipids), and 1, 2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC)  
monolayers (saturated phospholipids) (Table 1) at the air-water interface were chosen as the 
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phospholipids of interest. POPG was used as a model anionic monolayer, POPC and DPPC were 
used as model zwitterionic monolayers, and a 1:1 mixture of DPPC:POPG was used to study the 
effect of charge density on CPP insertion. By keeping the phospholipid monolayer area constant, 
changes in S.P. are recorded upon addition of CPPs to the subphase 32-35. Even if eukaryotic plasma 
membranes are mostly composed of zwitterionic phospholipids in their external layer, a very small 
proportion of anionic phospholipids is also present. It must also be noted that the external leaflet 
of the plasma membrane contains a high amount of negative charges due to the presence of 
glycosaminoglycans such as heparan sulfate at the cell surface. It is therefore hypothesized that 
negatively charged lipids, although small in number, and glycosaminoglycans play a significant 
role in the mechanism of internalization of the positively charged CPPs, by facilitating electrostatic 
interactions with the cell membrane 6, 36-38. Therefore, in accordance with previous studies in this 
area, POPG was chosen as a representative negatively charged phospholipid for our studies.   
Alterations in the membrane packing as well as the peptides’ penetration activity at the 
air/phospholipid monolayer interface was studied for five hydrophilic CPPs (dTAT, R9, L9, H9, 
and RH9) and three amphiphilic CPPs (RA9, RL9, and RW9) (Table 2). Most of these CPPs share 
a common high density of arginine residues (6 arginine residues) except for K9 and H9. Our choice 
of peptides is influenced by previous research in this area. R8 and R9 are the most extensively 
studied arginine-rich peptides, and are inspired by the highly basic minimal transduction domain 
of the HIV-1 TAT protein, typically consisting of 9 amino acids (RKKRRQRRR) 39. Based on 
prior reports 1, 37, four of the arginine rich CPPs (RH9, RA9, RL9, and RW9) have replaced the 
arginine residues at positions 3, 4 and 7 with histidine, alanine, leucine, or tryptophan in order to 


















































Table 2. Identification of the eight CPPs and their properties (peptide sequence, number of 
residues, classification, molecular weight, and sequence composition). 
 
* Hydrophobic/ Neutral/ Basic amino acid % = (Nx/N)*100 , Nx : Number of hydrophobic/ 
neutral/ basic amino acid residues present in the input sequence. N : Input sequence length (net 


















Sequence Composition (in 
percentage) * 
Hydrophobic          Basic       Neutral 
dTAT R K K R R Q R R R H R R K K R 15 Hydrophilic 2200.75 0 93.33 6.67 
H9 H H H H H H H H H 9 Hydrophilic 1251.38 0 100 0 
K9 K K K K K K K K K 9 Hydrophilic 1170.65 0 100 0 
R9 R R R R R R R R R 9 Hydrophilic 1422.74 0 100 0 
RH9 R R H H R R H R R 9 Hydrophilic 1365.62 0 100 0 
RA9 R R A A R R A R R 9 Amphiphilic 1167.41 33.33 66.67 0 
RL9 R R L L R R L R R 9 Amphiphilic 1293.68 33.33 66.67 0 
RW9 R R W W R R W R R 9 Amphiphilic 1512.83 33.33 66.67 0 
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4.2. Materials and Methods  
4.2.1. Materials  
dTAT (RKKRRQRRRHRRKKR; Mw = 2201.7 Da) peptide, H9 (HHHHHHHHH; Mw = 1251.38 
Da) peptide, K9 (KKKKKKKKK; Mw = 1170.65 Da) peptide, R9 (RRRRRRRRR; Mw = 1422.74 
Da) peptide, RH9 (RRHHRRHRR; Mw = 1365.62 Da) peptide, RA9 (RRA ARRARR; Mw = 
1167.41 Da) peptide, RL9 (RRLLRRLRR; Mw = 1293.68 Da) peptide, and RW9 
(RRWWRRWRR; Mw = 1512.83 Da) peptide were purchased from  Biomatik Corporation 
(Cambridge, Ontario, Canada) (Purity > 95%). 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-
rac-glycerol) (sodium salt) (POPG), 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3 
phosphocholine (sodium salt) (POPC),  and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
were purchased from Avanti Polar Lipids, Alabaster, AL, as organic mixtures in chloroform at a 
final concentration of 5 mg/mL. Texas Red ® 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt, (TXR-DHPE) lipid dye was purchased in the dried 
form from Life Technologies (Invitrogen Corp., Carlsbad, CA, USA). All organic solvents used 
for this work was purchased from Fisher Scientific. Dulbecco's phosphate-buffered saline (PBS) 
(pH 7.4) were purchased from Fisher Scientific Inc. in powder form and made into solution using 
a Millipore Gradient System (Billerica, MA). Petri dishes (Falcon 1008, Becton-Dickinson 
Labware, Franklin Lakes, NJ) were purchased from Fisher Scientific. All samples and lipid 






4.2.2. Methods  
4.2.2.1. Langmuir Trough Experiments 
The insertion potential of the different synthetic CPPs was measured using model phospholipid 
monolayers containing different amounts of a negatively charged phospholipid (POPG, POPC, 
DPPC, and POPG/DPPC (1:1)) at the air-PBS buffer interface. Surface pressure changes were 
recorded by a Wilhelmy plate sensor, which is part of the KSV-NIMA Langmuir trough purchased 
from Biolin Scientific, while petri dishes (volume 4 ml, 35 x 10) were used as “mini-troughs” for 
the experiments that did not involve fluorescence imaging. Penetration of the CPPs into preformed 
monoalyers was recorded in the presence of the phospholipid monolayers. A wet calibrated filter 
paper flag was dipped into this buffer solution and used as a probe to monitor changes in the 
surface pressure due to adsorption of surface active material. The phospholipid monolayers were 
spread from chloroformic solutions, on PBS subphase, pH 7.4, using a Hamilton microsyringe 
(Hamilton Co., Reno, NV). The spreading phospholipid solvents were allowed to evaporate for 20 
minutes prior to compression and adding the CPPs. The CPPs aqueous solutions were injected 
underneath the surface of phospholipid monolayers, and the changes in surface pressure with 
respect to time were measured immediately. The final concentration of the CPPs in the subphase 
was maintained at 10 µM (using dTAT, RW9, and RL9, this concentration was found to be beyond 
a so-called “saturation concentration”). The peptide-to-lipid (P/L) molar ratio at an initial surface 
pressure of 20 and 30 mN/m is ≈ 0.5 (at peptide concentration 1 µM) 5. Precaution was taken to 
ensure that the injection did not disrupt the phospholipid monolayer. Adsorption to a bare air-
buffer interface was recorded for all the CPPs studied here to ensure that the changes in the surface 
pressure of the monolayers were due to interaction of the CPPs. Each experiment was run for 30 
minutes at 22 ± 2 °C.  
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4.2.2.2. Fluorescence Microscopy  
Fluorescence microscopy was used concurrently with penetration experiments to monitor the 
morphology of the phospholipid monolayers on insertion of CPPs. These measurements were 
performed using a Teflon trough (volume 40 ml, area 174 X 50 mm) adapted for microcopy (Biolin 
Scientific). The Langmuir trough was mounted on a Leica DM fluorescence microscope with a 
custom designed stage equipped with a 10x or 40x long working distance objective designed for 
fluorescent light. A dichoric mirror/barrier filter assembly directed the excitation light onto the 
monolayer films at a normal angle of incidence and filtered the emitted light. An 89 North 
PhotoFluor II 200 W Metal Halide lamp was used for excitation of the probe. Alterations in the 
surface morphology of the phospholipid monolayers due to the CPPs were visualized with a fast 
camera (Andor Luca S). Short image sequences (5 frames) were recorded for a period of 30 
minutes and stored for further analysis using the Andor capture software. The image processing 
and analysis were performed offline by using the software, ImageJ 1.47 (NIH) for Windows. 
It must be noted that unsaturated phospholipid films such as POPG and POPC do not display any 
lipid domains, when viewed using the fluorescence microscopy technique. Therefore, a 1:1 
mixture of DPPC:POPG was used for all imaging experiments. To initiate each experiment, the 
trough was cleaned with methanol, ethanol, isopropanol and chloroform and thoroughly rinsed 
with Mili-Q water prior to each experiment. A mixed DPPC/POPG monolayer with 1% TXR-
DHPE dye was formed by spreading an organic mixture of this lipid composition dropwise onto 
38 mL of a PBS buffer subphase (at pH=7.4), using a Hamilton airtight glass syringe. The solvent 
was allowed to evaporate completely, by waiting 30 minutes before starting a measurement. 
Changes in surface pressures with time were recorded by a Wilhelmy plate sensor. The 
concentration of the CPPs used was such that the final concentration in the subphase is 10 µM. 
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Images from at least two different monolayers for each sample were taken, and the lens frequently 
translocated to different areas of the trough to ensure uniformity and reproducibility of the data. 
4.2.2.3. Statistical Analysis  
Data were analyzed by using GraphPad software. Statistical evaluation between the means of the 
data was performed using an unpaired t test. One-way ANOVA, Tukey post-test was used to 
analyze the differences when more than two data sets were compared. Each monolayer penetration 
experiment was repeated at least three times (n = 3). 
4.3. Results and Discussion 
A Langmuir monolayer approach coupled with fluorescence microscopy was used to 
determine the differences in ability of the synthetic CPPs to penetrate into cell membranes. 
Phospholipid monolayers with varying composition and headgroup charges representing one 
leaflet of a cell membrane were used as model membranes. Penetration to a phospholipid 
membrane is typically recorded by one of two methods, a constant area method or constant surface 
pressure method. In the constant area method used here, the surface pressure of the phospholipid 
monolayer is fixed at a particular surface pressure (here 20 mN/m and 30 mN/m). Membrane 
insertion of injected peptide is accompanied by an increase in the surface pressure, since the area 
of the trough surface is kept constant. Using a fluorescence microscope, we also directly visualize 
the changes in packing of lipid domains due to peptide insertion. Insertion of the peptides is 
expected to alter the monolayer packing. Since contrast in the images is due to the selective 
segregation of the lipid dye into more fluid regions, disruptions in monolayers manifest themselves 





4.3.1. Penetration of CPPs into POPG Phospholipid Monolayers 
In order to establish a correlation between the chemical structure of the CPPs and their 
penetration activity, we recorded their affinity to insert into phospholipid monolayers with 
different compositions of an anionic phospholipid. We used POPG is as the phopholipid of choice, 
since the penetration of TAT to this phospholipid monolayer has previously been reported. It was 
reported that TAT demonstrated an inability to penetrate the monolayer at bilayer equivalent 
surface pressures 5. Therefore, as a first step, increasing amounts of CPPs (dTAT, R9, and RW9) 
were injected into PBS subphase and alterations in the surface pressure recorded.  
Figure 1, shows changes in surface pressure as a function of peptide concentration (1, 5, 
10 and 20 µM) for dTAT (Figure 1A), R9 (Figure 1B), and RW9 (Figure 1C), keeping the initial 
pressure of POPG to be 20 mN/m. The saturation surface pressure attained in each case as a 
function of concentration of the CPPs is summarized in Figure 1D. Our results illustrate that the 
surface pressure increased in each case, reaching a saturation plateau after about 10 to 30 minutes 
after injection for all penetration experiments which indicates quick migration of the CPPs to the 
phospholipid monolayers. However, the time taken to reach a saturation value also depended on 
the bulk concentration of protein. Further, Figure 1D indicates that a statistically significant 
difference was observed in the penetration ability of the three peptides. RW9 (maximum change 
in surface pressure of 11.26 mN/m,) interacted more strongly with the monolayer, when compared 
with dTAT (the gold standard) and R9 (an arginine rich sequence expected to have high potency 
in cell penetration). We believe that this increased penetration in case of RW9 may be due to the 
hydrophobicity or the aromatic ring of tryptophan amino acids, which also increased the 
amphiphilicity of the peptide. Further, our data show a saturation in the total change in surface 
pressure for all three cases, beyond a concentration of 10 µM, which appears to be a “critical 
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concentration.” Therefore, this concentration was chosen for all other studies described in this 













Figure 1. Changes in surface pressure recorded after adsorption of 1, 5, 10, and 20 µM of (A) 
dTAT, (B) R9, and (C) RW9 to a POPG phospholipid monolayer spread at an initial surface 
pressure of 20 mN/m. (D) The maximum change in surface pressure (plateau values) recorded at 
concentrations of 1, 5, 10 and 20 µM of the three CPPs. dTAT, R9, and RW9 were found to rapidly 
adsorb to the phospholipid monolayer. The results are presented as mean ± SD (n = 3). 
 
In order to better understand the impact of phospholipid packing on peptide insertion, the 
kinetics of surface pressure changes as a function of time, following dTAT injection into the 
subphase, were studied at different initial surface pressures (0, 15, 20, 30, and 40 mN/m) as shown 
in Figure 2A. The total change in surface pressure in the  presence of dTAT resulted in increased 
maximum surface pressure values (Figure 2B) at the initial surface pressures (15, 20, and 30 
mN/m) due to the fact that packing of the phospholipids is not so dense (low phospholipid 
densities) to facilitate dTAT peptides to attach and penetrate. On the other hand, penetration 











































































































decreased when the phospholipid packing density increased (the initial surface pressure 40 mN/m). 
At a high initial surface pressure (40 mN/m), there is a limited incorporation of the CPP into the 
phospholipid monolayer, and the process is much slower. From the figures, we conclude that the 
maximum surface pressure value is at the initial surface pressure 20 mN/m. Therefore, in addition 
to the bilayer equivalent pressure of 30 mN/m, we also report the insertion of our peptides at an 








Figure 2. (A) Time course for surface pressure changes following adsorption of dTAT peptides at 
a bulk concentration of 10 µM to a POPG monolayer spread at initial surface pressures of 0, 15, 
20, 30 and 40 mN/m. (B) The maximum surface pressure (plateau values) reached due to peptide 
adsorption to the phospholipid monolayer, showing that the penetration of the CPPs is the 
maximum for phospholipid films held at a surface pressure of 20 mN/m. Results are presented as 
mean ± SD (n = 3). 
 
Figure 3 illustrates the changes in the surface pressure of the POPG monolayers as a 
function of time, following interactions with eight CPPs (10 µM) at initial surface pressures of 20 
mN/m (Figure 3A) and 30 m/Nm (Figure 3B). It is clear from the figures that the kinetics of 
insertion of RW9 and RL9 are dramatically faster than the other CPPs. Figures 3C and 3D present 
the maximum change in surface pressure for each of the eight peptides, when injected below a 
POPG monolayer held at an initial surface pressure of 20 mN/m (Figure 3C) or 30 mN/m (Figure 
3D). From these figures, it is clear that for both surface pressures, the change in surface pressure 























































with time is significantly higher for RW9 and RL9 compared to other CPPs (p >0.0001). It must 
also be noted that the hydrophilic CPPs (dTAT, H9, K9, R9, and RH9) and RA9 do exhibit 

















Figure 3. Changes in surface pressure as a function of time following injection of the eight CPPs 
below POPG monolayers held at an initial surface pressure of (A) 20 mN/m and (B) 30 mN/m. 
The corresponding maximum surface pressures (plateau values) recorded for the eight CPPs 
(peptide concentration = 10 µM) for initial phospholipid pressures of (C) 20 mN/m and (D) 30 
mN/m. The p of different peptides were compared with each CPP. Results are presented as mean 
± SD (n = 3), (*** = p < 0.0001, one-way ANOVA, Tukey post-test). 
 
Phospholipid monolayers are used as model systems to study insertion of biomolecules 
and/or other particles into biological membranes. Such studies have been exhaustively used to 
study interaction of antimicrobial peptides with membranes 30, 40. Since CPPs share some 
commonalities with antimicrobial peptides, in this study, we have used these model membranes to 

















































































































































gain insight into the biophysical mechanisms of interaction in case of synthetic CPPs. In general, 
it is now accepted that particles that interact only with the head groups of phospholipid monolayers 
typically induce slight changes in surface pressure. On the other hand, insertion into the 
hydrophobic "tail" region (the fatty acyl core) of the phospholipid monolayer can cause a 
significant increase in surface pressure 40. Although numerous studies were interested in the 
“arginine magic,” i.e. the ability of arginine rich peptide sequences to penetrate the cell membrane,  
only  a limited number of studies dealt with model systems (e.g. dTAT and R9) to explain the 
binding mechanism of polyarginine peptides to phospholipid membranes 17. It has been shown that 
physical characteristics (e.g. the hydrophobicity/hydrophilicity and the surface charge) of CPPs 
can influence their binding with phospholipid monolayers 32. However, to the best of our 
knowledge, the influence of introducing other amino acids into an arginine sequence has not been 
extensively studied in model phospholipid systems, such as those described here 1. Our results 
suggest that the introduction of tryptophan and leucine residues into polyarginine 9 improve the 
penetration activity significantly.  
Additionally, numerous studies have mentioned the importance of peptide structural 
conformational changes upon phospholipid interactions to facilitate membrane translocation41-43. 
It was found that the different penetration properties of the cationic CPPs and amphiphilic CPPs 
may arise from the insertion mechanism into phospholipid monolayers 37. Walrant et al. indicated 
that while RW9 and RL9 have an affinity for anionic phospholipids, the affinity is just a little 
higher for RW9 than RL9. The interactions are mostly ruled by hydrophobic assistances in both 
CPPs 6, 37. Additionally, they found that a flip of the CPP occurs where the arginine residues aid 
as a hinge, letting the hydrophobic amino acids insert deeper in the plasma membrane 37. Although 
alanine is a hydrophobic amino acid, RA9 demonstrates only a moderate surface activity when 
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compared to RW9 and RL9. This behavior is possibly due to the chemical structure of the 
hydrophobic residues; alanine has a very small side chain when compared with the more bulky 
tryptophan. Before studying the incorporation of the CPPs with the phospholipid monolayers, we 
examined the behavior of the eight CPPs at a bare air/water interface by using the Langmuir 
technique described above in the absence of the phospholipids (Figure Appendix 3). All eight 
CPPs showed no or little surface activity for the 30 minutes duration, which is in agreement with 
the nature of the five hydrophilic CPPs (dTAT, H9, K9, and RH9) and weak amphiphilic characters 
of the three CPPs (RA9, RL9, and RW). These results indicate that the change in surface pressure 
recorded in Figure 3 is clearly due to interactions with the anionic phospholipid films.  
4.3.2. Penetration of the CPPs in DPPC and POPC Phospholipid Monolayers 
In order to test the effect of electrostatic interactions versus hydrophobic interactions on 
the insertion potential of these synthetic peptides into model membranes, we compare the insertion 
potential of the eight CPPs into zwitterionic monolayers (POPC [unsaturated] and DPPC 
[saturated]) compared with the POPG monolayer. Figure 4A shows the change in surface pressure 
as a function of time, for the POPC film initially held at a surface pressure of 20 mN/m. As seen 
in the figure, low penetration activity was observed for the synthetic peptides, except for RW9 and 
RL9. In fact, the penetration activity of RW9 and RL9 is found to be significantly higher than the 
other CPPs. Figure 4B shows the change in surface pressure versus time for an initial surface 
pressure of 30 mN/m. The maximum surface pressures reached in each case is summarized in bar 
graphs in Figure 4C and 4D. As seen, both RW9 and RL9 have significant surface activity 
compared to other CPPs (p >0.0001) as shown by the maximum values of 5.9 and 4.3 mN/m 
respectively (at the initial surface pressure of 20 mN/m) and 3.7 and 1.9 mN/m respectively (at the 
initial surface pressure of 30 mN/m). In contrast, even though RA9 is an amphiphilic peptide, it 
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does not display significant insertion into the POPC films. Figure 5 presents a summary of the 
comparison of the maximum surface pressure values that were recorded at a concentration of 10 
µM (the initial surface pressures 20 mN/m [Figure A] and 30 mN/m [Figure B]) for the eight 
CPPs, for an anionic phospholipid film (POPG) and a zwitterionic phospholipid film (POPC). This 
graph clearly indicates that anionic phospholipid head groups play an important role for 
interactions with the eight CPPs. However, for two of the three arginine-rich peptides modified by 
hydrophobic residues, the membrane penetration potential is significantly enhanced.   
Figure 6A shows the change in surface pressure as a function of time, for the DPPC (more 
tightly packed monolayer) film initially held at a surface pressure of 20 mN/m. As seen in the 
figure, no penetration activity was observed for the synthetic peptides, except for RW9 and RL9. 
In fact, the penetration activity of RW9 and RL9 is found to be significantly higher than the other 
CPPs. Figure 6B shows the change in surface pressure versus time for an initial surface pressure 
of 30 mN/m. For clarity, we only show the change in surface pressure for RW9 and RL9. The 
maximum surface pressures reached in each case is summarized in bar graphs in Figure 6C and 
6D. As seen, both RW9 and RL9 have significant surface activity compared to other CPPs (p 
>0.0001) as showed by the maximum values of 4.0 and 1.7 mN/m respectively (at the initial 
surface pressure of 20 mN/m) and 4.5 and 0.6 mN/m respectively (at the initial surface pressure of 
30 mN/m). The smaller penetration activity for zwitterionic DPPC monolayers (saturated 
phospholipids) in some CPPs when compared to anionic POPG and POPC (both unsaturated 
phospholipids) monolayers indicate weak interactions between the CPPs and DPPC. The reduced 
insertion of all but RW9 into the DPPC phospholipid monolayer may also be the result of a well-


















Figure 4. Changes in surface pressure as a function of time following injection of the eight CPPs 
below POPC monolayers held at an initial surface pressure of (A) 20 mN/m and (B) 30 mN/m. 
The corresponding maximum surface pressures (plateau values) recorded for the eight CPPs 
(peptide concentration = 10 M) for initial phospholipid pressures of (C) 20 mN/m and (D) 30 
mN/m. The p of different peptides were compared with each CPP. Results are presented as mean 
































































































































































Figure 5. The  maximum change in surface pressure of the phospholipid monolayers (POPG and 
POPC) initially held at surface pressures of  20 mN/m (A) and 30 mN/m (B) for the eight CPPs. 
Results are presented as mean ± SD (n = 3), (*** = p < 0.0001, ** = p < 0.001, and * = p < 0.05 
unpaired t test). The p of different peptides were compared for an initial surface pressure of POPG 
phospholipid monolayers with POPC phospholipid monolayers for each CPPs. 
 
Figure 6 also shows that the penetration activity of RW9 is significantly higher than RL9 
or RA9 in both initial surface pressures, even though all three of these arginine-rich peptides were 
modified by hydrophobic moieties. It was found that the addition of one tryptophan residue to a 
polyarginine 7 peptide (R7) increased its penetration efficiency 44. Clearly, tryptophan residue has 
a key role in cell penetration, possibly due to the bulky side chains 1, 37, 45, 46. In summary, our 
results show that in addition to electrostatic effects, hydrophobic interactions as well as the 
chemical nature of the amino acids do influence the differences in membrane penetration potential 
of the CPPs. 
4.3.3. Penetration of the CPPs in Mixed (POPG:DPPC) Phospholipid Monolayers 
The mixing properties of a mixed monolayer of DPPC and POPG was used as a model to 
understand the role of different composition of the anionic phospholipid headgroup on peptide 
insertion in order to simultaneously image the insertion and possible alterations in monolayer 

















































































(section 3.4.). The mixture of saturated PC (DPPC) phospholipids and fluid unsaturated PG 














Figure 6. Surface pressure change as a function of time for a DPPC monalyer (A) at an initial 
surface pressure of 20 mN/m following interaction with eight CPPs (10 µM) (B) at an initial 
surface pressure of 30 mN/m following injection of RL9 and RW9. The maximum change in 
surface pressure (plateau values) recorded for the eight CPPs at initial phospholipid surface 
pressure of (C) 20 mN/m for the 8 peptides and (D) 30 mN/m for RL9 and RW9. The p of different 
peptides were compared with each CPP. Results are presented as mean ± SD (n = 3), (***   = p < 
0.0001, one-way ANOVA, Tukey post-test).  
 
 Figure 7 shows change in surface pressure of a mixed phospholipid film as a function of 
time, for the eight CPPs (10 µM) at the initial surface pressure 20 (Figure 7A) and 30 m/Nm 
(Figure 7B).  Our results indicated that reducing the surface charge density of the phospholipid 
monolayers by using mixed phospholipids (POPG/DPPC) caused a decrease in the surface 
pressure. Figure 7C and 7D summarize the maximum change in surface pressure for the eight 
























































































































CPPs. Our results show that the hydrophilic CPPs (dTAT, H9, K9, R9, and RH9) and RA9 have 
moderate surface activity when the maximum surface pressure values are between 1.5 and 3.0 
mN/m (the initial surface pressure 20 mN/m) and between 1.2 and 2.6 mN/m (the initial surface 
pressure 30 mN/m). Conversely, RW9 and RL9 have large surface pressure increases as shown by 
the maximum values of 8.0 and 9.4 mN/m, respectively, (the initial surface pressure 20 mN/m) 
and 5.6 and 4.9 mN/m respectively (the initial surface pressure 30 mN/m). Figure 8 presents the 
summary of the maximum surface pressure values that were recorded at a concentration of 10 µM 
(the initial surface pressures 20 and 30 mN/m) for the eight CPPs, for all four phospholipid films 
(POPG, POPC, DPPC and, POPG:DPPC). This summary clearly indicates that while anionic 
phospholipid headgroups play the most important role for interactions with the hydrophilic CPPs 
(dTAT, H9, K9, R9, and RH9), the insertion of the arginine peptides is also significantly influenced 
by the presence of tryptophan residues.  
To further our understanding of the role of the 3D peptide structure on the insertion 
potential of the CPPS, we used circular dichroism spectroscopy (CD) to determine the helicity of 
the eight CPPs in PBS solution (Figure Appendix 4). Our data confirmed that the free CPPs had 
random coil conformations, suggesting that the initial steps in peptide insertion are not influenced 
by the 3-D structure. However, NMR, CD and molecular dynamics simulation studies by other 
groups have shown that insertion into the lipid bilayers can induce different degrees of structural 
re-orientation depending on the amino acid sequence 6, 47 37, 48.  This may also explain the 
differences in a peptide’s ability to translocate through the membrane. Therefore, we conclude that 
while the 3D structure in solution does not seem to influence the surface activity of the 8 CPPs, 
the penetration and translocation through cell membranes may be influenced by a lipid bilayer 
induced alteration in the protein structure. This suggests that while the surface pressure changes in 
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a Langmuir trough may be a good screening test to determine the penetration potential of synthetic 
peptides into cell membranes, the ultimate translocation potential of the peptide may be dictated 
















Figure 7. Changes in surface pressure as a function of time for the mixed phospholipids 
(POPG/DPPC at a ratio of 1:1) held at an initial surface pressure of (A) 20 mN/m and (B) 30 
mN/m, following injection of the eight CPPs into the subphase. The maximum change in surface 
pressure (plateau values) recorded for the phospholipids held at an initial surface pressure of (C) 
20 mN/m and (D) 30 mN/m. The p of different peptides were compared with each peptide. Results 
are presented as mean ± SD (n = 3), (*** = p < 0.0001, and ** = p < 0.001, one-way ANOVA, 



































































































































































































































































































































































































































































































Figure 8. Summary of results showing the  maximum change in surface pressure of the 
phospholipid monolayers (POPG, POPC, DPPC, and POPG:DPPC) initially held at surface 
pressures of  20 and 30 mN/m for the eight CPPs: (A) dTAT, (B) H9, (C) K9, (D) R9, (E) RH9, 
(F) RA9, (G) RL9, and (H) RW9 Results are presented as mean ± SD (n = 3), (*** = p < 0.0001, 
** = p < 0.001, and * = p < 0.05 unpaired t test). The p of different peptides were compared for an 
initial surface pressure of 20 mN/m with 30 mN/m for each CPPs. 
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It is expected that analysis of the kinetics and thermodynamics of the 8 CPPs will provide 
a more complete understanding of the nature of the CPP partitioning into the phospholipid 
monolayers. Using Langmuir models of protein insertion into phospholipid monolayers 49-55, we 
can calculate the kinetics of protein partitioning into different monolayer systems. Such analysis 
will form the topic for a future manuscript currently under preparation. 
4.3.4. Fluorescence Microscopy 
Using fluorescence imaging of the monolayer surface, it is possible to gain insight into the 
structure of the phospholipid monolayers. Fluorescence microscopy helps us to understand 
alterations in organization of phospholipid monolayers after injection of the CPPs in the subphase. 
Furthermore, it is an appropriate effective technique to study the structural phase separation and 
disruption induced by CPP interactions with phospholipid monolayers 30, 56. Figure 9A 
demonstrates the morphology of the POPG/DPPC (1:1) phospholipid monolayer domains (at the 
surface pressure 30 mN/m) before injection of the CPPs. It shows characteristic stripe patterns 
with dark regions (the bright regions in the dark domains looked like veins on a leaf). Contrast in 
these images is due to selective segregation of the lipid dye molecules into the liquid expanded 
regions, while the closely packed liquid condensed domains exclude the bulky dye molecules. The 
domains were magnified as compression proceeded, and the view field becomes almost dark 57 at 
the bilayer equivalent pressures studied here. The images were obtained at 1, 5, 10, 20, and 30 
minutes, respectively after injection of the CPPs into the subphase.  
Remarkably, the domain morphology altered significantly depending on the nature of the 
CPP. The images display that CPPs induce different morphologies even at the first minutes after 
injection. In the case of dTAT, H9, K9, R9, RH9, and RA9 (Figure 9B, C, D, E, F, and G, 
respectively), the overall change in the domain morphology is limited (a very slight increase in the 
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gray regions) for the first 10 minutes (after the CPP was injected) except for RW9. In case of RW9 
(Figure 9I), within 10 minutes of CPP injection, the dark domains completely disappeared (no 
domains could be observed) after aproximitly 5 minutes of the injection. Interestingly, after 20 
minutes the morphologies of the domains were vividly different for all CPPs. In the case of RL9 
(Figure 9H), blurred gray patches began to appear, while all other CPPs showed an increase in the 
brightness and width of the stripe pattern. At 30 minutes all of the peptides (except H9) showed 
either blurred gray patches, or more disrupted monolayers like RL9 and RW9. Our results also 
show that H9 shows the minimum perturbation of the phospholipid packing among all the CPPs 
studied, even after 30 minutes (darker domains are still visible). Moreover, the arginine-rich 
peptides all induce significantly higher changes in the phospholipid packing compared to dTAT. 
Peptide RW9 demonstrates the maximum disruption of monolayer packing, followed by RL9 and 
RA9. R9 and RH9 seem to induce very similar membrane perturbation.  
In general, our results reinforce the role of not only electrostatics and hydrophobic 
interactions, but also the chemical nature of amino acids on the membrane penetration potential of 
CPPs. While all CPPs show the maximum membrane penetration in the presence of anionic 
headgroups, amphiphilic CPPs with tryptophan residues show a significant membrane insertion 
potential for all model lipid monolayers. Moreover, we present direct evidence of destabilization 
of phospholipid packing induced by amphiphilic arginine-rich CPPs, which is also most 







Figure 9. Fluorescent micrographs of a POPG/DPPC (1:1) monolayer at a surface pressure of 30 
mN/m on PBS buffer: (A) before injection of peptides (0 minutes), after injection of (B) dTAT (10 
µM) into the sub-phase, (C) H9 (10 µM) in the sub-phase, (D) K9 (10 µM) in the sub-phase, (E) 
R9 (10 µM) in the sub-phase, (F) RH9 (10 µM) in the sub-phase, (G) RA9 (10 µM) in the sub-
phase, (H) RL9 (10 µM) in the sub-phase, and (I) RW9 (10 µM) in the sub-phase. The relative 
increase in the bright area from 1 to 30 minutes corresponds to the increase in the disordered fluid 
phase caused by peptides insertion. The scale bar in the lower right represents 50 µm. The shape 
























































Understanding the interactions of synthetic CPPs with phospholipid membranes is an 
important step when designing future synthetic CPPs capable of intracellular drug delivery. In this 
study, phospholipid monolayers with different composition of anionic headgroups (POPG, POPC, 
DPPC, or POPG/DPPC) have been used to study the penetration, and/or interaction with eight 
synthetic peptides including hydrophilic CPPs (dTAT, H9, K9, R9, and RH9) and the amphiphilic 
CPPs (RA9, RL9, and RW9). Insertion of the CPPs into the phospholipid monolayers were 
followed using Langmuir monolayer techniques and fluorescence microscopy. As expected, the 
incorporation of the cationic CPPs into the anionic phospholipids (POPG) was much higher when 
compared with the zwitterionic phospholipids (POPC and DPPC).  
In addition to electrostatic interactions, hydrophobic interactions as well as the chemical 
nature of the amino acid residues influenced the membrane insertion potential. The presence of 
tryptophan residues induced maximum perturbation of the phospholipid packing. All CPPs 
interacted with anionic phospholipids, but the interactions of RW9 and RL9 with membrane 
monolayers was significantly different when compared with the other peptides. RW9 and RL9 
strongly penetrated the model cell membranes and also induced the maximum alterations in 
phospholipid packing. The five hydrophilic CPPs (dTAT, R9, L9, H9, and RH9) and RA9 peptides 
also showed penetration into the model membranes, but did not appear to cause significant 
membrane disruption. The different mechanisms of the eight CPPs compel additional 
investigations using these CPPs for delivery of macromolecules in cellular systems. Further 
elucidating performance in light of these mechanistic findings will aid the design of the next 
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5.1. Introduction  
Efficient intracellular delivery of genetic material (DNA and RNAi) suffers from several 
bottlenecks. Unlike micromolecules that can enter the cell by passive diffusion or through specific 
channels, the larger size and anionic nature of the macromolecules prevent them from penetrating 
through the plasma membrane. As a result, most macromolecules enter the cell through the 
endocytosis mechanism 1, 2. However, this process suffers from bottlenecks of its own, including 
effective cellular uptake as well as timely escape from the endosomal pathway to prevent 
enzymatic degradation of the nucleic acids in lysosomes 3-6. The plasma membranes as well as the 
membranes in the intracellular compartment serve as barriers that prevent penetration or escape of 
macromolecules and are the principal deterrents to efficient intracellular delivery 7, 8. 
Subsequently, tremendous efforts have been made to develop gene vectors (both viral and 
nonviral) that can easily penetrate the plasma membrane as well as effectively avail of the cell’s 
intracellular transport mechanism to enable intracellular delivery of genetic material. Vector 
unpacking at the intracellular site is also a necessary step in this process 9. Viral vectors are highly 
efficient in this process, but safety concerns (e.g., immunogenicity) still persist 10-12. Nonviral 
vectors, on the other hand, offer several advantages over viral vectors, such as ease of synthesis, 
low cost, and low degree of immunogenicity 12-14. Therefore, efficient design of nonviral vectors 
for intracellular gene delivery necessitates an understanding of the mechanisms through which the 
nonviral vectors can effectively trigger cellular uptake, as well as escape from late endosomes to 
deliver their payload.   
The main structural component of the plasma membrane, as well as the various 
compartments in the intracellular trafficking pathway, is phospholipids. While the zwitterionic 
phosphatidylcholine (PC) headgroups make up the major phospholipid content of all eukaryotic 
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cell membranes, anionic phospholipids such as phosphotidylserine (PS) are present in the inner 
leaflet of the plasma membrane, as well as the lipid membranes that make the endosomes 7, 15. Cell 
membranes also contain very small amounts of anionic phosphotidylglycerol (PG), while late 
endosomes are unique in their composition of Bis (Monoacylglycero) Phosphate (BMP), which is 
a structural isomer of PG. In fact, compared to the outer leaflet of the cell membrane, the 
endosomes are significantly enriched in anionic lipids such as PS and BMP 16.  In addition to the 
change in the lipid headgroup moieties, the intracellular pH also decreases along the endocytic 
pathway, from the early endosome to the lysosomes 15. Therefore, understanding the mechanisms 
of nonviral gene delivery vectors requires an understanding of their interactions with these 
biological barriers.  
Noncovalent complexation of genetic material (e.g., DNA and siRNA) using polycations 
is being considered as a potential nonviral gene vector that can deliver larger genetic payloads at 
the required delivery site 12. Unfortunately, the most efficient polycations, such as 
polyethylenimine (PEI), are also the most toxic. Further, while high-molecular-weight polycations 
are often essential to condense larger genetic material such as plasma DNA (pDNA) into small 
particles, the increase in molecular weight often increases cytotoxicity as well 17. We and others 
have shown that the use of synthetic cell penetrating peptides (CPPs) is a potentially interesting 
method for condensation of genetic material as well as their delivery across the cell membrane 6, 
11, 12, 18-20.  CPPs consist of low-molecular-weight cationic or amphiphilic sequences of about 30 
residues 12, 17, 18, 21. Since their discovery in the early 1990s, they have attracted a lot of attention 
as potential candidates for delivery of biomolecules to cells 12, 22, 23. In general, CPPs can be 
classified into three types, depending on their origin: natural CPPs (protein-derived) (e.g., TAT 
peptide); synthetic CPPs (e.g., polyarginine); and chimeric CPPs (e.g., transportan) 12. Simple 
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polyarginine or polylysine molecules influenced by a highly basic minimal transduction domain 
of the protein-derived TAT protein, typically consisting of nine amino acids (RKKRRQRRR) were 
shown to cross the plasma membrane even more readily than the TAT peptide 2, 24. Due to the faith 
in “arginine’s magic” several groups, including us have previously reported on the ability of using 
these polypeptides as CPPs 25-27. It has also been shown that the membrane insertion potential of 
synthetic peptides is dependent on the positive charge on the CPPs interacting with anionic 
phospholipids within the membrane.28 Particularly, synthetic CPPs with 7-9 amino acids have 
demonstrated the best cell penetration efficiency, and this efficiency has been found to go down 
as the residue sequence length is either increased or decreased 17, 29, 30. Further, we and others have 
shown that the presence of hydrophobic moieties, such as tryptophan can also enhance 
phospholipid penetration 2, 31. Particularly, the properties of the guanidyl group were extremely 
efficient in increasing the membrane penetration behavior of arginine polypeptides 25.   
Numerous studies have also demonstrated that adding calcium chloride (CaCl2) to CPP-
siRNA or pDNA complexes produced stable and small nanoparticles that improved the 
transfection efficiency of these gene complexes in vitro and in vivo 6, 11, 14, 20, 32. It was also found 
that adding 100 mM CaCl2 to the CPP-pDNA samples yielded the highest gene expression 
compared to 50, 150, and 300 mM 17, possibly by enhancing their endosomal release before 
degradation by lysosomes 33, 34. However, how does complexing CPPs with genetic material in the 
presence of CaCl2 impacts their cell insertion potential has not been previously reported. While 
the calcium condensed CPP-pDNA complex uptake may be aided by endocytosis or cell 
penetration, which in turn involves interactions with specific cell membrane lipids or possibly 
interactions with membrane associated proteoglycans, the desirable goal of endosomal escape is 
typically destabilization of the endosomal membrane to allow timely escape of genetic material 22, 
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35-37. Therefore, understanding the mechanism of cell penetration (or cellular uptake) of these CPP 
induced condensed complexes as well as the mechanisms of escape of these nonviral gene vectors 
from endosomal compartments is essential for designing efficient CPP-pDNA vectors 2, 38, 39. 
In order to better understand the stability of gene complexes and their interactions with 
phospholipid membranes in the endocytic pathway (plasma, endosome, and lysosome 
membranes), the mechanisms of interactions between the condensed gene complexes with 
phospholipid membranes form the focus of this study. In particular, we report on the interactions 
of seven different gene complexes with model PC, PS and PG phospholipid monolayers at two 
pHs (7.4 and 4.4). Based on previous studies, our choice of CPPs consists of four hydrophilic CPPs 
(i.e., dTAT, K9, R9, and RH9) and three amphiphilic arginine-rich peptides (RW9, RL9, RA9) 
(Table 1). Positively charged synthetic polypeptides (polyarginine R9 and polylysine K9) were 
used to study the effect of specific amino acids on gene complex formation and interaction with 
the plasma membrane. Arginine-rich CPPs where the arginine residues at positions 3, 4, and 7 are 
replaced with tryptophan, leucine, alanine, and histidine (RW9, RL9, RA9, and RH9) were used 
to study the effect of a combination of positively charged and hydrophobic residues on the insertion 
efficiency of the CPP-gene complexes 2. dTAT (double-TAT) is a natural HIV protein derived 
CPP that was used as a control.  In our studies, unsaturated fatty acids with mixed alkyl chains 
were used as simple models of the phospholipid barriers. POPC monolayers were used as model 
zwitterionic monolayers, while POPS and POPG phospholipids were used as model anionic 
monolayers (Table 2) to study the effect of lipid headgroup charge density on the phospholipid 
insertion potential of gene complexes. One of the advantages of using model membranes is that 
their packing can be easily controlled and varied. Additionally, model membranes have previously 
been used to study the individual interactions of DNA as well as CPPs, to better understand their 
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mechanisms of interaction. The two pHs represent the extreme limits in the acidic nature of the 
environment in the endocytic pathway. Finally, since several previous in vitro and in vivo studies 
have shown that calcium improves the transfection efficiency of gene complexes 6, 11, 14, 17, 20, 32, 40, 
41, here we also present the effect of the addition of calcium on the stability and membrane insertion 





Table 1. Identification of the seven CPPs and their properties (peptide sequence, number of 


















15 Hydrophilic +13 +14 2200.75 
K9 KKKKKKKKK 9 Hydrophilic +9 +9 1170.65 
R9 RRRRRRRRR 9 Hydrophilic +9 +9 1422.74 
RH9 RRHHRRHRR 9 Hydrophilic +6 +9 1365.62 
RA9 RRAARRARR 9 Amphiphilic +6 +6 1167.41 
RL9 RRLLRRLRR 9 Amphiphilic +6 +6 1293.68 
RW9 RRWWRRWRR 9 Amphiphilic +6 +6 1512.83 
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Table 2. Name, synonyms, classification, and structure of the POPC, POPS and POPG membrane 
models. 
* Marsh, D. CRC handbook of lipid bilayers. 1990. 
 
5.2. Materials and Methods 
5.2.1. Materials 
Plasmid DNA (pDNA) encoding firefly luciferase (pGL3, 4818 bp) was obtained from Promega 
(Madison, Wisconsin). The pDNA purity level was determined by UV-Spectroscopy and agarose 
gel electrophoresis. dTAT (RKKRRQRRRHRRKKR; Mw = 2201.7 Da) peptide, K9 
(KKKKKKKKK; Mw = 1170.65 Da) peptide, R9 (RRRRRRRRR; Mw = 1422.74 Da) peptide, 
RH9 (RRHHRRHRR; Mw = 1365.62 Da) peptide, RA9 (RRA ARRARR; Mw = 1167.41 Da) 
peptide, RL9 (RRLLRRLRR; Mw = 1293.68 Da) peptide, and RW9 (RRWWRRWRR; Mw = 
1512.83 Da) peptide were purchased from  Biomatik Corporation (Cambridge, Ontario, Canada) 
(Purity > 95%). 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3 phosphocholine (sodium salt) 
Name Synonyms Classification 
Relative  Charge * 
pH 7.4         pH 4.4 
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(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (POPS), and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (POPG) were purchased 
from Avanti Polar Lipids, Alabaster, AL, as organic mixtures in chloroform. Agarose (Medium-
EEO/Protein Electrophorisis Grade) was purchased from Fisher Scientific. Bench Top DNA 
Ladder was purchased from Promega (Madison, WI). SYBR Green I Nucleic Acid Gel Stain was 
obtained from Invitrogen (Carlsbad, CA). Calcium chloride dehydrate (CaCl2. 2H2O) was 
purchased from Fisher Scientific. Other organic chemicals used for this work was purchased from 
Fisher Scientific. Petri dishes (Falcon 1008, Becton-Dickinson Labware, Franklin Lakes, NJ) were 
purchased from Fisher Scientific. All samples and lipid mixtures were stored at -20 °C when not 
in use. 
 
5.2.2. Methods  
5.2.2.1. Preparation of CPP-pDNA-Ca2+ Complexes 
CPP-pDNA complexes were prepared by adding 15 µL of CPPs solution (0.28 µg/µL) to 10 µL 
(0.1 µg/µL) of pDNA (TAE Buffer (1x) was used as a solution for DNA storage), followed by fast 
pipetting for 20 seconds. At that point, 15 µL of CaCl2 of desired molarity (100 mM in most cases) 
was added and mixed by fast pipetting for a further 20 seconds. This process resulted in the 
formation of condensed complexes containing pDNA and the CPP. After preparing the gene 
complexes, they were stored at 4°C for 15 to 20 minutes and then used for further analysis. The 
peptide-to-lipid (P/L) molar ratio at an initial S.P. of 20 and 30 mN/m was 0.25. 
5.2.2.2. Agarose Gel Electrophoresis 
4 µL (1 x) of Tris-acetate-EDTA (TAE) buffer was added to the solution containing the gene 
complexes of interest. EDTA interacts with the divalent metal ions in solution and thus inhibits 
metal-dependent nucleases. 4 µL of SYBR Green 1 (a highly sensitive DNA gel stain used for 
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visualization of DNA in agarose or acrylamide gels) was mixed with the gene complexes. The 
mixture was well-mixed and stored at 4°C for 15 to 20 minutes. After the storage, 7 µL of 6X 
DNA Loading Dye (dye used to prepare DNA markers and samples for loading on agarose gels) 
was added to allow visual tracking of DNA migration during electrophoresis. A one kb DNA 
ladder was used. The presence of glycerol ensures that the DNA in the ladder and sample forms a 
layer at the bottom of the well. The approximate mass of DNA in each of the bands is provided for 
approximating the mass of DNA in comparatively concentrated samples of similar size. The 
mixture solutions were loaded onto a 1 % agarose gel, and electrophoresed for 30 minutes at 110 
V. 
5.2.2.3. Particle Size 
The particle size (effective diameter (nm)) of CPP-pDNA complexes with calcium chloride was 
determined by dynamic light scattering (Brookhaven Instruments, Holtsville, NY). All samples 
intended for particle size measurements were prepared using PBS at pH 7.4 and 4.4.  
5.2.2.4. Zeta Potential 
The zeta potentials of the complexes were measured by Zeta PALS dynamic light scattering 
(Brookhaven Instrument, Holtsville, NY). All samples intended for particle size measurements 
were prepared using PBS, nuclease free water (NFW), and serum-free media (SFM). All samples 
intended for zeta potential measurements were prepared using PBS at pH 7.4 and pH 4.4. 
5.2.2.5. Langmuir Trough Experiments 
The insertion potential of the different synthetic complexes and CPPs was measured using model 
phospholipid monolayers (PMs) containing different amounts of a zwitterionic (POPC) or 
negatively charged phospholipid (POPS, and POPG) at the air-PBS buffer interface. S.P. changes 
were recorded by a Wilhelmy plate sensor, which is part of the KSV-NIMA Langmuir trough 
purchased from Biolin Scientific, while petri dishes (volume 4 ml, 35 x 10) were used as “mini-
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troughs” for the experiments. Insertion of the gene complexes and CPPs into preformed 
monoalyers was recorded in the presence of phospholipid membranes. A wet calibrated filter paper 
flag was dipped into this buffer solution and used as a probe to monitor changes in the surface 
pressure due to adsorption of surface active material. The phospholipid membranes were spread 
from chloroform solutions, on PBS subphase, at pH 7.4 and 4.4, using a Hamilton microsyringe 
(Hamilton Co., Reno, NV). The spreading phospholipid solvents were allowed to evaporate for 20 
minutes prior to adding of the gene complexes (or free CPPs). The gene complexes (and free CPPs) 
aqueous solutions were injected underneath the surface of lipid membranes, and the changes in 
surface pressure with respect to time were measured immediately. Precaution was taken to ensure 
that the injection did not disrupt the phospholipid monolayer. Adsorption to a bare air/buffer 
interface was recorded for all the gene complexes (and free CPPs) studied here to ensure that the 
changes in the S.P. of the monolayers were due to interaction of the gene complexes (or free CPPs) 
with the cell membrane. Each experiment was run for 60 minutes at 22 ± 2 °C. All figures were 
normalized by subtraction of the control (the phospholipids [POPC, POPS, and POPG] without 
complexes or free CPPs) at pH 7.4 and 4.4 to ensure that the differences in the S.P. of the 
monolayers were due to interaction of complexes and peptides. 
5.2.2.6. Statistical Analysis 
Data were analyzed by using the GraphPad software. Statistical evaluation between the means of 
the data was performed using an unpaired t test. One-way ANOVA, Tukey post-test was used to 
analyze the differences when more than two data sets were compared. Each experiment was 





5.3. Results and Discussion 
5.3.1. Physical Characterization of the CPP-pDNA-Ca2+ Complexes 
Two important characteristics of CPP-pDNA-Ca2+ complexes are their particle size and 
overall charge. Figure 1A illustrates the particle size of the seven CPP (dTAT, K9, R9, RH9, RA9, 
RL9, and RW9)-pDNA-Ca2+ complexes in PBS (ionic strength, 185 mM) at pH 7.4 and 4.4. 
Overall, the particle size of the complexes was around 250 nm at pH 7.4 (with relatively narrow 
polydispersity (<0.2)), irrespective of the CPP used, suggesting that the choice of CPP has little 
effect on the particle size at normal pH. Further, an increase in particle size was noted at low pH 
(4.4), compared to the physiological pH (7.4), suggesting that an acidic environment reverses the 
condensing effect of Ca2+. Moreover, a reduction in the photon counting rate (kilo-counts per 
second; Kcps), at the more acidic pH also supports the argument that these gene complexes may 
be partially dissociated or are no longer condensed at pHs that are relevant to the late endosomal 
or lysosomal environment. Such acidic pH induced dissociation has previously been reported for 
DNA-calcium complexes 17, 42. Figure 1B presents the zeta potential of these gene complexes at 
normal and acidic pHs. We find that at the neutral pH, the zeta potential values are positive, 
although there are small differences in the individual values. This is possibly due to the charge on 
the CPPs making up the condensed gene complexes. The net positive zeta potential of our 
condensed complexes verifies the cationic nature of the complexes, and confirms that while there 
is a core of pDNA, the CPP, being in excess form the shell of these gene complexes. Figure 1B 
also shows that the net charge on the particles is switched when the pH is lowered, and the gene 
complexes become anionic or neutral. These observations confirm that a lowering of the 
environmental pH destabilized the noncovalently condensed pDNA complexes, allowing the 















Figure 1. (A) Particle size of the seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9)-pDNA-
Ca2+ complexes, which was measured in phosphate buffer saline and at pH 7.4 and 4.4. For missing 
data points, diameter was undetectable. (B) Zeta potentials of CPPs (dTAT, K9, R9, RH9, RA9, 
RL9, and RW9)-pDNA-Ca2+ complexes in phosphate buffer saline and at pH 7.4 and 4.4. Results 
are presented as mean ± SD (n = 3). 
 
To further prove that at pH ~ 7.4, the pDNA is immobilized with the CPP to form 
complexes, we ran agarose gel electrophoresis assay for these complexes. Figure 2 illustrates the 
results of this assay for these complexes. Free pDNA was used as a control, while the leftmost 
column shows the molecular weight marker. When an electric field is applied across the cells, the 
appearance of different bands along the column corresponds to the migration of any free DNA. 
Our results show that most of the gene complexes completely immobilized the pDNA (no bands 




































































































































































































Figure 2. Agarose gel electrophoresis study of the seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, 
and RW9)-pDNA-Ca2+ complexes. “M” Refers to the size marker. 
 
 
5.3.2. Insertion of the CPP/pDNA-Ca2+ Complexes into Model Membranes 
As cell membranes are complex systems, many model membranes have become commonly 
used for studying the membrane activity of various natural and synthetic compounds (e.g., 
peptides, drugs, and surfactants). Lipid monolayers are the most common biomimetic systems used 
to study the insertion of biomolecules into cell membranes. These monolayers can be considered 
as models for one leaflet of the cell membrane. These two-dimensional models show many 
advantages compared to other models (e.g., lipid vesicles). Some parameters (e.g., the composition 
of the subphase [pH and ionic strength], temperature, and the packing of the molecules) can be 
easily varied in a controlled manner allowing several biophysical studies of the phospholipid-gene 
complex interactions. However, one of the limitations of the monolayer system is that they 
represent only one leaflet of the cell membranes without any other components such as membrane 
proteins. Therefore, they do not reflect the complexity of cell structures 2, 43.  Yet, these simple 
models are often used to understand the biophysical interactions governing molecular interactions 
in phospholipid membranes. For example, it is well known that if the area of the monolayer is kept 
constant (constant area assay), adsorption followed by insertion of molecules into the hydrophobic 
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region of phospholipid monolayers (tails) can cause a significant increase in the surface pressure. 
On the other hand, particles that interact with the hydrophilic region (head groups) typically induce 
only slight changes in surface pressure 2, 44. In order to understand the physical mechanisms of 
interactions of calcium condensed gene complexes with cell membranes in the endosomal 
environment, the membrane insertion potential of seven different complexes was recorded using 
two model phospholipid monolayers. Zwitterionic phospholipid (POPC) and anionic 
phospholipids (POPS and POPG) were used as simple mimics of the cell membranes. PC is the 
most common phospholipid in the cell membrane of eukaryotic cells 45, whereas anionic PS is 
normally found in the inner leaflet of the plasma membrane as well as endosomal membranes 7, 46, 
47. Even though PG headgroups are present at 1 to 2% in the plasma membrane, they have often 
been used as model anionic lipids to study the function of CPP 7, 46. More relevant to this study, 
BMP, an isomer of PG with the same headgroup charge 48, 49, but differences in the position of the 
glycerol units on the phosphate moiety, is a unique anionic lipid found in significant fractions in 
the late endosomes 7, 49, 50. Since BMP was not stable as a monolayer in our experimental set-up 
because of its high solubility and tendency to form vesicles 51-53, we chose to use PG headgroups 
as model lipid system that remains anionic at the pHs relevant to this study, in order to understand 
the interactions of the CPPs with anionic headgroups that are enriched in the late endosomes 48-50. 
The effect of hydrophobic interactions versus electrostatic interactions on the phospholipid 
membrane insertion potential of gene complexes was monitored using gene complexes that 
contained both hydrophilic and amphiphilic peptides. Additionally, we have studied the effect of 
pH of the cytoplasm/early endosome versus late endosome/lysosome on this insertion process by 
monitoring the changes in the surface pressures at two different pHs, 7.4 and 4.4. Therefore, by 
studying the insertion potential of these different cationic gene complexes into phospholipids at 
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different pHs, we expect to develop a mechanistic understanding of interactions of the gene 
complexes with phospholipids in the endosomal pathway. While the insertion potential of the gene 
complexes was initially measured for different monolayer surface pressures (20-40 mN/m), our 
previous 2 and current work indicate that the maximum difference in the results between the 
samples was monitored at a surface pressure of 20 mN/m (Figure Appendix 5). Therefore, in this 
work, we report the insertion of our gene complexes into monolayers held at an initial surface 
pressure of 20 mN/m.  
Figure 3 shows the changes in surface pressure of the three phospholipid monolayers as a 
function of time, following interactions with the seven complexes at pH 7.4. Figure 3A presents 
the change in surface pressure with time while Figure 3D presents the maximum change in surface 
pressure (∆ surface pressure, the maximum absolute value of the surface pressure recorded during 
the 60 minutes period) for each of the seven complexes, when injected below the POPC monolayer. 
The change in surface pressure with time is significantly higher for gene complexes condensed 
using the CPPs and calcium when compared with the control (pDNA alone), indicating that the 
gene complexes have significantly higher insertion efficiency into the model zwitterionic 
phospholipid monolayer, when compared with an equal amount of free pDNA. However, no 
significant difference in the surface pressure was observed between the different cationic gene 
complexes. Since the size of these condensed complexes are comparable, our results suggest that 
at physiological pH, the gene complexes do not show significant insertion into the zwitterionic 
phospholipids. However, the significant difference in the insertion potential of the complexes 
when compared to the change in surface pressure of the PC monolayer in the presence of free 
pDNA suggest that condensing the complex with CPPs enabled increased interactions of the 
genetic material with the plasma membrane. Further, this observation also confirms that the 
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increased interactions in the presence of gene complexes cannot be associated with pDNA 
phospholipid monolayer interactions that occur in lipoplexes 54. To further verify that the increase 
in surface pressure was not due to the presence of cations, we also performed control experiments 
in the presence of 100 mM calcium chloride without any complexes, even though we do not expect 
such a high concentration of free ions (the calcium is added during the complexation process and 
is expected to associate with the pDNA-CPP complex). As shown in Figure 3, the increase in 
surface pressure in the presence of gene complexes was highly significant, when compared with 
calcium chloride alone, verifying that the change in the surface pressure is due to phospholipid-
gene complex interactions, and not due to the presence of calcium ions.  
Figure 3B and 3E show the recorded changes in the surface pressure for the seven 
complexes, when injected below the anionic POPS monolayer. Similarly, changes in the surface 
pressure with time and the maximum change in surface pressure, of a POPG monolayer, due to 
insertion of the seven complexes, are shown in Figure 3C and 3F. Our results demonstrated that 
for both anionic lipids studied here, the increase in surface pressure with time was significantly 
higher for all the complexes, when compared with the free pDNA. Moreover, the amphiphilic RL9 
and RW9 containing complexes demonstrated a significant increase in the surface pressure of the 
anionic phospholipid monolayer, when compared with the hydrophilic complexes. Therefore, 
Figure 3 provides conclusive evidence that gene complexes containing amphiphilic RL9 and RW9 























Figure 3. Changes in surface pressure as a function of time following injection of the seven CPPs 
(dTAT, K9, R9, RH9, RA9, RL9, and RW9)-pDNA-Ca2+ complexes below POPC (A), POPS (B), 
and POPG (C) monolayers held at an initial surface pressure of 20 mN/m and at pH 7.4. The 
maximum change in surface pressure (plateau values) of the seven complexes when inserted below 
(D) POPC, (E) POPS, (F) POPG monolayers. Results are presented as mean SD (n = 3), (*** = p 
< 0.0001, ** = p < 0.001, and * = p < 0.05, one-way ANOVA, Tukey post-test).  
 
We and others have previously shown that electrostatic interactions between CPP and 
phospholipids are enhanced by hydrophobic interactions, if the peptide is also able to penetrate the 
phospholipid membrane 2, 55.  To elucidate if this cooperative interaction is also true for our gene 











































































































































































































































































complexes, Figure 4 presents a comparison of the maximum change in surface pressure of each 
of the seven complexes with the three monolayers (POPC, POPS and POPG) at pH 7.4. The 
hydrophilic, positively charged dTAT, K9, R9 and RH9 containing gene complexes as well as the 
amphiphilic RA9 complex showed a slight increase in the maximum surface pressure change in 
case of POPS monolayers, when compared to the POPC monolayers. However, unlike the gene 
complexes containing hydrophilic CPPs, the complexes composed of amphiphilic RW9 and RL9 
peptides demonstrated a significantly higher increase in surface pressure, when they were injected 
below a POPS monolayer, compared to a POPC monolayer. Further, POPG showed the maximum 
increase in surface pressure for all the gene complexes. The overall increase in the insertion 
potential of gene complexes into anionic POPS and POPG phospholipids can be attributed to 
electrostatic interactions between the anionic phospholipid monolayers and the cationic gene 
complexes. However, the significant increase in surface pressure for anionic lipid monolayers, in 
the presence of gene complexes containing RL9 and RW9 support the idea that addition of 
hydrophobic amino acids potentially enhances the insertion potential of these complexes. Based 
on our results, we conclude that for the cationic gene complexes studied here, the initial surface 
activity of the complexes in the presence of anionic lipids is probably driven by electrostatic 
interactions between the charged amino acids and the anionic lipid headgroups, while the insertion 
is controlled by the hydrophobic nature of the tryptophan and leucine residues. Complexes 
containing RW9, presents the highest insertion into the anionic lipids, possibly because of the 
strong hydrophobicity or the aromatic ring of tryptophan amino acids in RW9. Complexes with 
amphiphilic RA9 peptides do not follow this trend, possibly because of the weak hydrophobicity, 
and small size of the alanine amino acid, which prevents the complexes from penetrating deeper 
into the monolayer. Therefore, we conclude that calcium condensed gene complexes containing 
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hydrophilic cationic peptides do not disrupt the phospholipid monolayers, but the presence of large 


























































































































































































































































































































































































































Figure 4. The maximum change in the 
surface pressure (plateau values) following 
injection of the seven CPPs ((A) dTAT, (B) 
K9, (C) R9, (D) RH9, (E) RA9, (F) RL9, 
and (G) RW9)-pDNA-Ca2+ complexes 
below POPC, POPS, and POPG 
monolayers held at an initial pressure of 20 
mN/m and at pH 7.4. Results are presented 
as mean SD (n = 3), (*** = p < 0.0001, and 
** = p < 0.001, one-way ANOVA, Tukey 




However, the difference in the maximum surface pressure of the anionic POPS and POPG 
lipids in the presence of the gene complexes cannot be explained by electrostatic or hydrophobic 
interactions. To understand the difference in the insertion into POPS and POPG monolayers, 
differences in the organization of the phospholipid headgroups should also be considered.   Even 
though both POPS and POPG are anionic phospholipids, the dipole moment P--N+ for the PS and 
PG headgroups are different. The polar PS headgroup has both a positive charge due to the NH3
+, 
and a negative charge due to the presence of COO- groups. As a result, the cationic gene complexes 
can interact with the phospholipid headgroup without significant insertion into the membrane. On 
the other hand, the polar PG headgroup is itself uncharged. The negative charge on PG is due to 
the phosphate moiety that binds the polar headgroup with the glycerol backbone. This implies that 
the gene complexes would have to insert deeper into the PG membranes to interact with the 
negatively charged phosphate moiety, which was indeed found to be the case.   
 
5.3.3. Insertion of the CPP-pDNA-Ca2+ Complexes into POPC, POPS, and POPG PMs at 
Acidic pH 
 
Cytoplasmic delivery of genetic material to subcellular targets can be achieved by initiating 
endosomal escape of the macromolecules and thus preventing their enzymatic degradation in the 
lysosome 56. One possible route of endosomal escape is via disruption of the endosomal 
membranes, which would result in leakage of the genetic payload 12, 25. Since the transmembrane 
pH has been proposed to play a significant role in endosomal escape of peptides, we hypothesized 
that changes in the subphase pH (from a neutral pH in the plasma membrane to an acidic pH in 
endosomes) can also effect the interactions of our gene complexes with model phospholipid 
membranes 25. Since the pH decreases along the endocytic pathway from the early endosome (pH 
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6) via the late endosome (pH 5.0) to the lysosome (pH 4.5), we have chosen to study the effect of 
the most acidic pH on the penetration potential and stability of our CPP-pDNA complexes 15. 
Figure 5 shows the changes in surface pressure of a phospholipid monolayer as a function 
of time, following interactions with the seven complexes at a subphase pH of 4.4. Figure 5A 
represents the measured change in surface pressure with time while Figure 5D shows the 
maximum change in surface pressure that was measured for each of the complexes, when injected 
below a POPC monolayer. We found that there was no statistically significant difference in the 
insertion potential of the gene complexes compared with pDNA. On the other hand, Figure 5B 
and 5E show that both the measured change in surface pressure with time and the maximum change 
in surface pressure is significantly higher for the gene complexes containing arginine based CPPs 
compared to the free pDNA, when injected below the POPS monolayers. The other complexes 
also exhibit higher surface activities compared to the free pDNA. Similarly, Figure 5C and 5F 
show that both the measured change in surface pressure with time and the maximum change in 
surface pressure of POPG monolayers is significantly higher for the gene complexes compared to 
the free pDNA, although, the change is lower than for the POPS monolayers. In order to explore 
the role of electrostatics on the insertion potential of each gene complex into different phospholipid 
membranes at acidic sub-phase pH, Figure 6 presents a comparison of the maximum change in 
surface pressure of each of the seven complexes, when injected below POPC, POPS, or POPG 
monolayers at a sub-phase pH of 4.4. Further, Figure 7 presents a comparison of the maximum 
change in surface pressure of the seven complexes, when injected below POPC, POPS or POPG 
monolayers at the two pHs, to develop a fundamental understanding of the effect of pH on the 
change in the surface pressure of different phospholipid monolayers. Complexes containing 
hydrophilic peptides show an increase in membrane insertion in a more acidic pH, compared to 
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neutral pH. However, as seen in Figure 7C, the gene complexes showed a reduced tendency to 
change the surface pressure when injected below POPG monolayers at a sub-phase pH of 4.4.  
To interpret the differences in the pH induced changes in the membrane insertion potential 
of our condensed CPP-pDNA complexes, we first discuss the effects of pH on the phospholipid 
headgroup charge. While the zwitterionic PC headgroups are stable at both pHs, the acidic 
environment can lower the relative charge on the anionic lipids. The POPS phospholipid has three 
pKas ~ 11.55, 5.5, and 2.6 (R-NH3, R-COOH, and R-H2PO respectively), whereas the POPG 
phospholipid has one pKa ~3.5 (R2-HPO4) at an ionic strength of 0.1 M (NaCl) 57. Therefore, both 
PS and PG lipids undergo a decrease in the relative headgroup charge at lower pHs, although this 
effect is more pronounced for the PS monolayers. For the PS and PC monolayers, the net 
headgroup charge is zero (i.e. the lipid headgroups are zwitterionic) at a pH of 4.4, while the PG 
headgroup has a negative relative charge. Since the charge on the zwitterionic PC headgroup 
remains unaltered by a drop in the subphase pH, the increase in phospholipid insertion potential 
of the complexes at pH 4.4 is unclear at this time. It can be attributed to the physical characteristics 
of the gene complexes at pH 4.4. Particle size analysis shows that the gene complexes become 
larger at the lower pH, while zeta potential measurements demonstrate that the particles become 
neutral or anionic. Previous results with gold nanoparticles show that positively charged 
nanoparticles penetrate into a zwitterionic bilayer at a neutral pH, while negatively charged 
particles do not 58. Applying this knowledge to our system would imply that the gene complexes 
demonstrate a lowering of the surface pressure change, contrary to results presented here. 
Therefore, we conclude that the increase in the environmental acidity helps the ability of the gene 
complexes to penetrate the zwitterionic phospholipid monolayer by increasing the size of the 
complex. In the case of the PS phospholipid, a pure electrostatic interaction based argument would 
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imply a decrease in the maxium surface pressure in the acidic pH, which is contrary to the observed 
results. Therefore, based on our results, we conclude, that even for the PS lipids, the increased size 
of the gene complexes helps with their insertion potential. In fact, even for complexes that seem 
to dissociate at lower pHs  (RA9 and RL9), a significant increase in the insertion was noted, further 
validating our conclusion that for phospholipid with a net neutral headgroup charge, unstable 
complexes or complexes with large size increase the insertion potential of the complex into 
phospholipids, when compared with condensed complexes. However, the behavior of the 
complexes when interacting with the POPG lipids is possibly controlled by the electrostatic 
repulsion between the anionic gene complexes and the anionic lipid headgroup, which results in a 
decrease in the insertion potential into the POPG monolayers. It must be noted that while PG 
headgroups are not common in the late endosome membranes, late endosomes are characterized 
by an increase in the composition of anionic lipids including BMP, which is a structural isomer of 
PG. Our results imply that for the calcium condensed gene complexes studied here, the enrichment 
of anionic lipids in the late endosome would prevent the insertion and escape of the genetic 
payload, but early endosomes rich in anionic lipids can enable endosomal escape and delivery of 



























Figure 5. Changes in the surface pressure as a function of time following injection of the seven 
CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9)-pDNA-Ca2+ complexes below POPC (A), POPS 
(B), and POPG (C)  monolayers held at an initial surface pressure of 20 mN/m and at pH 4.4. The 
maximum change in the surface pressure (plateau values) of the seven complexes upon interaction 
with (D) POPC, (E) POPS, (F) POPG monolayers. Results are presented as mean SD (n = 3), (*** 

























































































































































































































































































































































































































































































































































































































































































































































Figure 6. The maximum change in surface 
pressure (plateau values) following injection 
of the seven CPPs [(A) dTAT, (B) K9, (C) 
R9, (D) RH9, (E) RA9, (F) RL9, and (G) 
RW9]-pDNA-Ca2+ complexes below POPC, 
POPS, and POPG PMs held at an initial S.P. 
of 20 mN/m and at pH 4.4. Results are 
presented as mean SD (n = 3), (*** = p < 
0.0001, and ** = p < 0.001, one-way 























Figure 7. The maximum change in surface pressure (plateau values) of (A) POPC, (B) POPS, and 
(C) POPG held at an initial S.P. of 20 mN/m and at pH 7.4 and 4.4. in the presence of the seven 
CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9)-pDNA-Ca2+ complexes . Results are presented 




























































































































































































































































































































































































































































To further understand if the insertion is due to the pDNA, the CPPs or both, we have also 
measured the changes in the surface pressure of the seven CPPs alone at pH 7.4 and 4.4, when 
injected below the POPC, POPS, and POPG monolayers (Figure Appendix 6 and 7). Our results 
are summarized in Figure 8, which presents a comparison of the maximum change in the S.P. of 
the seven complexes and the seven CPPs at pH 7.4 and 4.4. Generally, the maximum change in 
surface pressure of the phospholipids was found to be higher for the gene complexes compared to 
the free CPPs when they were injected below the anionic phospholipids (i.e., POPS and POPG) 
(Figure 8B, C, E, and F), particularly for the complexes containing amphiphilic peptides RW9 
and RL9. On the other hand, no difference was noted when the different complexes were injected 
below the zwitterionic lipid (POPC) (Figure 8A and D). Since the total CPP concentration was 
kept constant in both the experiments (free CPPs versus condensed complexes), and we expect 
most of the CPP to exist as a condensed complex with the pDNA, the increase in the surface 
pressure of the phospholipids in the presence of gene complexes can be attributed to the presence 
of CPPs on the complexes.   
Therefore, our results suggest that the mechanisms of interactions of gene complexes with 
phospholipid membranes during cellular uptake and intracellular delivery are determined by both 
the changes in the physical characteristics of the gene complexes as well as the phospholipid 
headgroup charge. Further, our results also confirm that among all the polypeptides used as CPPs, 
condensed complexes of pDNA with amphiphilic CPPs show the maximum membrane insertions 
into anionic phospholipids at normal pH. However, no difference is noted in the insertion potential 
of the seven peptides into zwitterionic POPC monolayers.  A schematic of our proposed 
mechanism of gene complex action is shown in Figure 9.  Based on our results, we propose that 
the CPP-pDNA complexes initially interact with the zwitterionic PC headgroups and trigger 
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cellular uptake, regardless of the composition of the CPP. Once endocytosed, the complexes 
undergo a pH induced partial disassembly of the complex. This uncondensed gene complex 
induces changes in the membranes, possibly by interacting with the CPP, allowing the pDNA to 
escape into the cytosol. Surprisingly, we found that at the more acidic pH, the insertion potential 
of the gene complexes did not depend on the composition of the CPPs. Analysis of kinetics of 
adsorption of the complexes into different phospholipid systems will provide additional 
understanding of the nature of the adsorption and insertion of the complexes into different 
monolayer systems at neutral and acidic pHs and is the topic for a future publication. The findings 
described here make the noncovalently condensed gene complexes interesting candidates as 
nonviral gene delivery vectors. Future studies will focus on in vitro and in vivo performance of 






































Figure 8. The maximum change in surface pressure (plateau values) of (A) POPC at pH 7.4, (B) 
POPS at pH 7.4, (C) POPG at pH 7.4, (D) POPC at pH 4.4, (E) POPS at pH 4.4, and (F) POPG at 
pH 4.4 due to interactions with the seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9) and 
the seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9)-pDNA-Ca2+ complexes. The initial 






































































































































































































































































































































































































































































































































































































































































































































Figure 9. A schematic of our proposed mechanism of gene complex action at neutral pH 














5.4. Conclusions  
Understanding the interactions of gene complexes with phospholipid membranes can be an 
important first step in predicting the membrane insertion efficiency of calcium condensed gene 
complexes containing CPPs and efficiently delivering genetic material to the cytosolic 
environment. In this study, phospholipid membranes POPC, POPS, and POPG have been used to 
study the membrane insertion of the seven CPP-pDNA-Ca2+ complexes, containing hydrophilic 
(i.e., dTAT, K9, R9, and RH9) and amphiphilic (i.e., RA9, RL9, and RW9) CPPs,  at different pHs 
(pH 7.4 and 4.4). Our results showed that using CPPs with differences in the net charge and 
hydrophobicity did not alter their ability to form complexes with pDNA. In fact, the complexes 
had the same size at neutral pH. Further, the complexes were found to be cationic, due to an excess 
of the CPP during the synthesis process. However, an increase in the acidity of the environment 
did cause a decrease in the particle size, possibly because of partial dissociation of the gene 
complex, which also caused a decrease in the surface charge on the particles. Using Langmuir 
monolayers as our model phospholipid membranes, we also showed that there was no difference 
in the insertion potential of gene complexes of different composition, when interacting with a 
zwitterionic phospholipid at a neutral pH. However, when interacting with anionic phospholipid 
membranes, all complexes showed an increase in their insertion potential, although there was a 
significant difference in the membrane insertion potential of complexes containing amphiphilic 
CPPs. This suggests that while the initial interactions of our calcium condensed gene complexes 
with phospholipid membranes are facilitated by electrostatic interactions, the hydrophobic amino 
acids further facilitated membrane insertion. However, in more acidic environments such as those 
in the intracellular vesicles (endosomes/lysosomes) all gene complexes show a greater insertion 
into the POPC and POPS membranes, irrespective of the composition. Since both POPC and POPS 
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are zwitterionic at the acidic pH, we conclude that the acidic pH induced an increase in the size of 
the gene complexes possibly due to a reversal of the condensing effect of Ca2+. This increase in 
the complex size may trigger the disturbance and even disruption of endosomal membranes, 
leading to escape of the genetic payload into the cytosol. In conclusion, the Langmuir monolayer 
technique can help to determine the type and degree of interaction of gene complexes with 
membrane systems. We believe that measuring the insertion potential of gene complexes into 
model membranes will serve as a screening method to test the potential insertion ability of gene 
complexes, before they are tested in cells or in more involved therapeutic situations. Our results 
also suggest that overall, designing gene complexes with amphiphilic peptides may not necessarily 
demonstrate more transfection efficiency, because of the differences in the insertion potential of 
the amphiphilic peptides at neutral and acidic pH, even though the amphiphilic peptides have the 
potential to disrupt anionic membranes at neutral pH. However, additional experiments with in 
vitro cell assays are essential to obtain a complete understanding on the mechanism of action of 
the full transfection mechanism. Ultimately, our results will aid in the design of the next generation 
of CPP based nonviral gene complexes and is a first step in our overall goal of using short synthetic 
CPPs for efficient intracellular delivery of nucleic acids.  Further, our results also propose the 
potential of synthetic CPPs with hydrophobic amino acid sequences for use in designing anti-
bacterial membranes, where the CPPs will interact with anionic PG headgroups and may enable 









1. Doherty, G. J.; McMahon, H. T.  Mechanisms of endocytosis. Annual review of 
biochemistry 2009, 78, 857-902. 
2. Alhakamy, N. A.; Kaviratna, A.; Berkland, C. J.; Dhar, P.  Dynamic Measurements of 
Membrane Insertion Potential of Synthetic Cell Penetrating Peptides. Langmuir 2013, 29, (49), 
15336-15349. 
3. Figueiredo, I. R.; Freire, J. M.; Flores, L.; Veiga, A. S.; Castanho, M. A.  Cell‐penetrating 
peptides: A tool for effective delivery in gene‐targeted therapies. IUBMB life 2014, 66, (3), 182-
194. 
4. Margus, H.; Padari, K.; Pooga, M.  Cell-penetrating peptides as versatile vehicles for 
oligonucleotide delivery. Molecular Therapy 2012, 20, (3), 525-533. 
5. Nakamura, Y.; Kogure, K.; Futaki, S.; Harashima, H.  Octaarginine-modified 
multifunctional envelope-type nano device for siRNA. Journal of controlled release 2007, 119, 
(3), 360-367. 
6. Baoum, A. A.; Berkland, C.  Calcium condensation of DNA complexed with cell‐
penetrating peptides offers efficient, noncytotoxic gene delivery. Journal of pharmaceutical 
sciences 2011, 100, (5), 1637-1642. 
7. Yang, S.-T.; Zaitseva, E.; Chernomordik, L. V.; Melikov, K.  Cell-penetrating peptide 
induces leaky fusion of liposomes containing late endosome-specific anionic lipid. Biophysical 
journal 2010, 99, (8), 2525-2533. 
8. Belting, M.; Wittrup, A.  Macromolecular drug delivery: basic principles and therapeutic 
applications. Molecular biotechnology 2009, 43, (1), 89-94. 
168 
 
9. Chen, H. H.; Ho, Y.-P.; Jiang, X.; Mao, H.-Q.; Wang, T.-H.; Leong, K. W.  Quantitative 
comparison of intracellular unpacking kinetics of polyplexes by a model constructed from 
quantum dot-FRET. Molecular Therapy 2008, 16, (2), 324-332. 
10. Karagiannis, E. D.; Alabi, C. A.; Anderson, D. G.  Rationally Designed Tumor-Penetrating 
Nanocomplexes. ACS nano 2012, 6, (10), 8484-8487. 
11. Khondee, S.; Baoum, A.; Siahaan, T. J.; Berkland, C.  Calcium condensed LABL-TAT 
complexes effectively target gene delivery to ICAM-1 expressing cells. Molecular pharmaceutics 
2011, 8, (3), 788-798. 
12. Alhakamy, N. A.; Nigatu, A. S.; Berkland, C. J.; Ramsey, J. D.  Noncovalently associated 
cell-penetrating peptides for gene delivery applications. Therapeutic delivery 2013, 4, (6), 741-
757. 
13. Chen, S.; Han, K.; Yang, J.; Lei, Q.; Zhuo, R.-X.; Zhang, X.-Z.  Bioreducible Polypeptide 
Containing Cell-Penetrating Sequence for Efficient Gene Delivery. Pharmaceutical research 
2013, 30, (8), 1968-1978. 
14. Baoum, A.; Xie, S.-X.; Fakhari, A.; Berkland, C.  “Soft” Calcium Crosslinks Enable 
Highly Efficient Gene Transfection Using TAT Peptide. Pharmaceutical research 2009, 26, (12), 
2619-2629. 
15. Hullin-Matsuda, F.; Taguchi, T.; Greimel, P.; Kobayashi, T. In Lipid compartmentalization 
in the endosome system, Seminars in cell & developmental biology, 2014; Elsevier. 
16. Zaitseva, E.; Yang, S.-T.; Melikov, K.; Pourmal, S.; Chernomordik, L. V.  Dengue virus 




17. Alhakamy, N. A.; Berkland, C. J.  Polyarginine molecular weight determines transfection 
efficiency of calcium condensed complexes. Molecular pharmaceutics 2013, 10, (5), 1940-1948. 
18. Ziegler, A.; Li Blatter, X.; Seelig, A.; Seelig, J.  Protein transduction domains of HIV-1 
and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic 
analysis. Biochemistry 2003, 42, (30), 9185-9194. 
19. Lindgren, M.; Hällbrink, M.; Prochiantz, A.; Langel, Ü.  Cell-penetrating peptides. Trends 
in pharmacological sciences 2000, 21, (3), 99-103. 
20. Baoum, A.; Ovcharenko, D.; Berkland, C.  Calcium condensed cell penetrating peptide 
complexes offer highly efficient, low toxicity gene silencing. International journal of 
pharmaceutics 2012, 427, (1), 134-142. 
21. Wagstaff, K. M.; Jans, D. A.  Protein transduction: cell penetrating peptides and their 
therapeutic applications. Current medicinal chemistry 2006, 13, (12), 1371-1387. 
22. Witte, K.; Olausson, B. E.; Walrant, A.; Alves, I. D.; Vogel, A.  Structure and dynamics of 
the two amphipathic arginine-rich peptides RW9 and RL9 in a lipid environment investigated by 
solid-state NMR and MD simulations. Biochimica et Biophysica Acta (BBA)-Biomembranes 2012. 
23. Järver, P.; Langel, Ü.  Cell-penetrating peptides—a brief introduction. Biochimica et 
Biophysica Acta (BBA)-Biomembranes 2006, 1758, (3), 260-263. 
24. Deshayes, S.; Morris, M.; Divita, G.; Heitz, F.  Cell-penetrating peptides: tools for 
intracellular delivery of therapeutics. Cellular and Molecular Life Sciences CMLS 2005, 62, (16), 
1839-1849. 
25. Schwieger, C.; Blume, A.  Interaction of poly (l-arginine) with negatively charged DPPG 
membranes: calorimetric and monolayer studies. Biomacromolecules 2009, 10, (8), 2152-2161. 
170 
 
26. Rothbard, J. B.; Jessop, T. C.; Lewis, R. S.; Murray, B. A.; Wender, P. A.  Role of 
membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich 
peptides into cells. Journal of the American Chemical Society 2004, 126, (31), 9506-9507. 
27. Futaki, S.  Oligoarginine vectors for intracellular delivery: Design and cellular‐uptake 
mechanisms. Peptide Science 2006, 84, (3), 241-249. 
28. Dennison, S. R.; Phoenix, A. J.; Phoenix, D. A.  Effect of salt on the interaction of Hal18 
with lipid membranes. European Biophysics Journal 2012, 41, (9), 769-776. 
29. Futaki, S.; Goto, S.; Sugiura, Y.  Membrane permeability commonly shared among 
arginine‐rich peptides. Journal of Molecular Recognition 2003, 16, (5), 260-264. 
30. Futaki, S.; Nakase, I.; Tadokoro, A.; Takeuchi, T.; Jones, A.  Arginine-rich peptides and 
their internalization mechanisms. Biochemical Society Transactions 2007, 35, (4), 784. 
31. Witte, K.; Olausson, B. E.; Walrant, A.; Alves, I. D.; Vogel, A.  Structure and dynamics of 
the two amphipathic arginine-rich peptides RW9 and RL9 in a lipid environment investigated by 
solid-state NMR and MD simulations. Biochimica et Biophysica Acta (BBA)-Biomembranes 2013, 
1828, (2), 824-833. 
32. Kawabata, A.; Baoum, A.; Ohta, N.; Jacquez, S.; Seo, G.-M.; Berkland, C.; Tamura, M.  
Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor 
gene attenuates lung cancer growth. Cancer research 2012, 72, (8), 2057-2067. 
33. Zaitsev, S.; Haberland, A.; Otto, A.; Vorob'ev, V.; Haller, H.; Böttger, M.  H1 and HMG17 




34. Khosravi-Darani, K.; Mozafari, M. R.; Rashidi, L.; Mohammadi, M.  Calcium based non-
viral gene delivery: an overview of methodology and applications. Acta Med. Iran 2010, 48, (3), 
133-141. 
35. Jiao, C.-Y.; Delaroche, D.; Burlina, F.; Alves, I. D.; Chassaing, G.; Sagan, S.  Translocation 
and endocytosis for cell-penetrating peptide internalization. Journal of Biological Chemistry 2009, 
284, (49), 33957-33965. 
36. Blume, A.  A comparative study of the phase transitions of phospholipid bilayers and 
monolayers. Biochimica et Biophysica Acta (BBA)-Biomembranes 1979, 557, (1), 32-44. 
37. Joanne, P.; Galanth, C.; Goasdoué, N.; Nicolas, P.; Sagan, S.; Lavielle, S.; Chassaing, G.; 
El Amri, C.; Alves, I. D.  Lipid reorganization induced by membrane-active peptides probed using 
differential scanning calorimetry. Biochimica et Biophysica Acta (BBA)-Biomembranes 2009, 
1788, (9), 1772-1781. 
38. Bally, M. B.; Harvie, P.; Wong, F. M.; Kong, S.; Wasan, E. K.; Reimer, D. L.  Biological 
barriers to cellular delivery of lipid-based DNA carriers. Advanced drug delivery reviews 1999, 
38, (3), 291-315. 
39. Peetla, C.; Jin, S.; Weimer, J.; Elegbede, A.; Labhasetwar, V.  Biomechanics and 
Thermodynamics of Nanoparticle Interactions with Plasma and Endosomal Membrane Lipids in 
Cellular Uptake and Endosomal Escape. Langmuir 2014, 30, (25), 7522-7532. 
40. Loyter, A.; Scangos, G. A.; Ruddle, F. H.  Mechanisms of DNA uptake by mammalian 
cells: fate of exogenously added DNA monitored by the use of fluorescent dyes. Proceedings of 
the National Academy of Sciences 1982, 79, (2), 422-426. 
172 
 
41. Haberland, A.; Knaus, T.; Zaitsev, S. V.; Stahn, R.; Mistry, A. R.; Coutelle, C.; Haller, H.; 
Böttger, M.  Calcium ions as efficient cofactor of polycation-mediated gene transfer. Biochimica 
et Biophysica Acta (BBA)-Gene Structure and Expression 1999, 1445, (1), 21-30. 
42. Bisht, S.; Bhakta, G.; Mitra, S.; Maitra, A.  pDNA loaded calcium phosphate nanoparticles: 
highly efficient non-viral vector for gene delivery. International journal of pharmaceutics 2005, 
288, (1), 157-168. 
43. Eeman, M.; Deleu, M.  From biological membranes to biomimetic model membranes. Base 
2010, 14, 719-736. 
44. Zhang, L.; Rozek, A.; Hancock, R. E.  Interaction of cationic antimicrobial peptides with 
model membranes. Journal of Biological Chemistry 2001, 276, (38), 35714-35722. 
45. Song, C.; Nerdal, W.  Olanzapine interaction with dipalmitoyl phosphatidylcholine 
(DPPC) and 1-palmitoyl-2-oleoyl phosphatidylserine (POPS) bilayer: A 13C and 31P solid-state 
NMR study. Biophysical chemistry 2008, 134, (1), 47-55. 
46. Van Meer, G.; Voelker, D. R.; Feigenson, G. W.  Membrane lipids: where they are and 
how they behave. Nature reviews molecular cell biology 2008, 9, (2), 112-124. 
47. Leventis, P. A.; Grinstein, S.  The distribution and function of phosphatidylserine in 
cellular membranes. Annual review of biophysics 2010, 39, 407-427. 
48. Bouvier, J.; Berry, K. A. Z.; Hullin-Matsuda, F.; Makino, A.; Michaud, S.; Geloën, A.; 
Murphy, R. C.; Kobayashi, T.; Lagarde, M.; Delton-Vandenbroucke, I.  Selective decrease of bis 
(monoacylglycero) phosphate content in macrophages by high supplementation with 
docosahexaenoic acid. Journal of lipid research 2009, 50, (2), 243-255. 
173 
 
49. Meikle, P.; Duplock, S.; Blacklock, D.; Whitfield, P.; Macintosh, G.; Hopwood, J.; Fuller, 
M.  Effect of lysosomal storage on bis (monoacylglycero) phosphate. Biochem. J 2008, 411, 71-
78. 
50. Hullin-Matsuda, F.; Kawasaki, K.; Delton-Vandenbroucke, I.; Xu, Y.; Nishijima, M.; 
Lagarde, M.; Schlame, M.; Kobayashi, T.  De novo biosynthesis of the late endosome lipid, bis 
(monoacylglycero) phosphate. Journal of lipid research 2007, 48, (9), 1997-2008. 
51. Frederick, T. E.; Goff, P. C.; Mair, C. E.; Farver, R. S.; Long, J. R.; Fanucci, G. E.  Effects 
of the endosomal lipid bis (monoacylglycero) phosphate on the thermotropic properties of DPPC: 
A 2H NMR and spin label EPR study. Chemistry and physics of lipids 2010, 163, (7), 703-711. 
52. Frederick, T. E.; Chebukati, J. N.; Mair, C. E.; Goff, P. C.; Fanucci, G. E.  Bis 
(monoacylglycero) phosphate Forms Stable Small Lamellar Vesicle Structures: Insights into 
Vesicular Body Formation in Endosomes. Biophysical Journal 2009, 96, (5), 1847. 
53. Urbina, P.; Flores-Díaz, M.; Alape-Girón, A.; Alonso, A.; Goñi, F. M.  Effects of bilayer 
composition and physical properties on the phospholipase C and sphingomyelinase activities of 
Clostridium perfringens α-toxin. Biochimica et Biophysica Acta (BBA)-Biomembranes 2011, 
1808, (1), 279-286. 
54. Gromelski, S.; Brezesinski, G.  DNA condensation and interaction with zwitterionic 
phospholipids mediated by divalent cations. Langmuir 2006, 22, (14), 6293-6301. 
55. Travkova, O. G.; Brezesinski, G.  Adsorption of the antimicrobial peptide arenicin and its 
linear derivative to model membranes–A maximum insertion pressure study. Chemistry and 
physics of lipids 2013, 167, 43-50. 
174 
 
56. Zhang, S.; Nelson, A.; Coldrick, Z.; Chen, R.  The effects of substituent grafting on the 
interaction of pH-responsive polymers with phospholipid monolayers. Langmuir 2011, 27, (13), 
8530-8539. 
57. Marsh, D.  CRC handbook of lipid bilayers. CRC Press: Boca Raton, FL 1990. 
58. Tatur, S.; Maccarini, M.; Barker, R.; Nelson, A.; Fragneto, G.  Effect of functionalized 
























Charge Type, Charge Spacing, and Hydrophobicity of Arginine-RichCell-Penetrating 




Alhakamy, N. A.; Dhar, P.; Berkland, C. J.  Charge Type, Charge Spacing, and Hydrophobicity 
















6.1. Introduction  
Gene therapy has become an auspicious strategy for the treatment of several diseases (e.g., 
hemophilia and cancer) that are considered incurable 1. The poor permeability of nucleic acids 
(e.g., pDNA and RNAi) as well as their sensitivity to enzymatic degradation considerably 
complicates the development of most gene therapies. The success of gene therapy largely depends 
on the design of safe and efficient gene vectors 2-6.  Viral vectors have dominated clinical 
applications, but nonviral vectors offer advantages such as the potential for biological safety, ease 
of synthesis, relatively unrestricted nucleic acid size for packing, low-cost, and potential low 
degrees of immunogenicity compared to viruses 1, 5-9. Unfortunately, the use of nonviral vectors is 
still hindered by their lower transfection levels compared to viral vectors 1. Numerous methods 
have been studied to overcome this problem. Among them, cell penetrating peptides (CPPs), which 
consist of cationic or amphiphilic sequences of about 30 or fewer amino acids, seem particularly 
promising 8, 10, 11. 
Several colloid properties such as molecular weight, charge, and colloidal stability can 
affect the efficiency of gene delivery systems. In the case of polyelectrolyte nanoparticles, these 
properties are influenced by polycations. High-molecular-weight polycations often condense a 
large mass of genetic material (pDNA) into small and stable nanoparticles with high transfection 
efficiency. Unfortunately, these polycations have been plagued with cytotoxicity 12. On the other 
hand, low-molecular-weight polycations often produce large and unstable complexes with poor 
transfection efficiency, but with low cytotoxicity 13-16. Furthermore, the structure of the protonated 
group and charge spacing can influence the ability of CPPs to protect and complex with nucleic 
acids 17, 18. Two main approaches have indicated the efficient use of CPPs to deliver nucleic acids. 
The first approach uses linkers to covalently bind CPPs to their cargo, and the second approach 
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depends on electrostatic interactions (ionic interactions) to form complexes between CPPs and 
their cargo 8. The risk of reducing the activity of the CPPs may limit the benefit of the covalent 
approach 8, 19.  
 Polyarginine peptide is one of the widest cationic peptides used for gene delivery 12. Many 
studies have suggested that CPPs with 7 to 9 amino acids have optimal cell penetration efficiency 
20, 21. We have established that low-molecular-weight polyarginine peptides (e.g., polyarginine R9) 
are efficient for gene delivery and can condense pDNA into small nanoparticles (~150 nm) when 
calcium chloride (CaCl2) is added 
5, 9, 22-26. Calcium condensation of polyplexes is reversible, 
allowing the release of low-molecular-weight CPPs such as polyarginine R9 at low pH, which may 
increase membrane permeability within the cell 5, 12, 25, 27. Although the role of calcium in the 
transfection mechanism is ambiguous, these studies encouraged exploration of calcium with 
complexes formed from a diverse panel of hydrophilic and amphiphilic CPPs.  
In this study, the transfection efficiency of pDNA polyelectrolyte complex nanoparticles 
made using five different arginine-rich CPPs was investigated. CPPs included the well-known 
hydrophilic polyarginine R9 peptide (RRRRRRRRR), a hydrophilic RH9 peptide 
(RRHHRRHRR), and three amphiphilic peptides with similar charge distributions; RA9 
(RRAARRARR), RL9 (RRLLRRLRR), and RW9 (RRWWRRWRR) (Table 1). The RL9 and 
RW9 peptides originate from RL16 peptide (RRLRRLLRRLLRRLRR) and RW16 peptide 
(RRWRRWWRRWWRRWRR) respectively. RL9 and RW9 peptides were originally designed 
from a structure/function study of penetratin 28. The five arginine-rich CPPs (R9, RH9, RA9, RL9, 
and RW9) share a common high density of arginine residues providing nine positive charges to 
R9 and six positive charges to RH9, RA9, RL9, and RW9 at neutral pH. It has also been established 
that the penetration efficiency of CPPs increases with increased tryptophan content. Additionally, 
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the CPP activity is more efficient if the tryptophan residues are located in the center of the CPP 
sequences than if they are placed at the N-terminus 12, 16, 18. Many studies also reported that RW9 
is efficiently internalized into cells 16, 29. 
Our previous studies have shown that RL9 and RW9 peptides and RL9-pDNA-Ca2+ or 
RW9-pDNA-Ca2+ complexes strongly penetrated model cell membranes and also induced the 
maximum changes in phospholipid packing compared to R9, RA9, and RH9 peptides or complexes 
made using these peptides 16, 18. Here, we determined how these changes in CPP charge type, 
charge spacing, and hydrophobicity affected the transfection efficiency of the five CPP-pDNA-
Ca2+ complexes. The five CPPs were complexed with pDNA and condensed with CaCl2 to form 
small complexes. This simple formulation was explored using two human cell lines: 1) HEK-293 
kidney and 2) A549 lung cancer cells using a luciferase reporter plasmid (pGL3) to assess the 
relationship between CPP structure and transfection efficiency.  
 
Table 1. Identification of the Five CPPs and Their Properties: Peptide Sequence, the Number of 
Residues, Classification, Molecular Weight, Net Charge at pH 7, and Sequence Composition. 
* Hydrophobic/ Neutral amino acid % = (Nx/N)*100, Nx: Number of hydrophobic/ neutral amino 














at pH 7 
Sequence Composition (in 
percentage) * 
Hydrophobic              Basic 
R9 RRRRRRRRR 9 Hydrophilic 1422.74 9 0 100 
RH9 RRHHRRHRR 9 Hydrophilic 1365.62 6.3 0 100 
RA9 RRAARRARR 9 Amphiphilic 1167.41 6 33.33 66.67 
RL9 RRLLRRLRR 9 Amphiphilic 1293.68 6 33.33 66.67 
RW9 RRWWRRWRR 9 Amphiphilic 1512.83 6 33.33 66.67 
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6.2. Materials and Methods  
6.2.1. Materials 
Plasmid DNA (pDNA) encoding firefly luciferase (pGL3, 4818 bp) was purchased from Promega 
(Madison, Wisconsin). The pDNA purity level was determined by UV-spectroscopy and agarose 
gel electrophoresis. R9 peptide (RRRRRRRRR; Mw = 1422.74 Da), RH9 peptide (RRHHRRHRR; 
Mw = 1365.62 Da), RA9 peptide (RRA ARRARR; Mw = 1167.41 Da), RL9 peptide 
(RRLLRRLRR; Mw = 1293.68 Da), and RW9 peptide (RRWWRRWRR; Mw = 1512.83 Da) (the 
C-terminal of the five peptides is synthesized as an amide) were obtained from Biomatik 
Corporation (Cambridge, Ontario, Canada) (Purity > 95%). Branched polyethylenimine (PEI, 25 
kDa) was purchased from Sigma-Aldrich (Milwaukee, Wisconsin). A549 cell line (carcinogenic 
human alveolar basal epithelial) was purchased from American Type Culture Collection (ATCC; 
Rockville, Maryland). HEK-293 (human embryonic kidney) cell line was a gift from Dr. Cheng 
Lab (Nikki Cheng, Ph.D, University of Kansas Medical Center, Department of Pathology and 
Laboratory Medicine (obtained from American Type Culture Collection [ATCC; Rockville, 
Maryland]). F-12K Nutrient Mixture, Kaighn's modified with L-glutamine was purchased through 
Cellgro (Mediatech, Inc., Manassas, VA). Dulbecco’s Modified Eagle’s Medium (DMEM) was 
obtained from Invitrogen/Life Technologies (Gibco®) (Grand Island, NY 14072, USA). Fetal 
bovine serum (FBS) was purchased from Hyclone (Logan, UT). Penicillin-streptomycin was 
obtained from MB Biomedical, LLC (Solon, OH). Trypsin-EDTA was purchased from Invitrogen 
(Carlsbad, CA). Luciferase Assay System Freezer Pack and CellTiter 96® AQueous one solution 
cell proliferation assay (MTS) were purchased from Promega (Madison, Wisconsin). BCA Protein 
Assay Reagent (bicinchoninic acid) was purchased from Thermo Fisher Scientific Inc. Tris-
acetate-EDTA (TAE) Buffer (10 x) was purchased from Promega (Madison, Wisconsin). Sterile 
180 
 
water (DNase, RNase-free) was purchased from Fisher Scientific. Calcium chloride dihydrate 
(CaCl2. 2H2O) was purchased from Fisher Scientific. Agarose (Medium-EEO/protein 
electrophoresis grade) was obtained from Fisher Scientific. BenchTop DNA Ladder was obtained 
from Promega (Madison, WI). SYBR Green I Nucleic Acid Gel Stain was obtained from 
Invitrogen (Carlsbad, CA). Dextran Sulfate Sodium Salt was purchased from Fisher Scientific. 
Other organic chemicals used for this work were obtained from Fisher Scientific. Gelatin solution 
(Type B, 2% in H2O, tissue culture grade, sterile, BioReagent, suitable for cell culture) was 
purchased from Sigma-Aldrich (Milwaukee, Wisconsin). 1-Hexadecanoyl-2-(9Z-octadecenoyl)-
sn-glycero-3 phosphocholine (sodium salt) (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
L-serine (sodium salt) (POPS), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
(sodium salt) (POPG) were purchased from Avanti Polar Lipids (Alabaster, AL) as organic 
mixtures in chloroform. Agarose (medium-EEO/protein electrophoresis grade) was purchased 
from Fisher Scientific. 
6.2.2. Methods  
6.2.2.1. Nanoparticle Formation 
CPP-pDNA-Ca2+ nanoparticles were prepared by adding 15 µL of the CPP solution (N/P ratios: 5, 
10, 20, and 30 represent different polymer nitrogen to pDNA phosphate (N/P), molar ratios) to 10 
µL (0.1 µg/µL) of pDNA (TAE Buffer (1x) was used as a solution for DNA storage), followed by 
repeated pipetting for 20 to 25 seconds. At that point, 15 µL of CaCl2 (0, 50, 100, or 300 mM) was 
added and mixed by pipetting. After formulating the complexes, they were stored at 4°C for ~20 
minutes. PEI-pDNA complexes were prepared by adding 15 µL of PEI solution (N/P ratio 10) to 
10 µL (0.1 µg/µL) of pDNA followed by fast pipetting for 20 to 25 seconds. After preparing the 
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complexes, they were stored at 4°C for ~20 minutes. All complexes were prepared immediately 
before each experiment. 
6.2.2.2. Agarose Gel Electrophoresis  
Complexes were prepared as defined previously and subsequently, 4 µL of Tris-acetate-EDTA 
(TAE) buffer were added. Then, 4 µL of SYBR Green 1 was mixed with the complexes. Afterward, 
the mixture was stored at 4°C for 20 to 25 minutes. Then, 7 µL of 6X DNA Loading dye were 
added. A one kb DNA ladder was used. The mixture solutions were loaded onto a 1% agarose gel, 
and electrophoresed for 30 minutes at 110V. 
6.2.2.3. Size and Zeta Potential 
The particle size (effective diameter (nm)) of CPP-pDNA complexes with or without CaCl2 was 
determined by dynamic light scattering (DLS, Brookhaven Instruments, Holtsville, NY). The zeta 
potentials of the complexes were measured by Zeta PALS dynamic light scattering (Brookhaven 
Instrument, Holtsville, NY). All samples intended for particle size measurements were prepared 
using phosphate buffered saline (PBS), serum-free media (SFM) and nuclease free water (NFW). 
All samples intended for zeta potential measurements were prepared using KCl (1 mM). 
6.2.2.4. Cell Culture 
HEK-293 and A549 cell lines were grown in F-12K Nutrient Mixture media (Kaighn's modified 
with L-glutamine, for A549) and Dulbecco’s Modified Eagle’s Medium (DMEM, for HEK-293) 
with 1% (v/v) Penicillin-streptomycin and 10% (v/v) fetal bovine serum (FBS) at 37°C in 5% CO2 
humidified air. 
6.2.2.5. Transfection Studies 
HEK-293 and A549 cell lines were cultured in 96-well plates for 24 hours prior to transfection. 
The concentration of the cells in every well was approximately 800,000 cells/mL. The wells were 
washed once with serum-free media (SFM) and later a 100 µL sample (which consisted of 20 µL 
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of the complexes and 80 µL of SFM) was added to each well. Then, a 96-well plate was incubated 
for 5 hours in an incubator. After the incubation, the sample was replaced with 100 µL of fresh 
serum medium and then incubated again for approximately 48 hours. Our previous studies 
indicated that serum did not significantly inhibit the transfection mediated by CPPs (e.g. R9)-Ca-
pDNA complexes (a slight decrease in transfection efficiency was observed) 9, 24. 
To determine the gene expression of the complexes, the Luciferase Reporter Assay from Promega 
was used. The results of the transfections were expressed as relative light units (RLU) per 
milligram (mg) of cellular protein, and PEI-pDNA was used as a control. BCA Protein Assay 
Reagent (bicinchoninic acid) was used to measure total cellular protein concentration in the cell 
extracts. The Luciferase Assay and BCA were measured by a microplate reader (SpectraMax; 
Molecular Devices Crope, CA). HEK-293 cells are semiadherent, and can easily lift from the 
growth surface during the transfection assays that required multiple washes. Gelatin solution was 
used to coat the 96-well plate for the culture of HEK-293 cells. The wells were washed once with 
sterile water and later 300 L of 2% (w/v) gelatin solution was added to each well. Then, the plate 
was incubated for 1 hour in an incubator (37°C). The wells were washed two times with sterile 
water. After washing, the plate was left to dry in TC hood (LABCONCO Purifier Class II Biosafety 
Cabinet) for 30 to 60 minutes before use.  
6.2.2.6. Cytotoxicity Assay 
Cytotoxicity of CPPs, PEI, and CaCl2 was determined using a CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) obtained from Promega (Madison, Wisconsin). HEK-
293 and A549 cells were cultured in a 96-well plate as described previously. Cells were treated 
with the samples for ~24 hours. After the incubation, the media were replaced with a mixture of 
100 µL of fresh serum medium and 20 µL of MTS. Then, the plate was incubated for 3 to 4 hours 
183 
 
in the incubator. To determine cell viability, the absorbance of each well was measured by a 
microplate reader (SpectraMax; Molecular Devices Crope, CA) at 490 nm and normalized to 
untreated control cells.  
6.2.2.7. SYBR Green Assay 
The degree of pDNA accessibility following complexation with the five CPPs or PEI was assessed 
by the double-stranded-DNA-binding reagent SYBR Green (Invitrogen). Briefly, 10 μL (0.1 
mg/mL) of pDNA was mixed with 15 μL of CPPs or PEI solution, then 15 μL of deionized water 
or CaCl2 solution were added. The complexes were allowed to form for 30 minutes at room 
temperature prior to use. After incubation, 120 μL of PBS and 160 μL of 10X SYBR Green 
solutions were added. Then, 100 μL of the sample were added to one well of a 96-well cell culture 
plate. The fluorescence was measured using a fluorescence plate reader (SpectraMax M5; Ex., 250 
nm; Em, 520 nm). 
6.2.2.8. The Effect of Dextran Sulfate on the Stability of CPPs and PEI Nanoparticles 
The effect of dextran sulfate on the stability of complexes was evaluated by means of the change 
in fluorescence intensity obtained with the fluorescent probe SYBR Green. R9, RH9, RA9, RL9, 
RW9, and PEI complexes were prepared with or without CaCl2 (300 mM) as described above. 
Dextran sulfate solution (120 µL) was added to complexes suspensions to yield final 
concentrations up to 50 µg/µL, then incubated for 30 minutes at room temperature before 160 µL 
10X SYBR Green were added. Three samples (80 µL) of each sample of each test article were 
added to a 96-well plate and the fluorescence was measured (SpectraMax M5; Ex., 250 nm; Em, 





6.2.2.9. Langmuir Trough Experiments 
The surface pressure (Langmuir trough) experiments were described in detail previously 16, 18. The 
surface pressure changes were recorded by a Wilhelmy plate sensor, which is part of the KSV-
NIMA Langmuir trough purchased from Biolin Scientific, and petri dishes (volume 4 ml, 35 x 10) 
were used as “mini-troughs” for the experiments. A Langmuir monolayer approach was used to 
determine the differences in the ability of the CPPs and complexes to penetrate into cell 
membranes. Phospholipid monolayers with varying composition and headgroup charges, 
representing one leaflet of a cell membrane, were used as model membranes. Penetration to a 
phospholipid membrane is typically recorded by a constant area method. In this method, the 
surface pressure (millinewton per meter (mN/m)) of the phospholipid monolayer is fixed. 
Membrane penetration of injected CPPs or complexes is accompanied by an increase in the surface 
pressure, because the area of the trough surface is kept constant. The penetration of the CPPs or 
complexes is expected to alter the monolayer packing. Here, the penetration potential of the 
different CPPs and complexes was measured using model phospholipid monolayers containing 
different amounts of a zwitterionic (1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine [POPC]) or 
negatively charged phospholipids (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine [POPS], 
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol [POPG]) at the air-PBS buffer 
interface.   
6.2.2.10. Statistical Analysis 
Data were analyzed by using GraphPad software. A statistical evaluation comparing the 
significance of the difference in gene expression (RLUs/mg protein) between the means of two 
data sets was performed using a t test. One-way ANOVA, Tukey post-test was used to analyze the 
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differences when more than two data sets were compared. The Pearsons correlation coefficient 
was calculated with one-tailed probability. 
 
6.3. Results and Discussion 
Five arginine-rich CPPs were studied for their ability to complex pDNA (Table 1). 
Nanoparticles were formulated at various N/P ratios (different polymer nitrogen [positive charge] 
to pDNA phosphate [negative charge] ratios) and then CaCl2 was added to decrease the particle 
size. Agarose gel electrophoresis studies showed that some of the nanoparticles were robust 
enough to immobilize pDNA when complexed with the arginine-rich CPPs (Figure 1). 
Uncomplexed pDNA (free pDNA, pGL3) was used as a control. PEI complexes (without CaCl2) 
and R9, RH9, and RW9 complexes (with 100 mM CaCl2) at N/P ratio 10 immobilized pDNA 
(Figure 1A). On the other hand, RA9 and RL9 complexes exhibited some free pDNA. 
Additionally, CaCl2 alone showed negligible ability to complex pDNA (without CPPs) even at a 
high concentration (600 mM) (Figure 1B). Figures 1C to H show the five CPP-pDNA complexes 
across a range of N/P ratios 1 to 5 (without CaCl2). R9 complexes were able to immobilize pDNA 
completely at minimum N/P ratio 4 (Figure 1D). PEI and RW9 were able to immobilize pDNA 
completely at all N/P ratios (Figure 1C and 1H). RH9 complexes were able to immobilize pDNA 
completely at minimum N/P ratio 9 (Figure Appendix 8A). Clearly, RA9 and RL9 did not 
complex pDNA (all bands were observed during electrophoresis) at all N/P ratios (Figure 1A, 1F, 
and 1G). However, RA9 and RL9 complexes were able to immobilize pDNA completely at 
minimum N/P ratios 13 and 11 respectively (Figure Appendix 8B and 8C).  
R9 and RW9 formed stable complexes with pDNA at low N/P ratios (N/P ratio 1 to 5). In 
addition, RH9, RA9, and RL9 (the six positive charges (amphiphilic CPP)) did not form stable 
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complexes at the low N/P ratios, probably due to the nine positive charges of the R9 at neutral pH 
compared to six positive charges for the other peptides. On the other hand, RW9 (amphiphilic with 
six positive charges) was able to complex pDNA. This is may be due to the aromatic ring of 
tryptophan interacted with pDNA or perhaps stabilized the nanoparticles via self-associations 30.  
The particle size and zeta potential are important characteristics of the five CPP-pDNA-
Ca2+ complexes. The effect of CaCl2 concentration (0, 100, and 300 mM) on particle size was 
determined in nuclease free water (NFW) (Figure 2A), and in serum-free F-12 media (SFM) 
(Figure 2B). The CPP-pDNA-Ca2+ complexes generally showed a decrease in particle size as 
CaCl2 concentration increased (with relatively narrow polydispersity, < 0.15) in both NFW and 
SFM. In comparison, PEI-pDNA complexes showed an increase in particle size as the calcium 
concentration increased 9. The net positive charge of the complexes also plays a significant role in 
transfection efficiency that can increase the attractive force to the negative charge of the cell 8. 
Figure 2C indicates that the zeta potential of the complexes is generally increased with higher 
concentration of CaCl2 (100 and 300 mM). The net positive charge of the complexes confirms the 
cationic nature of the complexes and verifies that the CPPs, being in excess, form the shell of the 
complexes. Interestingly, PEI and R9 complexed with pDNA (without CaCl2) at an N/P ratio of 1 
had higher positive charges (~ 6 to ~ 10 mV) compared to the other complexes (RH9, RA9, RL9, 
and RW9), which had net negative charges (-3 to -10 mV) (Figure 2D). Interestingly, replacing 
three residues of R9 peptide with a hydrophilic (histidine) or hydrophobic residues (alanine, 










Table 1. Identification of the five CPPs and their properties (peptide sequence, the number of 
residues, classification, molecular weight, net charge at pH 7, and sequence composition). 
 
* Hydrophobic/ Neutral amino acid % = (Nx/N)*100, Nx: Number of hydrophobic/ neutral 























at pH 7 
Sequence Composition (in 
percentage) * 
Hydrophobic              Basic 
R9 RRRRRRRRR 9 Hydrophilic 1422.74 9 0 100 
RH9 RRHHRRHRR 9 Hydrophilic 1365.62 6.3 0 100 
RA9 RRAARRARR 9 Amphiphilic 1167.41 6 33.33 66.67 
RL9 RRLLRRLRR 9 Amphiphilic 1293.68 6 33.33 66.67 






















Figure 1. Agarose gel electrophoresis study of gene complexes at N/P ratios 10, 5, 4.5, 4.25, 4, 
3.5, 3.25, 3, 2.5, 2.25, 2, 1.5, 1.25, and 1. (A) PEI, R9, RH9, RA9, RL9, and RW9-pDNA-Ca2+ 
complexes (N/P ratio 10 and 100 mM CaCl2). (B) CaCl2-pDNA complexes; 0, 50, 100, 150, 200, 
300, and 600 mM of CaCl2. (C) PEI-pDNA complexes. (D) R9-pDNA complexes. (E) RH9-pDNA 
complexes. (F) RA9-pDNA complexes. (G) RL9-pDNA complexes. (H) RW9-pDNA complexes. 
“Star” (*) refers to the minimum N/P ratio whereas CPPs were able to immobilize pDNA 














Figure 2: Particle size (effective diameter) and zeta potential of R9-, RH9-, RA9-, RL9-, or RW9-
pDNA complexes at N/P ratio 10 with and without CaCl2. The particle size of complexes with 
CaCl2 concentration (100, 200, and 300 mM) were determined (A) in nuclease free water (NFW), 
and (B) in serum-free F-12 media (SFM). For missing data points, the diameter was > 1 µm. The 
zeta potential of the five CPPs and PEI complexes: (C) CaCl2 concentration: 0, 100, and 300 mM 
and N/P ratio 10. (D) CaCl2 concentration 0 mM and N/P ratio 1. Results are presented as mean ± 
SD (n = 3).  
 
The SYBR green assay provides a simple, nondestructive, and high-throughput technique 
for examining DNA accessibility within the complexes. Figure 3 shows the effect of CaCl2 
concentration (0 and 100 mM) on the five CPP-pDNA and PEI-pDNA complexes by using the 
SYBR Green assay to assess pDNA accessibility. Overall, PEI, R9, RL9, and RW9 complexes 
showed weak fluorescence intensity, which suggests that these CPPs condensed pDNA. However, 
the other complexes (RH9 and RA9 complexes) showed strong fluorescence intensity (high RFU 





































































































































Figure 3. Effect of CaCl2 concentration (A) 100 mM and (B) 0 mM on PEI-pDNA complexes and 
R9-, RH9-, RA9-, RL9-, or RW9-pDNA complexes (N/P ratio 10) by using the SYBR Green assay 
to assess pDNA accessibility. Results are presented as mean ± SD (n = 3) (*** = P < 0.0001, one-
way ANOVA, Tukey post-test comparison to pDNA). 
 
Next, the stability of the five CPP-pDNA and PEI-pDNA complexes when exposed to 
dextran sulfate was studied by determining changes in the SYBR Green fluorescence. Exposing 
the complexes to dextran sulfate increased the fluorescence signal, suggesting exposure or 
complete release of the plasmid DNA from the complexes as the dextran sulfate concentration 
increased (0.001 to 100 mg/mL) and at different N/P ratios (1, 2, 3, 4, and 10) (Figure Appendix 
9). Figure 4 shows the fluorescence of the five CPP-pDNA and PEI-pDNA complexes by dextran 
sulfate (0.01 mg/mL) displacement of pDNA (without CaCl2) across a range of N/P ratios (1-3). 
Overall, PEI, R9, and RW9 limited pDNA accessibility within the complexes (weak fluorescence 
intensity), which suggests that these CPPs strongly complexed pDNA when compared to RH9, 










































































Figure 4. SYBR Green fluorescence of R9-, RH9-, RA9-, RL9-, or RW9-pDNA and PEI-pDNA 
complexes by dextran (0.01 mg/mL) displacement of pDNA. (A) N/P ratio 1, (B) N/P ratio 2, and 
(C) N/P ratio 3. Results are presented as mean ± SD (n = 3) (*** = P < 0.0005, ** = P < 0.001, 
comparison to PEI, t test). 
 
Next, the five CPPs were complexed with pDNA, and the transfection of A549 cells was 
studied as a function of N/P ratio (5, 10, 20, and 30) and CaCl2 concentration (0, 50, 100, 200, and 
300 mM) (Figure 5A-D). In general, the five nanoparticles had the maximum-gene expression 
levels at CaCl2 concentrations of 100 and 200 mM. Additionally, it seemed that there was no 
significant difference in the transfection efficiency across a range of N/P ratios (5-30). Some of 
the CPP-pDNA complexes showed higher levels of gene expression at 100 mM of added calcium 
when compared to PEI (Figure 5E and 5F), which had high transfection efficiency in the absence 
of CaCl2. The transfection efficiency of PEI-pDNA complexes and the five CPP-pDNA-Ca
2+ (0, 
100, and 300 mM) at N/P ratio 10 was assessed in A549 cells (Figure 5E) and HEK-293 cells 
























































































































































































































































































































































Figure 5. Transfection efficiency R9-, RH9-, RA9-, RL9-, or RW9-pDNA and PEI-pDNA with 
different concentrations of added CaCl2 (0, 50, 100, 200, and 300 mM) in A549 cells at an N/P 
ratio of (A) 5, (B) 10, (C) 20, and (D) 30. The transfection efficiency of pDNA-Ca2+, the five 
CPPspDNA, and PEI-pDNA complexes with different concentrations of added CaCl2 (0, 100, and 
300 mM) at N/P ratio 10, (E) in A549 cells, (F) in HEK-293 cells. PEI-pDNA complex (N/P ratio 
10) was used as a standard. RLUs refers to relative light units. Results are presented as mean ± SD 
(n = 4) (xxx = < 0.0001, xx = P < 0.001, x = P < 0.05, comparison to pDNA) (+++ = < 0.0001, ++ 
= P < 0.001, + = P < 0.05, comparison to PEI) (*** = P < 0.0001, ** = P < 0.001, * = P < 0.05, 
one-way ANOVA, Tukey post-test). 
 
Remarkably, there was no notable gene expression observed for the five CPP-pDNA 
complexes without CaCl2 in both of the cell lines. Data from the A549 cell line showed RH9, RA9, 
and RL9 complexes had low-gene expression even when adding CaCl2 to condense the complexes; 
however, R9 and RW9 complexes yielded high-gene expression values. The HEK-293 cell line 
showed that all five CPP-pDNA-Ca2+ complexes had a high-gene expression with CaCl2 (100 and 
300 mM) compared to PEI. Clearly, R9 and RW9 complexes yielded the maximum-gene 
expression values. Generally, RH9, RA9, and RL9 complexes appeared significantly less effective 
than R9 and RW9 complexes for transfection in both of the cell lines. As mentioned earlier, the 
electrophoretic mobility of RH9, RA9, and RL9 complexes exhibited free pDNA at low N/P ratios 
(1 to 5). On the other hand, R9 and RW9 complexes were able to immobilize pDNA. These 
findings support the notion that the low gene expression values of these complexes were due to 
poor DNA packaging or instability of the complexes. 
The guanidine headgroups of polyarginine peptides are a critical structural component 
responsible for biological activity 31. This is in part due to the ability of the guanidine group to 
form a very stable bidentate hydrogen bond with anions (e.g., phosphate or sulfate) 31. Our previous 
studies 16, 18 established that the interaction of CPPs or CPP-pDNA complexes with three 
phospholipid monolayers (POPG, POPS, and POPC) was not different when comparing CPPs used 
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here (Table 2, Figure Appendix 10). POPG, POPS, and POPC are extensively used as a model 
for one leaflet of the cell membrane. In the previous reports, RW9 and RL9 peptides or complexes 
strongly penetrated model cell membranes and induced the maximum alterations in phospholipid 
packing (high Δ surface pressure (mN/m)) 16. Conversely, the other CPPs or complexes (R9, RH9, 
and RA9) also showed penetration into the model membranes but did not appear to cause 
significant membrane disruption (low Δ surface pressure). This suggests that although the initial 
interaction of the complexes with cell membranes is facilitated by ionic interactions, the 
hydrophobic residues (tryptophan and leucine) further facilitate membrane penetration. Yet, RW9 
complexes appeared significantly more effective than RL9 complexes for transfection, suggesting 
that the high membrane penetration efficiency of RL9 and RW9 complexes did not explain 
increased levels of gene expression compared to R9 complexes. The difference in the transfection 
efficiency between R9, RH9, and RA9 complexes was also probably not due to the penetration 













Table 2. Maximum Change in Surface Pressure, Plateau Values, of the Five Complexes When 
Inserted below POPG, POPS, POPC Monolayers. Results are presented as mean ± SD (n = 3). 
 
CaCl2 was an essential component to condense the complexes, yielding small nanoparticles 
with the ability to release nucleic acids and CPPs as pH drops. Only combinations of CPPs and 
CaCl2 effectively boosted gene transfection, because the transfection efficiency of pDNA-Ca
2+ 
complexes without R9 and RW9 peptides was significantly lower than that of the complexes with 
R9 and RW9 peptides at the same CaCl2 concentration (Figure 5E and 5F).  
An efficient gene delivery method should be able to transport nucleic acids to the target 
cells without negatively affecting the viability of the host cell. To examine whether the five CPPs, 
PEI, and CaCl2 affected the viability of the four cell lines, an MTS cytotoxicity assay of the five 
CPPs, PEI, and CaCl2 was conducted. The cytotoxicity profiles of the five CPPs, PEI, and CaCl2 
was determined in A549 cells (Figure 6A) and HEK-293 cells (Figure 6B). Generally, the data 
indicated that CaCl2 and R9, RH9, RA9, and RL9 peptides revealed no evidence of cytotoxicity at 
low or medium concnetrations, and cells maintained high viability, whereas some of the peptides 
showed moderate cytotoxicity at very high concentrations in both of the cell lines. Clearly, PEI 
induced significant cytotoxicity in both of the cell lines.  
Complexes 







R9 2.9 ± 0.71 1.9  ± 0.50 0.9  ± 0.31 
RH9 3.3  ± 0.75 1.4  ± 0.37 1.2  ± 0.62 
RA9 2.5 ± 0.70 1.4  ± 0.99 1.1  ± 0.38 
RL9 7 ± 0.67 5.4  ± 0.35 1.9  ± 0.56 










Figure 6. Cytotoxicity profiles of R9, RH9, RA9, RL9, RW9, PEI, and CaCl2 (A) in A549 cells 
and (B) in HEK-293 cells. Viability is expressed as a function of the CPPs, PEI, and CaCl2 
concentration. Results are presented as mean ± SD (n = 3). 
 
One possible mechanism of the enhanced transfection efficiency could be the disintegration 
of the complexes as pH decreases (late endosome/lysosome) 8, 18.  Figure Appendix 11 shows the 
particle size of the nanoparticles in PBS at different pH values (7.4, 6.4, 5.4, 4.4, and 3.4). Particle 
size increased as pH value decreased, suggesting complexes dissociated at these conditions. The 
decrease photon counting rate (kilo-counts per second; Kcps) at low pH suggested complexes 
dissociated, which is also supported by our previous studies 8, 12. Furthermore, earlier reports of 
calcium and DNA precipitates were reported to dissociate when exposed to similar conditions 32. 
In contrast, PEI-pDNA complexes showed no significant change in particle size. Additionally, 
Figure Appendix 12 shows the zeta potential of the five complexes at neutral (7.4) and acidic 
(4.4) pH values. In general, the total charge of the complexes is positive at pH 7.4, which may be 
due to charge on the CPPs making up the complexes, whereas, the net charge of the complexes 
become neutral or anionic when the pH was lowered. The drop in pH appeared to destabilize the 
complexes, allowing the pDNA to be exposed. 






















































Since transfection efficiency did not correlate to the membrane activity of CPPs, other 
mechanisms were explored. RW9 and R9 complexes were able to immobilize pDNA completely 
at low N/P ratios, 1 and 4, respectively (Figure 1). As mentioned before RW9 and R9 complexes 
displayed weak fluorescence intensity (RFU), which indicated that these complexes bound 
strongly to pDNA (Figures 3 and 4). Figure 7 shows the correlation coefficient between 
RLUs/mg protein (Figure 5E and 5F) and the change in the maximum surface pressure (Table 2) 
of the five CPP complexes. Figures 7A to 7F indicate that there was no significant correlation 
between the transfection efficiency (in A549 and HEK-293 cell lines) and the CPP membrane 
penetration efficiency (below POPG, POPS, and POPC phospholipid monolayers). On the other 
hand, Figure 8 indicates a significant correlation between the transfection efficiency of the five 
CPP complexess and the ability of CPPs to immobilize pDNA completely by using agarose gel 
electrophoresis experiments (N/P ratios 1 to 15, integer numbers) (excluding PEI complexes, 
Figure 1 and Figure Appendix 8). Furthermore, Figure 9 shows the correlation coefficient 
between the transfection efficiency and unpackaging of the complexes by dextran sulfate 
displacement of pDNA across a range of N/P ratios 1-3 in A549 cells (Figures 9A-C) and HEK-
293 cells (Figures 9D-E). In general, there was a significant correlation between the transfection 
efficiency and the unpackaging. Thus, the high transfection efficiency of R9 and RW9 complexes 
may be driven by the strong interaction between CPPs and pDNA, rather than differences in the 
membrane penetration efficiency of the complexes. R9 complexes had high transfection efficiency 
when compared with RH9, RA9, and RL9 complexes, which may be due to the larger number of 
positively charged arginine residues. RW9 complexes also had high transfection efficiency when 
compared with RH9, RA9, and RL9 complexes. This behavior is possibly due to the chemical 
structure of tryptophan residues (the aromatic ring), which may facilitate peptide binding with 
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nucleic acids even though the peptide charge is significantly lower than R9 16. On the basis of these 
results, we concluded that the structure of the CPPs dictated the ability of CPPs to protect and 







































Figure 7. No correlation was observed between the transfection efficiency (in A549 and HEK-293 
cell lines, 100 mM CaCl2 concentration and at N/P ratio 10) and the changes in surface pressure 
as following injection of R9-, RH9-, RA9-, RL9-, or RW9-pDNA complexes into model 
phospholipid monolayers (POPG, POPS, or POPC). (A) A549 cell line and POPG phospholipid 
monolayer. (B) A549 cell line and POPS phospholipid monolayer. (C) A549 cell line and POPC 
phospholipid monolayer. (D) HEK-293 cell line and POPG phospholipid monolayer. (E) HEK-
293 cell line and POPS phospholipid monolayer. (F) HEK-293 cell line and POPC phospholipid 




















































































































































































Figure 8. Correlation was found between the transfection efficiency and the minimum N/P ratio 
where PEI and CPPs were able to immobilize pDNA completely (Agarose gel electrophoresis) for 
R9-, RH9-, RA9-, RL9-, or RW9-pDNA complexes (100 mM CaCl2 concentration and at N/P ratio 
10). (A) A549 cells. (B) HEK-293 cells. The Pearsons correlation coefficient was calculated with 




















































































Figure 9. Correlation was found between the transfection efficiency and unpackaging of R9-, 
RH9-, RA9-, RL9-, RW9-, or -PEI pDNA complexes by dextran sulfate displacement of pDNA at 
N/P ratios 1, 2, 3, and 4 in A549 or HEK-293 cells. (A) A549 N/P ratio 1, (B) A549 N/P ratio 2, 
(C) A549 N/P ratio 3, (D) HEK-293 N/P ratio 1, (E) HEK-293 N/P ratio 2, and (F) HEK-293 N/P 
















































































































































































The addition of CaCl2 to low-molecular-weight hydrophilic CPPs (R9 and RH9) and amphiphilic 
CPPs (RA9, RL9, and RW9) complexed with pDNA, produced small nanoparticles, leading to 
gene expression levels higher than detected for PEI complexes in a normal cell line (HEK-293) 
and a cancer cell line (A549). Clearly, replacing three residues of the R9 peptide with a hydrophilic 
residue (histidine) or hydrophobic residues (alanine, leucine, and tryptophan) at positions 3, 4, and 
7 did not enhance the transfection efficiency compared to R9 complexes. R9 and RW9 complexes 
appeared especially effective compared to other CPP complexes, whereas RH9, RA9, and RL9 
complexes seemed to have moderate- to low-gene expression. Initially, this suggested CPPs with 
better membrane penetration yielded higher gene expression. After further exploration, we 
discovered the charge spacing of CPPs affected the ability of CPPs to complex with nucleic acids 
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7.1. Conclusion  
Gene therapy utilizes the delivery of genetic material into target cells to correct a genetic 
defect or alter protein expression to address disease. Notwithstanding advances in the field, the 
delivery of genetic material (e.g., pDNA and siRNA) to target cells or tissues is still challenging. 
There are many hindrances to overcome in developing effective gene therapy including toxicity, 
immunogenicity, tissue and cellular transport barriers, enzymatic degradation, endosomal escape, 
and rapid clearance after administration.   
Successful transfer of genetic material into target cells usually relies on the use of efficient 
carriers. Notable efforts are being made to develop viral and nonviral vectors that can cross the 
plasma membrane and deliver pDNA or siRNA into target cells. Viral vectors (e.g., retroviruses 
and adenoviruses) can be highly efficient and are currently used in the majority of ongoing clinical 
trials. Unfortunately viral vectors are deficient in several areas such as the induction of host 
immune response and challenging, expensive scale-up. Consequently, nonviral vectors are being 
pursued as flexible, easy, and potentially safer alternatives, yet, they continue to lack the necessary 
efficiency required for clinical application. Cationic lipids, polymers, and peptides are the most 
commonly employed nonviral carriers.  
The objective of this thesis has been to design high transfection efficiency and less toxic 
vectors for gene delivery. Cell penetrating peptides (CPPs) were considered as potential 
polycations to complex and deliver genetic material. Calcium was found to compact CPP 
complexes through “soft” crosslinks that could be competitively disrupted in order to increase 
transfection efficiency. Polyarginines have been successfully used as cell penetrating peptides for 
delivering large cargo such as genetic material. Polyarginine-pDNA complexes condensed with 
calcium chloride possessed excellent transfection efficiency compared to PEI complexes in A549 
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lung epithelial cells. Furthermore, the low-molecular-weight polyarginine peptides (5, 7, 9 and 11) 
showed negligible cytotoxicity up to 5 mg/mL and maintained the expected cell proliferation rates. 
Polyarginine 7 appeared especially effective compared to the other polyarginines. Polyarginine 5 
was ineffective compared to the other polyarginines, suggesting the minimum size should be > 5 
amino acids.  
K9-(pAT2R or pLUC)-Ca2+ complexes produced small and stable complexes. These 
complexes exhibited high in vitro gene expression in various human and mouse cancer cells 
comparable to PEI-pDNA complexes. Also, single IV or IT administrations of the K9-pAT2R-
Ca2+ complexes significantly attenuated the growth of LLC cell allografts in mouse lungs, 
suggesting that K9 peptide-based gene therapy is effective and that the AT2R gene is potentially 
useful for lung cancer gene therapy. K9 peptide showed negligible cytotoxicity in cell culture, 
supporting the notion that this CPP is a safe delivery vehicle for genetic materials. The 
incorporation of CPPs into polyelectrolyte complexes using this strategy potentially offers a safe 
and effective approach (in vitro and in vivo) to gene delivery. 
Since CPPs interact with the plasma membranes, understanding the interactions of 
synthetic CPPs with phospholipid membranes is an important step when designing future synthetic 
CPPs capable of intracellular drug delivery. Insertion of the hydrophilic CPPs (dTAT, H9, K9, R9, 
and RH9) and the amphiphilic CPPs (RA9, RL9, and RW9) into the phospholipid monolayers 
(POPG, POPC, DPPC, or POPG/DPPC) were followed using Langmuir monolayer techniques and 
fluorescence microscopy. In addition to electrostatic interactions, hydrophobic interactions, as 
well as the chemical nature of the amino acid residues, influenced the membrane insertion 
potential. The presence of tryptophan residues induced maximum perturbation of the phospholipid 
packing. All CPPs interacted with anionic phospholipids, but the interactions of RW9 and RL9 
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with membrane monolayers was significantly different when compared with the other peptides. 
RW9 and RL9 strongly penetrated the model cell membranes and also induced the maximum 
alterations in phospholipid packing.  
Furthermore, zwitterionic phospholipid membranes (POPC) and anionic phospholipid 
membranes (POPS and POPG) have been used to study the membrane insertion of the seven CPP-
pDNA-Ca2+ complexes, containing hydrophilic (i.e., dTAT, K9, R9, and RH9) and amphiphilic 
(i.e., RA9, RL9, and RW9) CPPs, at different pHs (pH 7.4 and 4.4). Our data showed that there 
was no difference in the insertion potential of gene complexes of different composition, when 
interacting with a zwitterionic phospholipid at a neutral pH. However, when interacting with 
anionic phospholipid membranes, all complexes showed an increase in their insertion potential, 
although there was a significant difference in the membrane insertion potential of complexes 
containing amphiphilic CPPs. This suggests that while the initial interactions of the complexes 
with phospholipid membranes are facilitated by electrostatic interactions, the hydrophobic amino 
acids further facilitated membrane insertion. However, in more acidic environments such as those 
in the intracellular vesicles (endosomes/lysosomes) all gene complexes show a greater insertion 
into the membranes, irrespective of the composition. In conclusion, our results also suggest that 
overall, designing gene complexes with amphiphilic peptides may not necessarily demonstrate 
more transfection efficiency, because of the differences in the insertion potential of the amphiphilic 
peptides at neutral and acidic pH, even though the amphiphilic peptides have the potential to 
disrupt anionic membranes at neutral pH.  
Finally, replacing three residues of the R9 peptide with a hydrophilic residue (histidine) or 
hydrophobic residues (alanine, leucine, and tryptophan) at positions 3, 4, and 7 did not enhance 
the transfection efficiency compared to R9 complexes. R9 and RW9 complexes appeared 
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especially effective compared to other CPP complexes, whereas RH9, RA9, and RL9 complexes 
seemed to have moderate to low-gene expression. Initially, this suggested CPPs with better 
membrane penetration yielded higher gene expression. After further exploration, we discovered 
the charge spacing of CPPs affected the ability of CPPs to complex with nucleic acids and this 
property correlated to gene expression levels. 
 
7.2. Future Directions 
Gene therapy has incredible potential to revolutionize the way we treat human diseases and 
other medical conditions. Improved gene delivery, however, remains a major obstacle that must 
be overcome before gene therapy can advance beyond the clinical setting and into the doctor’s 
office. Major strides are being made currently in terms of developing improved vectors to transport 
genes from the laboratory bench top to the diseased tissue within a patient and ultimately to the 
cell nucleus. CPPs are opening possibilities for addressing other drawbacks that are currently 
associated with nonviral vectors. While improving viral gene delivery vectors will probably have 
the most immediate impact, the long-term goal for many of us in the field is to develop completely 
synthetic nonviral vectors that perfectly mimic the efficiency of a virus with none of the 
drawbacks. CPPs are having immediate impacts on moving us one step closer to this goal. Nonviral 
vectors complexed with CPPs are being delivered directly to the cell cytosol across the cell 
membrane, escaping endosomal vesicles with greater efficiencies, and being transported to the cell 
nucleus in ways that are traditionally only associated with viruses. CPPs have been studied for 
more than 20 years, but their impact on the field of gene delivery has been limited predominantly 
to the last several years. While they have improved significantly existing vectors, further design 
and development of simpler and more effective CPPs will undoubtedly continue to greatly benefit 
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the development of nonviral gene delivery vectors as the field continues to advance. Future work 
with CPP gene delivery systems should further explore the mechanism of a positive effect of 
calcium on the gene delivery when incorporated in the nonviral gene vectors. Further emphasis on 
immunohistochemical and imaging studies of CPP-pDNA- Ca2+ complexes would provide more 
information on the exact mechanism of enhanced transfection. The internalization and trafficking 
should be investigated since it cannot be excluded from the effect of calcium on gene transfer when 
using CPP complexes. Moreover, further studies are required to confirm the in vivo safety of the 



































































































































Figure Appendix 1. The transfection efficiencies of the pLUC-Ca2+ and the K9-pLUC-Ca2+ 
complexes in various cell lines designated in the figure were determined in the presence of 38 mM 
calcium chloride at an N/P ratio 10. RLUs refers to relative light units. Results are presented as 












Figure Appendix 2.  Bar graphs show average lung weight (A) and number of lung tumor nodules 
(B) in LLC tumor-bearing C57BL/6 mice treated with PBS (n=5), K9-pLUC-Ca2+ IV (K9-pLUC 
IV; n=5), or K9-pLUC-Ca2+ IT (K9-pLUC IT; n=5). K9, nine amino acid polylysine; IT, 




























Figure Appendix 3. (A) Changes in the surface pressure versus time following adsorption of the 
eight CPPs into a phospholipid-free interface. The peptides are at a final concentration of 10 µM 
(B) Maximum change in surface pressure (plateau values) recorded for the eight CPPs. The results 



























































































Figure Appendix 4. CD analysis of the eight CPPs. The peptide concentration used was 10 µM 
using a 0.1 cm path length quartz cuvette was used with a total volume of 200 µL )in PBS). Full 
CD spectra were collected at 22 °C for wavelengths ranging from 260 to 200 nm. CD spectra 
analysis of the eight CPPs showed that the eight CPPs in the PBS solution contain random-coil 
conformations. The results are presented as mean ± SD (n = 3). CD spectra were recorded using a 
























































Figure Appendix 5. The maximum change in surface pressure of the seven CPPs (dTAT, K9, R9, 
RH9, RA9, RL9, and RW9) below POPG phospholipid monolayers held at an initial surface 
























































































































































Figure Appendix 6. Changes in surface pressure as a function of time following injection of the 
seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9) below (A) POPC, (B) POPS, and (C) 
POPG phospholipid monolayers held at an initial surface pressure of 20 mN/m and at pH 7.4. The 
maximum change in surface pressure (plateau values) of the (D) POPC, (E) POPS, (F) POPG due 




























































































































































































































































Figure Appendix 7. Changes in surface pressure as a function of time following injection of the 
seven CPPs (dTAT, K9, R9, RH9, RA9, RL9, and RW9) below (A) POPC, (B) POPS, and (C) 
POPG phospholipid monolayers held at an initial surface pressure of 20 mN/m and at pH 4.4. The 
maximum change in surface pressure (plateau values) of the (D) POPC, (E) POPS, (F) POPG due 

















































































































































































































































Figure Appendix 8. Agarose gel electrophoresis study of RH9-, RA9-, and RL9-pDNA 
complexes. (A) RH9-pDNA complexes at N/P ratios 6, 7, 8, 9, and 10. (B) RA9-pDNA complexes 
at N/P ratios 11, 12, 13, 14, and 15. (C) RL9-pDNA complexes at N/P ratios 11, 12, 13, 14, and 
15. "Star *" refers to the minimum N/P ratio whereas CPPs were able to immobilize pDNA 






























Figure Appendix 9. SYBR Green fluorescence of R9-, RH9-, RA9-, RL9-, RW9-, and PEI-pDNA 
complexes by dextran sulfate displacement of pDNA at different N/P ratios (1, 2, 3, 4, and 10) and 
with or without CaCl2 (300 mM). (A) At different dextran sulfate concentrations without CaCl2, 
(B) at different dextran sulfate concentrations with CaCl2, (C) with/without CaCl2 at dextran sulfate 
concentration of 0.01 mg/mL and N/P ratio 10, and (D) without CaCl2 at dextran sulfate 
concentration of 0.01 mg/mL and N/P ratios 1, 2, 3, and 4. Results are presented as mean ± SD (n 
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Figure Appendix 10. Changes in surface pressure as a function of time following injection of R9, 
RH9, RA9, RL9, or RW9-pDNA-Ca2+ complexes into model phospholipid monolayers: (A) 
POPC, (B) POPS, and (C) POPG held at an initial surface pressure of 20 mN/m and at pH 7.4. 




















































































































Figure Appendix 11. Particle size (effective diameter) of the five CPP-pDNA complexes with 
CaCl2 concentration (100 mM) at an N/P ratio 10, at different pH 7.4, 6.4, 5.4, 4.4 and 3.4. Results 
are presented as mean ± SD (n = 3). (A) All complexes, (B) PEI, (C) R9, (D) RH9, (E) RA9, (F) 
RL9, and  (G) RW9. For missing data points, the diameter was undetectable. Results are presented 






























































































































































































Figure Appendix 12. Zeta potentials of PEI-pDNA complexes and of CPPs (R9, RH9, RA9, RL9, 
and RW9)-pDNA complexes (100 mM CaCl2 and an N/P ratio: 10) at different pH values (i.e. 7.4 
and 4.4). Results are presented as mean ± SD (n = 3). 
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